TDP-43 Specific Binding Molecules

ABSTRACT

Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

FIELD OF THE INVENTION

The invention generally relates to novel TDP-43 (TAR DNA-binding protein of 43 kDa)-specific binding molecules, such as antibodies, including fragments, derivatives and variants thereof, that specifically recognize TDP-43. In addition, the invention relates to pharmaceutical and diagnostic compositions comprising such antibodies and other TDP-43-specific binding molecules and their use to detect and identify TDP-43 in plasma, cerebrospinal fluid, brain, and other samples, as well as in therapeutic applications including for example, passive vaccination strategies for treating disorders related to aggregates or other aberrations in TDP-43 expression, such as, frontotemporal lobar degeneration and/or, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease and other TDP-43 proteinopathies.

BACKGROUND OF THE INVENTION

Frontotemporal lobar degeneration (FTLD) is the second most common cause of dementia affecting individuals younger than 65 years; see, e.g., McKhann et al., Arch. Neurol. 58 (2001), 1803; Forman et al., Ann. Neurol. 59 (2006), 952-62. On a cellular pathologic level, the characteristic lesions in the majority of FTLD brains are abnormal ubiquitinated protein inclusions. The biochemical composition of the ubiquitinated inclusions in the most common pathological form of FTLD, namely FTLD-U, remained unknown until 2006, when the TAR-DNA binding protein 43 (TDP-43) was identified as the major disease protein in the majority of sporadic and familial FTLD-U cases. Subsequently, the ubiquitinated compact inclusions, characteristic for amyotrophic lateral sclerosis (ALS) were also found to be composed of TDP-43, thereby providing evidence that both conditions are mechanistically linked and part of spectrum of diseases which can be classified as TDP-43 proteinopathies, see, e.g., Neumann et al., Science 314 (2006), 130-133.

Other than FTLD and ALS, TDP-43 is also known to accumulate in the nerve cells and glial cells of ALS-Parkinsonism dementia complex of Guam, corticobasal degeneration, Dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal dementia, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, Parkinson's disease dementia, Parkinson-dementia complex in Kii peninsula and Pick's disease and the like; see e.g., Lagier-Tourenne et al., Hum. Mol. Gen. 19 (2010), R46-64, which is herein incorporated by reference in its entirety. These diseases are collectively referred to as TDP-43 proteinopathies. Abnormal accumulation of TDP-43 is observed at the site of lesions of each disease which appears to imply involvement in the cause of nerve degeneration in these diseases. Increased cytoplasmic localization of TDP-43 in brains and spinal cords of patients termed as “pre-inclusions” has been proposed to be an early event in TDP-43 proteinopathies, with the implication of a possible pathogenic role in these diseases; see, e.g. Giordana et al., Brain Pathol. 20 (2010), 351-60. Consistently, increased cytoplasmic TDP-43 localization at presymptomatic stages has been reported to be found in mice overexpressing wild type TDP-43; see e.g., Wils et al., Proc. Natl Acad. Sci. USA 107 (2010), 3858-63 as well as in an acute rat model with adenovirus-mediated wild-type TDP-43 expression; see, e.g., Tatom et al., Mol. Ther. 17 (2009), 607-613. Commercially available monoclonal murine antibodies are primarily used in the studies on TDP-43 and to conduct pathological diagnosis of TDP-43 proteinopathies. A monoclonal murine anti-TDP-43 antibody, which recognizes the phosphorylated form of TDP-43 is disclosed in European Patent Application No. 2 189 526 A1. Additional anti-TDP-43 antibodies are disclosed in Zhang et al., Proc Natl Acad Sci USA,106(18):7607-12 (2009) and U.S. Patent Application Pub. No. 20100136573.

The success in generating monoclonal antibodies rests among other things, on the efficient and selective fusion of antigen-stimulated B cells with a murine myeloma cell line followed by selection of stable antibody producing hybrids as originally described by Kóhler and Milstein, Nature 256 (1975), 495-497. However, the therapeutic utility of murine based antibodies in human is hampered by the human anti-mouse antibody (HAMA) response as a consequence of their non-human origin. Approaches for making human or human-like monoclonal antibodies became available through genetic engineering. However, these methods typically suffer from the drawback that they are not suitable for producing antibodies displaying many of the characteristics of antibodies that are endogenously produced by the human immune system during the course of a physiological human immune response. Furthermore, these genetically engineered antibodies may show undesired cross-reactivity with other proteins and/or the target protein in the context of the biologically relevant native conformation and normal physiological function of the target antigen. The resulting side effects upon systemic administration of the exogenous antibodies may range from for example, undesired autoimmune disease to anaphylactic reactions. These side effects have been reported in so-called “humanized antibodies,” which originally stem from non-human organisms, such as mice, as well as so called “fully human antibodies,” in vitro or in xenogeneic mice genetically engineered to express a repertoire of human antibodies. On the other hand, active immunization with pathologically relevant antigens bears the considerable risk of patients developing uncontrollable immune responses against these antigens and cross-reactivity with endogenous antigens that may consequently lead to dangerous autoimmune responses.

Furthermore, the development of assays to detect and monitor levels of normal and pathological TDP-43 in plasma, cerebrospinal fluid, and other samples as biomarkers of FTLD and ALS will provide the ability to diagnose and distinguish TDP-43 proteinopathies from other clinically similar neurodegenerative disorders, such as tauopathies or related proteinopathies. In addition, the development of imaging ligands that enable the detection and/or quantification of TDP-43 neuropathology in living patients will provide a powerful tool not only for diagnosis, but also for monitoring the response of patients having a neurodegenerative TDP-43 proteinopathy to disease-modifying therapies when they become available.

Thus, there is a need to overcome the above-described limitations and to provide therapeutic and diagnostic antibodies and other binding molecules that specifically recognizes biologically relevant conformations of TDP-43.

SUMMARY OF THE INVENTION

The invention relates to TDP-43 (TAR DNA-binding protein of 43 kDa)-specific binding molecules, such as antibodies, including fragments, derivatives and variants of antibodies that are capable of specifically recognizing TDP-43. By “specifically recognizing TDP-43”, “antibody specific to/for TDP-43” and “anti-TDP-43 antibody” is meant specifically, generally, and collectively, antibodies to TDP-43, or misfolded or oligomeric or aggregated or posttranslationally modified TDP-43. According to one embodiment, antibodies of the invention (including antigen-binding antibody fragments and derivatives) specifically recognize full-length, truncated, or aggregated human TDP-43. In an additional embodiment, the antibodies recognize full-length human TDP-43 having the sequence of SEQ ID NO:94 or a peptide consisting of residues 390-414 of the C-terminal sequence of SEQ ID NO:94 phosphorylated at residues 409 and 410.

In one embodiment, the TDP-43 specific binding molecule is an antibody (including antigen-binding fragments or derivatives thereof) having an immunological binding characteristic of an antibody described herein, such as, an antibody having the variable regions V_(H) and/or V_(L) of the amino acid sequence set forth in (SEQ ID NO:1) and (SEQ ID NO:6), (SEQ ID NO:10) and (SEQ ID NO:14), (SEQ ID NO:18) and (SEQ ID NO:22), (SEQ ID NO:26) and (SEQ ID NO:31), (SEQ ID NO:35) and (SEQ ID NO:40), (SEQ ID NO:45) and (SEQ ID NO:49), (SEQ ID NO:53) and (SEQ ID NO:57), (SEQ ID NO:61) and (SEQ ID NO:65), (SEQ ID NO:69) and (SEQ ID NO:73), (SEQ ID NO:77) and (SEQ ID NO:82), (SEQ ID NO:87) and (SEQ ID NO:122), (SEQ ID NO:130) and (SEQ ID NO:134), (SEQ ID NO:138) and (SEQ ID NO:142), (SEQ ID NO:146) and (SEQ ID NO:150), (SEQ ID NO:146) and (SEQ ID NO:151), (SEQ ID NO:155) and (SEQ ID NO:159), (SEQ ID NO:163) and (SEQ ID NO:167), (SEQ ID NO:171) and (SEQ ID NO:175), (SEQ ID NO:179) and (SEQ ID NO:183), (SEQ ID NO:187) and (SEQ ID NO:191), (SEQ ID NO:195) and (SEQ ID NO:199), (SEQ ID NO:203) and (SEQ ID NO:207), (SEQ ID NO:211) and (SEQ ID NO:215), (SEQ ID NO:219) and (SEQ ID NO:223), (SEQ ID NO:227) and (SEQ ID NO:213), (SEQ ID NO:235) and (SEQ ID NO:239), (SEQ ID NO:243) and (SEQ ID NO:247), (SEQ ID NO:251) and (SEQ ID NO:255), (SEQ ID NO:259) and (SEQ ID NO:263), or (SEQ ID NO:267) and (SEQ ID NO:271), respectively.

The invention also relates to compositions comprising an antibody of the invention (including TDP-43-binding antibody fragments and derivatives) or TDP-43 agonists and cognate molecules, or alternately, antagonists of the same and to immunotherapeutic and immunodiagnostic methods using such compositions in the prevention, diagnosis or treatment of a TDP-43 proteinopathy, wherein an effective amount of the composition is administered to a patient in need thereof.

Polynucleotides encoding TDP-43-binding molecules such as, antibodies (including TDP-43 binding antibody fragments or variants), are also encompassed by the invention. In some embodiments, the polynucleotide encodes at least a variable region of an immunoglobulin chain of an antibody of the invention. In an additional embodiment, the polynucleotide encodes at least one complementarity determining region (CDR) of a V_(H) and/or V_(L) variable region as depicted in FIGS. 1 and 3. In an additional embodiment, the polynucleotide encodes at least one complementarity determining region (CDR) of a V_(H) and/or V_(L) variable region encoded by a polynucleotide sequence as set forth in Table 3. Polynucleotides encoding derivatives or analogs of the above-encoded TDP-43 binding peptides and the polypeptides encoded by these polynucleotides are also encompassed by the invention.

Vectors containing polynucleotides encoding TDP-43-binding molecules (e.g., antibodies) of the invention and host cells transformed with these vectors and/or polynucleotides are also encompassed by the invention, as are their use for the production of an antibody and equivalent binding molecules which are specific for TDP-43. Means and methods for the recombinant production of antibodies and other binding polypeptides and mimics thereof as well as methods of screening for molecules, e.g., antibodies, that compete with these antibodies or other binding proteins for binding with TDP-43 are known in the art. As described herein, in some embodiments, for example those relating to therapeutic applications in human, the TDP-43 specific binding antibody of the invention is a human antibody in the sense that application of said antibody is substantially free of a HAMA response otherwise observed for chimeric and even humanized antibodies.

In one embodiment, the invention encompasses molecules that specifically bind

TDP-43 and the use of these molecules to detect the presence of TDP-43 in a sample. Accordingly, TDP-43 binding molecules of the invention, such as, anti-TDP-43 antibodies, can be used to screen human blood, CSF, and urine for the presence of TDP-43 in samples, for example, by using ELISA-based or surface adapted assay. The methods and compositions disclosed herein have applications in diagnosing TDP-43 proteinopathies such as, amyotrophic lateral sclerosis (ALS) or frontotemporal lobar degeneration (FTLD). The methods and compositions of the invention also have applications in diagnosing presymptomatic disease and in monitoring disease progression and therapeutic efficacy. According to some embodiments, an antibody specific for TDP-43 (e.g., a full-length antibody or a TDP-43 binding fragment or derivative of an antibody) is contacted with a sample (e.g., blood, cerebrospinal fluid, or brain tissue) to detect, diagnose or monitor frontotemporal lobar degeneration (FTLD) or Amyotrophic lateral sclerosis (ALS). In another embodiment, an antibody specific for TDP-43 is contacted with a sample to detect, diagnose or monitor a disease selected from Alzheimer's disease, Parkinson's disease, and Lewy Body disease: In another embodiment, an antibody specific for TDP-43 is contacted with a sample to detect, diagnose or monitor a disease selected from: argyrophilic grain disease, ALS-Parkinsonism dementia complex of Guam, corticobasal degeneration, Dementia with Lewy bodies, Huntington's disease, motor neuron disease, frontotemporal lobar degeneration (FTLD), frontotemporal dementia, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease dementia, Parkinson-dementia complex in Kii peninsula, Pick's disease, and Machado-Joseph disease or dementia.

In additional embodiments, the invention provides methods for treating or preventing a TDP-43 neurologic proteinopathy. According to one embodiment, the methods of the invention comprise administering an effective concentration of an antibody specific for TDP-43 (e.g., a full-length antibody or a TDP-43 binding fragment or derivative of an antibody) to a subject. In an additional embodiment, the invention provides a method for treating or preventing TDP-43 neurologic proteinopathies. According to some embodiments, an antibody specific for TDP-43 is administered to treat or prevent frontotemporal lobar degeneration (FTLD) or Amyotrophic lateral sclerosis (ALS). In another embodiment, an antibody specific for TDP-43 is administered to treat or prevent a neurodegenerative disease selected from Alzheimer's disease, Parkinson's disease, and Lewy Body disease. In another embodiment, an antibody specific for TDP-43 is administered to treat or prevent a disease selected from: argyrophilic grain disease, ALS-Parkinsonism dementia complex of Guam, corticobasal degeneration, Dementia with Lewy bodies, Huntington's disease, motor neuron disease, frontotemporal lobar degeneration (FTLD), frontotemporal dementia, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease dementia, Parkinson-dementia complex in Kii peninsula, Pick's disease, and Machado-Joseph disease or dementia.

Further embodiments of the invention are apparent from the description and Examples that follow.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A: lists the amino acid sequences of the variable region, i.e. heavy chain and kappa/lambda light chain of human antibody NI-205.3F10. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1B: lists the amino acid sequences of the VH and VL of NI-205.51C1. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1C: lists the amino acid sequences of the VH and VL of NI-205.21G2. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1D: lists the amino acid sequences of the VH and VL of NI-205.8A2. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1E: lists the amino acid sequences of the VH and VL of NI-205.15F12. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1F: lists the amino acid sequences of the VH and VL of NI-205.113C4. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1G: lists the amino acid sequences of the VH and VL of NI-205.25F3. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1H: lists the amino acid sequences of the VH and VL of NI-205.87E7. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1I: lists the amino acid sequences of the VH and VL of NI-205.21G1. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1J: lists the amino acid sequences of the VH and VL of NI-205.68G5. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 1K: lists the amino acid sequences of the VH and VL of NI-205.20A1. Framework (FR), complementarity determining regions (CDRs; underlined), heavy chain joining region (JH), and light chain joining region (JK) or (JL) are indicated. Amino acid positions modified to account for potential PCR-primer induced cloning artifacts and that have been modified to match the corresponding human germ line variable region sequences are provided in bold.

FIG. 2A: is a bar graph depicting the binding of human TDP-43 antibody, 205.51C1, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 2B: is a bar graph depicting the binding of human TDP-43 antibody, 205.21G2, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 2C: is a bar graph depicting the binding of human TDP-43 antibody, 205.3F10, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 2D: is a bar graph depicting the binding of human TDP-43 antibody, 205.8A2, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 2E: is a bar graph depicting the binding of human TDP-43 antibody, 205.15F12, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 2F: is a bar graph depicting the binding of human TDP-43 antibody, 205.113C4, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 2G: is a bar graph depicting the binding of human TDP-43 antibody, 205.25F3, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 2H: is a bar graph depicting the binding of human TDP-43 antibody, 205.87E7, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 2I: is a bar graph depicting the binding of human TDP-43 antibody, 205.21G1, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 2J: is a bar graph depicting the binding of Abnova 23435, Abcam 50930, Abcam 82695, and anti-human Fcγ, to amino terminal His-tagged fragments of TDP-43 consisting of amino acid residues 2-106 (domain I (SEQ ID NO:117)), 99-204 (domain II (SEQ ID NO:118)), 183-273 (domain III (SEQ ID NO:119)), 258-414 (domain IV (SEQ ID NO:120)), or 2-414 (full length (SEQ ID NO:121)).

FIG. 3A: lists the amino acid sequences of the variable region, i.e. heavy chain (VH) and kappa (VK)/lambda (VL) light chain of human anti-TDP-43 antibody, NI205.41D1. Complementarity determining regions (CDRs) are underlined.

FIG. 3B: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.29E11. Complementarity determining regions (CDRs) are underlined.

FIG. 3C: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.9E12. Complementarity determining regions (CDRs) are underlined.

FIG. 3D: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.98H6. Complementarity determining regions (CDRs) are underlined.

FIG. 3E: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.10D3. Complementarity determining regions (CDRs) are underlined.

FIG. 3F: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.44B2. Complementarity determining regions (CDRs) are underlined.

FIG. 3G: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.38H2. Complementarity determining regions (CDRs) are underlined.

FIG. 3H: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.36D5. Complementarity determining regions (CDRs) are underlined.

FIG. 3I: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.58E11. Complementarity determining regions (CDRs) are underlined.

FIG. 3J: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.14H5. Complementarity determining regions (CDRs) are underlined.

FIG. 3K: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.31D2. Complementarity determining regions (CDRs) are underlined.

FIG. 3L: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.8F8. Complementarity determining regions (CDRs) are underlined.

FIG. 3M: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.31C11. Complementarity determining regions (CDRs) are underlined.

FIG. 3N: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.8C10. Complementarity determining regions (CDRs) are underlined.

FIG. 3O: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.10H7. Complementarity determining regions (CDRs) are underlined.

FIG. 3P: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.1A9. Complementarity determining regions (CDRs) are underlined.

FIG. 3Q: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.14W3. Complementarity determining regions (CDRs) are underlined.

FIG. 3R: lists the amino acid sequences of the VH and VL of human anti-TDP-43 antibody, NI205.19G5. Complementarity determining regions (CDRs) are underlined.

FIG. 4A: is a graph of the half maximal effective concentration (EC₅₀) of human-derived TDP-43 antibody, 41D1, by direct ELISA to recombinant full length TDP-43 (●), Escherichia coli extract (▴) and BSA (▪).

FIG. 4B: is a graph of the EC₅₀ of human-derived TDP-43 antibody, 21G1, by direct ELISA to recombinant full length TDP-43 (●), Escherichia coli extract (▴) and BSA (▪).

FIG. 4C: is a graph of the EC₅₀ of human-derived TDP-43 antibody, 31D2, by direct ELISA to recombinant full length TDP-43 (●), Escherichia coli extract (▴) and BSA (▪).

FIG. 4D: is a graph of the EC₅₀ of human-derived TDP-43 antibody, 8F8, by direct ELISA to recombinant full length TDP-43 (●), Escherichia coli extract (▴) and BSA (▪).

FIG. 4E: is a graph of the EC₅₀ of human-derived TDP-43 antibody, 41D1, by direct ELISA to a synthetic peptide covering residues 390 to 414 of the C-terminal domain of TDP-43 with phosphorylation modification at residues 409/410 (●) and BSA (▪).

FIG. 4F: is a graph of the EC₅₀ of human-derived TDP-43 antibody, 21G1, by direct ELISA to a synthetic peptide covering residues 390 to 414 of the C-terminal domain of TDP-43 with phosphorylation modification at residues 409/410 (●) and BSA (▪).

FIG. 4G: is a graph of the EC₅₀ of human-derived TDP-43 antibody, 31D2, by direct ELISA to a synthetic peptide covering residues 390 to 414 of the C-terminal domain of TDP-43 with phosphorylation modification at residues 409/410 (●) and BSA (▪).

FIG. 4H: is a graph of the EC₅₀ of human-derived TDP-43 antibody, 8F8, by direct ELISA to a synthetic peptide covering residues 390 to 414 of the C-terminal domain of TDP-43 with phosphorylation modification at residues 409/410 (●) and BSA (▪).

FIG. 5A: is a bar graph depicting the binding specificity of the human-derived antibody, 41D1, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5B: is a bar graph depicting the binding specificity of the human-derived antibody, 1A9, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5C: is a bar graph depicting the binding specificity of the human-derived antibody, 14W3, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5D: is a bar graph depicting the binding specificity of the human-derived antibody, 98H6, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5E: is a bar graph depicting the binding specificity of the human-derived antibody, 44B2, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5F: is a bar graph depicting the binding specificity of the human-derived antibody, 9E12A, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5G: is a bar graph depicting the binding specificity of the human-derived antibody, 10D3, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5H: is a bar graph depicting the binding specificity of the human-derived antibody, 38H2, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5I: is a bar graph depicting the binding specificity of the human-derived antibody, 29E11, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5J: is a bar graph depicting the binding specificity of the human-derived antibody, 9E12D, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5K: is a bar graph depicting the binding specificity of the human-derived antibody, 31C11, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5L: is a bar graph depicting the binding specificity of the human-derived antibody, 10H7, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 5M: is a bar graph depicting the binding specificity of the human-derived antibody, 8C10, to TDP-43 domains comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and 2-414 (full length) of TDP-43 as determined by direct ELISA.

FIG. 6A: is an immunoblot showing the binding of the human-derived antibody, 41D1, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6B: is an immunoblot showing the binding of the human-derived antibody, 51C1, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6C: is an immunoblot showing the binding of the human-derived antibody, 21G2, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6D: is an immunoblot showing the binding of the human-derived antibody, 1A9, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6E: is an immunoblot showing the binding of the human-derived antibody, 3F10, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6F: is an immunoblot showing the binding of the human-derived antibody, 14W3, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6G: is an immunoblot showing the binding of the human-derived antibody, 98H6, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6H: is an immunoblot showing the binding of the human-derived antibody, 8A2, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6I: is an immunoblot showing the binding of the human-derived antibody, 15F12, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6J: is an immunoblot showing the binding of the human-derived antibody, 10D3, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6K: is an immunoblot showing the binding of the human-derived antibody, 31C11, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6L: is an immunoblot showing the binding of the human-derived antibody, 10H7, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6M: is an immunoblot showing the binding of the human-derived antibody, 21G1, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6N: is an immunoblot showing the binding of the human-derived antibody, 68G5, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6O: is an immunoblot showing the binding of the human-derived antibody, 20A1, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6P: is an immunoblot showing the binding of the antibody, Abnova 23435, to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 6Q: is an immunoblot showing the binding of the anti-human aIgG Fcγ antibody to TDP-43 domains comprising amino acids 2-414 (full length), 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), and 258-414 (domain IV) of TDP-43 as determined by Western Blot analysis.

FIG. 7A: is a bar graph showing NI-205.41D1 antibody binding to full length TDP-43 and TDP-43 fragments comprising amino acid residues 258-414, 258-384, 258-375, 258-362, 258-353, 258-319, 317-414 and 340-414.

FIG. 7B: is a bar graph showing NI-205.41D1 and 12892-1-AP antibody binding to full length TDP-43, TDP-43 fragment comprising amino acid residues 258-414, and to a mutant TDP-43 polypeptide fragment comprising amino acid residues 258-414 and the A to G substitution at residue 321, M to G substitution at residue 322, and M to G substitution at residue 323 (TDP-43 258-414 AMM321GGG).

FIG. 7C: is a bar graph showing NI-205.41D1 antibody binding to TDP-43 fragments comprising amino acid residues 316-353, 316-343, and 316-333.

FIG. 8A: is an image of a Coomassie stained SDS-PAGE gel of purified TDP-43 forms in the presence or absence of chaotrope KSCN. Lane 1 to 4, respectively: Molecular Weight standards, 6× His-TDP-43 (1-414), 6× His-SUMO-TDP-43 (1-414), 6His-SUMO-TDP-43 (220-414), all purified in the presence of 1.5M KSCN, and lane 5 and 6: 6× His-SUMO-TDP-43 (101-265) purified in the presence of KCl (lane 5) or KSCN (lane 6)

FIG. 8B: is a schematic diagram of the domain arrangement of purified proteins illustrating location of RNA binding domains (RRM1 and RRM2) as well as tags (6His and SUMO).

FIG. 8C: provides graphical depictions of analytical ultracentrifugation sedimentation coefficient distributions for purified 6His-SUMO and 6His tagged full-length TDP-43. Sedimentation coefficients and calculated molecular weights are shown above peaks.

FIG. 9A: is a graphical depiction of full-length TDP-43 binding to specific ((UG)₆) or control ((UU)₆) RNA in buffer containing 40 mM HEPES, 0.5 M KCl, 0.4 M Arginine, pH 7.4.

FIG. 9B: is a graphical depiction of RNA binding by TDP-43 (101-265) in the presence of a physiological buffer containing 20 mM HEPES, 80 mM potassium glutamate, 4 mM magnesium acetate, 5% glycerol, pH 7.5, 2 mM DTT, to determine K_(d).

FIG. 9C: is a graphical depiction of RNA binding by TDP-43 (101-265) in the presence of a physiological buffer containing 20 mM HEPES, 80 mM potassium glutamate, 4 mM magnesium acetate, 5% glycerol, pH 7.5, 2 mM DTT, to determine stoichiometry when purified in non-chaotropic conditions.

FIG. 9D: is a graphical depiction of RNA binding by TDP-43 (101-265) in the presence of a physiological buffer containing 20 mM HEPES, 80 mM potassium glutamate, 4 mM magnesium acetate, 5% glycerol, pH 7.5, 2 mM DTT, to determine stoichiometry when purified in mild chaotropic conditions.

FIG. 10A: is a graphical depiction of titration curves for human NI-205.41D1, NI-205.21G1, NI-205.51C1, NI-205.21G2, and NI-205.3F10 antibody binding to folded full-length TDP-43.

FIG. 10B: is a graphical depiction of titration curves for human NI-205.41D1, NI-205.21G1, NI-205.51C1, NI-205.21G2, and NI-205.3F10 antibody binding to TDP-43 fragment comprising residues 220-414 in a capture ELISA assay.

FIG. 11A: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibodies 2E2-D3.

FIG. 11B: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibodies 2E2-D3.

FIG. 11C: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibodies 2E2-D3.

FIG. 11D: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with control antibody p403/p404.

FIG. 11E: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with control antibody p403/p404.

FIG. 11F: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with control antibody p403/p404.

FIG. 11G: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with control antibody p409/p410.

FIG. 11H: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with control antibody p409/p410.

FIG. 11I: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with control antibody p409/p410.

FIG. 11J: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.10D3.

FIG. 11K: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.8C10.

FIG. 11L: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.15F12.

FIG. 11M: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.8A2.

FIG. 11N: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.3F10.

FIG. 11O: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.21G2.

FIG. 11P: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.8F8.

FIG. 11Q: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.31C11.

FIG. 11R: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.36D5.

FIG. 11S: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.31D2.

FIG. 11T: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.10H7.

FIG. 11U: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.14H5.

FIG. 11V: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.68G5.

FIG. 11W: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.14W3.

FIG. 11X: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.21G1.

FIG. 11Y: is an image of immunohistochemical staining of human FTLD-U hippocampus tissue with antibody NI-205.41D1.

FIG. 11Z: is an image of immunohistochemical staining of control hippocampus tissue with NI-205.41D1.

DETAILED DESCRIPTION OF THE INVENTION I. Definitions

As used herein, the phrase “neurodegenerative diseases” refers to presence of abnormal protein accumulation, cellular localization, or protein folding in the brain, spinal cord, or other neural tissue and are caused by the death or functional impairment of neurons. In some cases of neurodegenerative diseases, genetically defined abnormalities contribute to the development of the disease. Neurodegenerative diseases include for example, cerebral degenerative disease (e.g., Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, and Huntington's disease) and spinal degenerative diseases/motor neuron degenerative diseases e.g., amyotrophic lateral sclerosis and spinal muscular atrophy; see, e.g., Forman et al. Nat. Med. 10 (2004), 1055-63.

“TDP-43 proteinopathy” relates to the nervous system diseases, in particular to neurodegenerative diseases and are known as a heterologous group of disorders linked by the TAR (Transactivation responsive)-DNA-binding protein of 43 kDa. TDP-43 proteinopathies are characterized by the fact that TDP-43 is a disease protein that mechanistically links frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) with and without motor neuron disease to amyotrophic lateral sclerosis (ALS) argyrophilic grain disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ALS-Parkinsonism dementia complex of Guam, corticobasal degeneration, Dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration (FTLD), frontotemporal dementia, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, Parkinson's disease dementia, Parkinson-dementia complex in Kii peninsula, Pick's disease, Machado-Joseph disease and the like; see e.g., Lagier-Tourenne et al., Hum. Mol. Gen. 19 (2010), R46-64, which is herein incorporated by reference in its entirety.

Under normal physiological conditions, TDP-43 predominantly localizes to the nucleus. However, a substantial loss of nuclear TDP-43 is observed in neurons bearing aberrant cytoplasmic TDP-43 inclusions. TDP-43 exhibits a disease-specific biochemical signature; pathologically altered TDP-43. TDP-43 proteinopathies are distinct from most other neurodegenerative disorders in which protein misfolding leads to brain amyloidosis, as pathologic TDP-43 forms neuronal and glial inclusions lacking the features of brain amyloid deposits; see e.g., Neumann et al., Arch Neurol. 64 (2007), 1388-1394, herein incorporated by reference in its entirety.

As used herein, the term “pathologic TDP-43” refers to extracellular, cytoplasmic, neuritic, and nuclear inclusions, is also referred to as a “TDP-43 inclusion body” wherein the protein forms fibril-like clumps. Specifically, pathologic TDP-43 has been found to be hyperphosphorylated, ubiquitinated, and N-terminally truncated, thereby generating abnormal species of TDP-43 that migrate with a higher molecular mass at approximately 45 kDa, as well as a smear of high-molecular-mass proteins and C-terminal fragments of approximately 25 kDa; see, e.g., Neumann et al., Science 314 (2006), 130-133 and Arai et al., Biochem. Biophys. Res. Commun. 351 (2006), 602-611, each of which is herein incorporated by reference in its entirety. Additionally, TDP-43 has been found to exhibit multiple phosphorylation sites in carboxyl-terminal regions of deposited TDP-43 and it is suggested that phosphorylation leads to increased oligomerization and fibrillization of TDP-43; see, for example, Hasegawa et al., Annals of Neurology 64 (2008), 60-70.

TDP-43 inclusion body formation is accompanied by change in the subcellular distribution of TDP-43 with complete lack of normal diffuse nuclear TDP-43 staining in inclusion-bearing cells. The presence and extent of this pathologic signature in affected cortical gray and white matter, as well as the spinal cord, roughly correspond with the density of TDP-43-positive inclusions; see, e.g., Neumann et al., J. Neuropath. Exp. Neurol. 66 (2007), 177-183. The composition of the ubiquitinated inclusions (UBIs) in FTLD-U is characterized by a relative low abundance, uneven distribution of UBIs among different FTLD-U cases, and the non-amyloidogenic nature of them. Thus, TDP-43 is a specific and sensitive marker to detect the characteristic ubiquitin-immunoreactive lesions in FTLD-U, including neuronal cytoplasmic inclusions (NCIs), dystrophic neurites, and neuronal intranuclear inclusions (NIIs).

As used herein, the terms “TARDBP,” “Transactivation responsive-DNA binding protein of 43 kDa”, “Transactive responsive-DNA binding protein of 43 kDa”, “TAR-DNA binding protein of 43 kDA” and “TDP-43” are used interchangeably to refer to the native form of TDP-43. The term “TDP-43” is also used to refer collectively to all types and forms of TDP-43. “TDP-43” is also used to generally identify other conformers of TDP-43, including for example, phosphorylated forms of TDP-43 and ubiquitin-associated aggregates or aggregates of TDP-43.

The amino acid sequence of human TDP-43 is known in the art; see, e.g., Strausberg et al., TARDBP protein (Homo sapiens) GenBank Pubmed: AAH71657 version GI:47939520 herein incorporated by reference in its entirety. According to one embodiment, the amino acid sequence of native human TDP-43 is:

(SEQ ID NO: 94) MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQC MRGVRLVEGILHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAV QKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFV RFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTE DMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLII KGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLG NNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPS GNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGG FGSSMDSKSSGWGM

As used herein, the term “antibody” or “antibodies” is meant to refer to complete, intact antibodies, and Fab, Fab′, F(ab)₂, and other antibody fragments. Complete, intact antibodies include, but are not limited to, monoclonal antibodies such as murine monoclonal antibodies, polyclonal antibodies, chimeric antibodies, human antibodies, and humanized antibodies. Various forms of antibodies can be produced using standard recombinant DNA techniques (Winter and Milstein, Nature 349 (1991), 293-99. For example, “chimeric” antibodies can be constructed, in which the antigen binding domain from an animal antibody is linked to a human constant domain (an antibody derived initially from a nonhuman mammal in which recombinant DNA technology has been used to replace all or part of the hinge and constant regions of the heavy chain and/or the constant region of the light chain, with corresponding regions from a human immunoglobulin light chain or heavy chain) (see, e.g., U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. 81 (1984), 6851-6855. Chimeric antibodies reduce the immunogenic responses elicited by animal antibodies when used in human clinical treatments.

In addition, recombinant “humanized” antibodies can be synthesized. Humanized antibodies are antibodies initially derived from a nonhuman mammal in which recombinant DNA technology has been used to substitute some or all of the amino acids not required for antigen binding with amino acids from corresponding regions of a human immunoglobulin light or heavy chain. That is, they are chimeras comprising mostly human immunoglobulin sequences into which the regions responsible for specific antigen-binding have been inserted (see, e.g., International Patent Application Publication No. WO 94/04679). Animals are immunized with the desired antigen, the corresponding antibodies are isolated and the portions of the variable region sequences responsible for specific antigen binding are removed. The animal-derived antigen binding regions are then cloned into the appropriate position of the human antibody genes in which the antigen binding regions have been deleted. Humanized antibodies minimize the use of heterologous (inter-species) sequences in antibodies for use in human therapies, and are less likely to elicit unwanted immune responses. Primatized antibodies can be produced similarly.

Additional embodiments of the invention relate to human antibodies as well as the uses of these human antibodies. In one embodiment, the human antibodies are derived from human B cells or other immune cells and are generally referred to herein as “completely human antibodies.” Thus, the invention encompasses the immortalized human B memory lymphocyte and B cell, respectively, that produces the antibody having the distinct and unique characteristics as defined below. Alternatively, human antibodies can be produced in nonhuman animals, such as transgenic animals harboring one or more human immunoglobulin transgenes. Such animals can be used as a source for splenocytes for producing hybridomas, as is described in U.S. Pat. No. 5,569,825.

The antigen-binding fragments of antibodies of the invention can be a single chain Fv fragment, an F(ab′) fragment, an F(ab) fragment, and an F(ab′)₂ fragment. In additional embodiments, the antigen-binding fragment is a TDP-43-binding fragment that recognizes TDP-43 by one or more antibody variable domains, or fragments or variants thereto, such as, one or more CDRs or a derivative) of one or more CDS. In a specific embodiment, infra, the antibody or fragment thereof is a human IgG isotype antibody. Alternatively, the antibody is a chimeric human-murine or murinized antibody, the latter being particularly useful for diagnostic methods and studies in animals.

Antibody fragments, univalent antibodies, and single domain antibodies can also be used in the methods and compositions of the invention. Univalent antibodies comprise a heavy chain/light chain dimer bound to the Fc (or stem) region of a second heavy chain. “Fab region” refers to those portions of the chains which are roughly equivalent, or analogous, to the sequences which comprise the Y branch portions of the heavy chain and to the light chain in its entirety, and which collectively (in aggregates) have been shown to exhibit antibody activity. A Fab protein includes aggregates of one heavy and one light chain (commonly known as Fab′), as well as tetramers which correspond to the two branch segments of the antibody Y, (commonly known as F(ab)₂), whether any of the above are covalently or non-covalently aggregated, so long as the aggregation is capable of specifically reacting with a particular antigen or antigen family.

The TDP-43 antibodies of the invention specifically bind TDP-43, epitopes of

TDP-43, and to various conformations of TDP-43 and epitopes thereof. For example, disclosed herein are antibodies that specifically bind native TDP-43, full-length and truncated TDP-43, and pathologic TDP-43. As used herein, reference to an antibody that “specifically binds”, “selectively binds”, or “preferentially binds” or even more generally “binds TDP-43” or “TDP-43 binding”, refers to an antibody that binds TDP-43 preferentially over other distinct proteins. As used herein, an antibody that “specifically binds” or “selectively binds” an TDP-43 conformer does not bind at least one other TDP-43 conformer. For example, disclosed herein are antibodies that selectively bind full-length TDP-43 as well as those that selectively bind cytoplasmic TDP-43 over nuclear TDP-43.

It is to be noted that the term “a” or “an” entity refers to one or more of that entity;

for example, “an antibody,” is understood to represent one or more antibodies. As such, the terms “a” (or “an”), “one or more,” and “at least one” can be used interchangeably herein.

As used herein, the term “polypeptide” is used interchangeably with the term “polypeptide” and encompasses a singular polypeptide/protein as well as plural polypeptides/proteins and refers to any chain or chains of two or more amino acids, and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, “protein,” “amino acid chain,” or any other term used to refer to a chain or chains of two or more amino acids, are included within the definition of “polypeptide,” and the terms “polypeptide” is used instead of, or interchangeably with any of these terms.

As used herein, the terms “polypeptide” and “protein” also refer to products of post-expression modifications of the polypeptide, including without limitation glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids or other chemical moieties. A polypeptide can be derived from a natural biological source or produced by recombinant technology, but need not necessarily be translated from a particular nucleic acid sequence. Polypeptides of the invention can be generated in any manner, including by chemical synthesis.

A polypeptide of the invention can be of a size of about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more amino acids. Polypeptides can have a defined three-dimensional structure, although they do not necessarily have such structure. Polypeptides with a defined three-dimensional structure can be referred to herein as folded, and polypeptides which do not possess a defined three-dimensional structure, but rather can adopt a large number of different conformations, and may be referred to herein as unfolded. As used herein, the term glycoprotein refers to a polypeptide coupled to at least one carbohydrate moiety that is attached to the protein via an oxygen-containing or a nitrogen-containing side chain of an amino acid residue, e.g., a serine residue or an asparagine residue.

As used herein, an “isolated” polypeptide or a fragment, variant, or derivative thereof, refers to a polypeptide that is not in its natural milieu. No particular level of purification is required. For example, an isolated polypeptide can be removed from its native or natural environment. Recombinantly produced polypeptides and proteins expressed in host cells can be considered isolated for the purposes of the invention, as are native or recombinant polypeptides which have been separated, fractionated, or partially or substantially purified by any suitable technique.

Also included as polypeptides of the invention are fragments, derivatives, analogs, or variants of the foregoing polypeptides, and any combination thereof. The terms “fragment,” “variant,” “derivative” and “analog” when referring to antibodies or TDP-43 binding polypeptides of the invention include any polypeptides which retain at least some of the antigen-binding properties of the corresponding reference antibody or TDP-43 binding molecule. Fragments of TDP-43 binding polypeptides such as antigen binding antibody fragments, include proteolytic fragments, as well as deletion fragments, in addition to additional antibody fragments discussed herein. Variants of TDP-43 binding molecule, such as antibodies (including antigen binding antibody fragments) and also polypeptides with altered amino acid sequences due to amino acid substitutions, deletions, or insertions. Variants can occur naturally or be non-naturally occurring. Non-naturally occurring variants can be produced using art-known mutagenesis techniques. Variant polypeptides can comprise conservative or non-conservative amino acid substitutions, deletions or additions. Derivatives of TDP-43 specific binding molecules, e.g., antibodies and other TDP-43 specific binding molecules, are polypeptides which have been altered so as to exhibit altered or additional features not found on a reference polypeptide. Examples of derivatives of TDP-43 specific binding molecules include fusion proteins. Variant polypeptides can also be referred to herein as “polypeptide analogs”. As used herein, a “derivative” of a of TDP-43 specific binding molecules or fragment thereof, refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group. Also included as “derivatives” are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For example, according to some embodiments, 4-hydroxyproline can be substituted for proline; 5-hydroxylysine can be substituted for lysine; 3-methylhistidine can be substituted for histidine; homoserine can be substituted for serine; or ornithine can be substituted for lysine.

As used herein, the term “polynucleotide” or “nucleic acid” encompasses a singular nucleic acid as well as plural nucleic acids, and includes an isolated nucleic acid molecule or construct, e.g., messenger RNA (mRNA) or plasmid DNA (pDNA). A polynucleotide can comprise a conventional phosphodiester bond or a non-conventional bond (e.g., an amide bond, such as found in peptide nucleic acids (PNA)).

The term “polynucloetide acid” can also refer to any one or more nucleic acid segments, e.g., DNA or RNA fragments, present in a polynucleotide. By “isolated” nucleic acid or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, a recombinant polynucleotide encoding an antibody heavy or light chain variable domain contained in a vector is considered isolated for the purposes of the invention. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of polynucleotides of the invention. Isolated polynucleotides or nucleic acids according to the invention further include such molecules produced synthetically. In addition, polynucleotide or a nucleic acid can be or can include a regulatory element such as a promoter, ribosome binding site, or a transcription terminator operably associated with a sequence encoding a TDP-43 specific binding polypeptide of the invention.

As used herein, a “coding region” is a portion of nucleic acid which consists of codons translated into amino acids. Although a “stop codon” (TAG, TGA, or TAA) is not translated into an amino acid, it can be considered to be part of a coding region, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, and the like, are not part of a coding region. Two or more coding regions of the invention can be present in a single polynucleotide construct, e.g., on a single vector, or in separate polynucleotide constructs, e.g., on separate (different) vectors. Furthermore, any vector can contain a single coding region, or can comprise two or more coding regions, e.g., a single vector can separately encode an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region. In addition, a vector including a nucleic acid of the invention can optionally encode one or more heterologous coding regions, either fused or unfused to a nucleic acid encoding a TDP-43 binding polypeptide, including for example, an antibody or a fragment, variant, or derivative thereof. Heterologous coding regions include without limitation specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain.

In certain embodiments, the polynucleotide or nucleic acid of the invention is

DNA. A polynucleotide comprising a nucleic acid which encodes a polypeptide optionally includes a promoter and/or other transcription or translation control elements operably associated with one or more coding regions. An operable association is present when a coding region for a gene product, e.g., a polypeptide, is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s). Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are “operably associated” or “operably linked” if induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the linkage between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to direct the expression of the gene product or prevent with the ability of the DNA template to be transcribed. Thus, a promoter region can be operably associated with a nucleic acid encoding a polypeptide if the promoter is capable of effecting transcription of that nucleic acid. The promoter can be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells. The promoter can also be constitutive or regulatable. Other transcription control elements that are optionally operably linked with the nucleic acids of the invention include for example, enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription. Examples of suitable promoters and other transcription control regions are disclosed herein or otherwise known in the art.

A variety of transcription control regions that can be used to control the expression of the polynucleotides of the invention are known in the art. These include, without limitation, transcription control regions which function in vertebrate cells, including but not limited to, promoter and enhancer segments from cytomegaloviruses (the immediate early promoter, in conjunction with intron-A), simian virus 40 (the early promoter), and retroviruses (such as Rous sarcoma virus). Other transcription control regions include but are not limed to, those derived from vertebrate genes such as, actin, heat shock protein, bovine growth hormone and rabbit β-globin, as well as other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers as well as lymphokine-inducible promoters (e.g., promoters inducible by interferons or interleukins).

Similarly, a variety of suitable translation control elements are known to those of ordinary skill in the art. These include, but are not limited to, ribosome binding sites, translation initiation and termination codons, and elements derived from picornaviruses (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence).

In other embodiments, a polynucleotide or nucleic acid of the invention is RNA, for example, in the form of messenger RNA (mRNA).

Polynucleotide and nucleic acid coding sequences of the invention can be associated with additional heterologous coding sequences which encode for example, secretory or signal peptides, which direct the secretion of a polypeptide encoded by a polynucleotide of the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Those of ordinary skill in the art are aware that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the “full length” polypeptide to produce a secreted or “mature” form of the polypeptide. In certain embodiments, the native signal peptide, e.g., an immunoglobulin heavy chain or light chain signal peptide is used, or a functional derivative of that sequence that retains the ability to direct the secretion of a polypeptide to which it is operably associated. Alternatively, a heterologous mammalian signal peptide, or a functional derivative thereof, can be used. For example, the native signal peptide sequence can be substituted with the signal peptide sequence of human tissue plasminogen activator (TPA), mouse β-glucuronidase, or a signal sequence derived from a secreted protein of a preferred host cell.

Unless stated otherwise, the terms “disorder” and “disease” are used interchangeably herein.

A “binding molecule” as used herein relates primarily to antibodies (including

TDP-43 binding antibody fragments or derivatives), but can also refer to other proteins and polypeptides that specifically recognize TDP-43 including, but not limited to, hormones, receptors, ligands, major histocompatibility complex (MHC) molecules, chaperones such as heat shock proteins (HSPs), and cell-cell adhesion molecules such as, members of the cadherin, intergrin, C-type lectin and immunoglobulin (Ig) superfamilies. Fragments, variants, and derivatives of these polypeptides that specifically recognize TDP-43 are also encompassed by the invention. For the sake of clarity only and without restricting the scope of the invention most of the following embodiments are discussed with respect to antibodies (including antibody fragments and derivatives) which represent one embodiment of the molecules and compositions of the invention that specifically recognize TDP-43.

The terms “antibody” and “immunoglobulin” are used interchangeably herein. An antibody or immunoglobulin is an TDP-43-binding molecule which comprises at least the variable domain of a heavy chain, and normally comprises at least the variable domains of a heavy chain and a light chain. Basic immunoglobulin structures in vertebrate systems are well understood; see, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988). As will be discussed in more detail below, the term “immunoglobulin” comprises various broad classes of polypeptides that can be distinguished biochemically. As generally understood in the art, heavy chains are classified as gamma, mu, alpha, delta, or epsilon, (γ, μ, α, δ, ε) with some subclasses among them (e.g., γ1-γ4). It is the nature of this chain that determines the “class” of the antibody as IgG, IgM, IgA, IgG, or IgE, respectively. The immunoglobulin subclasses (isotypes) e.g., IgG1, IgG2, IgG3, IgG4, IgA1, etc. are well characterized and are known to confer functional specialization that can be incorporated or modified in the antibodies of the invention to modify functional or other properties of these antibodies. Modified versions of antibody classes and isotypes of the invention are readily discernible to person of ordinary skill in the art in view of the disclosure and are within the scope of the invention. Additionally while all immunoglobulin classes are encompassed by the scope of the invention, for brevity and exemplary purposes, the following discussion is generally directed to the IgG class of immunoglobulin molecules. With regard to IgG, a standard immunoglobulin molecule comprises two identical light chain polypeptides of molecular weight approximately 23,000 Daltons, and two identical heavy chain polypeptides of molecular weight 53,000-70,000 Daltons. The four chains are typically joined by disulfide bonds in a “Y” configuration wherein the light chains bracket the heavy chains starting at the mouth of the “Y” and continuing through the variable region.

Light chain polypeptides are classified as either kappa or lambda (κ, λ). Each heavy chain polypeptide class can be bound with either a kappa or lambda light chain. In general, the light and heavy chain polypeptides are covalently bonded to each other, and the “tail” portions of the two heavy chain polypeptides are bonded to each other by covalent disulfide linkages or non-covalent linkages when the immunoglobulins are generated either by hybridomas, B cells or genetically engineered host cells. In the heavy chain polypeptide, the amino acid sequences run from the N-terminus at the forked ends of the Y configuration to the C-terminus at the bottom of each heavy chain polypeptide.

Both the light and heavy chain polypeptides contain regions of structural and functional homology. The terms “constant” and “variable” are used functionally. In this regard, it will be appreciated that the variable domains of both the light (V_(L)) and heavy (V_(H)) chain regions determine antigen recognition and specificity. Conversely, the constant domains of the light chain (CL) and the heavy chain (CH1, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, and the like. By convention the numbering of the constant region domains increases as they become more distal from the antigen-binding site or amino-terminus of the antibody. The N-terminal portion of the heavy and light chain polypeptides is a variable region and at the C-terminal portion is a constant region; the CH3 and CL domains actually comprise the carboxy-terminus of the heavy and light chain, respectively.

As indicated above, the variable region allows the antibody to selectively recognize and specifically bind epitopes on antigens. That is, the V_(L) domain and V_(H) domain, or subset of the complementarity determining regions (CDRs), of an antibody combine to form the variable region that defines a three dimensional antigen-binding site. This quaternary antibody structure forms the antigen-binding site present at the end of each arm of the Y structure of the antibody. The antigen-binding site of a complete antibody is defined by three CDRs on each of the V_(H) and V_(L) chains. Any antibody (including antibody fragments, derivatives, and variants) which contains sufficient immunoglobulin related structure so as to allow it to specifically bind to TDP-43 is referred to herein interchangeably as a “binding fragment” or “immunospecific fragment,” and can generally be referred to as antibody that specifically recognizes TDP-43.

In naturally occurring antibodies, an antibody comprises six hypervariable regions that are often referred to as “complementarity determining regions” or “CDRs” present in each antigen-binding domain. CDRs are short, non-contiguous sequences of amino acids that form the antigen-binding domain as the antibody assumes its three dimensional configuration in an aqueous environment. The “CDRs” are flanked by four relatively conserved “framework” regions or “FRs” which show less inter-molecular sequence variability than the CDRs. The framework regions largely adopt a n-sheet conformation and the CDRs form loops which connect, and in some cases form part of, the n-sheet structure. Thus, the framework regions act to form a scaffold that provides for positioning the CDRs in correct orientation by inter-chain, non-covalent interactions. The antigen-binding domain formed by the collectively positioned heavy and light chain CDRs defines a surface complementary to the epitope on the immunoreactive antigen. This complementary surface promotes the non-covalent binding of the antibody to its cognate epitope. The amino acids comprising the CDRs and the framework regions, respectively, can be readily identified and defined for any given heavy or light chain variable region using methods known in the art; see, “Sequences of Proteins of Immunological Interest,” Kabat, E., et al., U.S. Department of Health and Human Services, (1983); and Chothia and Lesk, J. Mol. Biol., 196 (1987), 901-917, which are herein incorporated by reference in their entireties.

In the case where there are two or more definitions of a term which is used and/or accepted within the art, the definition of the term as used herein is intended to include all such meanings unless explicitly stated to the contrary. A specific example is the use of the term “complementarity determining region” (“CDR”) to describe the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. This particular region has been described by Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983) and by Chothia and Lesk, J. Mol. Biol., 196 (1987), 901-917, which are herein incorporated by reference in their entireties, where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term CDR as used herein. The appropriate amino acid residues which encompass the CDRs as defined in each of the above cited references are set forth in FIG. 1. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. A person of ordinary skill in the art provided with the variable region sequence of an antibody can routinely determine which residues comprise a particular hypervariable region or CDR of a human IgG antibody.

TABLE 1 CDR Definitions¹ Kabat Chothia VH CDR1 31-35 26-32 VH CDR2 50-65 52-58 VH CDR3  95-102  95-102 VL CDR1 24-34 26-32 VL CDR2 50-56 50-52 VL CDR3 89-97 91-96 ¹Numbering of all CDR definitions in Table 2 is according to the numbering conventions set forth by Kabat et al., (see below).

Kabat et al., also defined a numbering system for variable domain sequences that is applicable to any antibody. One of ordinary skill in the art can unambiguously assign this system of “Kabat numbering” to any variable domain sequence, without reliance on any experimental data beyond the sequence itself. As used herein, “Kabat numbering” refers to the numbering system set forth by Kabat et al., U.S. Dept. of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983). Unless otherwise specified, references to the numbering of specific amino acid residue positions in an antibody or antigen-binding fragment, variant, or derivative thereof of the invention are according to the Kabat numbering system, which, however, is theoretical and may not equally apply to every antibody of the invention. For example, depending on the position of the first CDR (i.e., CDR1), the following CDRs might be shifted in either direction.

In some embodiments, an antibody of the invention is a monoclonal antibody. In additional embodiments, an antibody of the invention is not a polyclonal antibody. According to some embodiments, an antibody of the invention is a bivalent, or multispecific antibody. In other embodiments, an antibody of the invention is a polyclonal antibody. In further embodiments, the compositions of the invention contain monoclonal antibodies. In additional embodiments, the compositions of the invention do not contain a polyclonal antibody.

In additional embodiments, the antibody is human (e.g., a fully human and/or completely human antibody), humanized, primatized, murinized or a chimeric antibody. In further embodiments, an antibody of the invention is a single chain antibody, epitope-binding fragment, e.g., Fab, Fab′ and F(ab′)₂, Fd, Fv single-chain Fv (scFv), single-chain antibody, disulfide-linked Fv (sdFv), a fragment comprising either a V_(L) or V_(H) domain, a fragment produced by a Fab expression library, or an anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies containing a variable domain sequence provided in FIG. 1, and other antibodies disclosed herein). ScFv molecules are known in the art and are described, e.g., in U.S. Pat. No. 5,892,019. Antibodies of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

In some embodiments, antibodies of the invention are IgG1. In other embodiments, antibodies of the invention are IgG3. In a further embodiment, the antibody of the invention is not IgM or a derivative thereof that contains a pentavalent structure. More particularly, in certain applications of the invention, especially those relating to therapeutic use, IgMs are less desirable than IgG and other bivalent antibodies or corresponding binding molecules since IgMs often show unspecific cross-reactivities and very low affinity as a consequence of their pentavalent structure and lack of affinity maturation.

In a particular embodiment, the antibody of the invention is not a polyclonal antibody, i.e., it substantially consists of one particular antibody species rather than being a mixture obtained from a plasma immunoglobulin sample.

According to one embodiment, an antibody of the invention is a “completely” human” monoclonal antibody that specifically recognizes human TDP-43 and that is isolated from a human. Compared to other human monoclonal antibodies, such as those derived from single chain antibody fragments (scFvs) identified using a phage display library or xenogeneic mice, completely human monoclonal antibodies of the invention are characterized by (i) being obtained using the human immune response rather than from animal surrogates, i.e. the antibody has been generated in response to native endogenous TDP-43 in its relevant conformation in the human body, (ii) having protected the individual or is at least significant for the presence of TDP-43, and (iii) having a reduced risks of self-reactivity against self-antigens due to the fact that the antibody is of human origin.

Thus, while the terms “completely human antibody,” or “human monoclonal autoantibody “encompasses the terms “human antibody,” “human monoclonal antibody,” and the like, these terms are used herein to denote a TDP-43 binding molecule which is of human origin, i.e. which has been derived from a human antibody producing cell such as a B cell or hybridoma thereof or a cell containing nucleic acids such as cDNA that is the cDNA of which has been directly cloned from or derived from a human antibody producing cell such as, a human memory B cell. An antibody is considered “completely human” for the purposes of this disclosure when the antibody contains one or more amino acid substitutions or other alterations of a completely human antibody, e.g., to improve binding characteristics. Optionally, the framework regions of the completely human antibody or other antibodies of the invention are or have been modified to conform with a human germ line variable region sequence or to conform with a portion of a human germ line variable region sequence, such as a sequence available for example, in Vbase (http://vbase.mrc-cpe.cam.ac.uk/) hosted by the MRC Centre for Protein Engineering (Cambridge, UK). Such modifications can be useful, inter alia, to reduce or eliminate germ line sequence deviations resulting from cloning artifacts, such as those that may result from PCR primers.

Antibodies derived from human immunoglobulin libraries or from animals transgenic for one or more human are generally referred to herein as human antibodies, or “human-like antibodies.” Such immunoglobulins do not correspond to endogenous human immunoglobulins, as described infra. See, e.g., U.S. Pat. No. 5,939,598). For example, the pairing of heavy and light chains of human-like antibodies such as synthetic and semi-synthetic antibodies typically isolated from phage display do not necessarily reflect the original pairing as it occurred in the original human B cell. Accordingly, Fab and scFv fragments obtained from recombinant expression libraries can be considered to be artificial and may display immunogenicity and stability effects as a result of their artificial composition. By contrast, completely human antibodies of the invention are isolated, affinity-matured antibodies from selected human subjects and the antibodies have been characterized by their tolerance in man.

As used herein, the term “murinized antibody” or “murinized immunoglobulin” refers to an antibody comprising one or more CDRs from a human antibody or other antibody of the invention; and for example a human framework region that contains amino acid substitutions and/or deletions and/or insertions that are based on a mouse antibody sequence. In this case, the human or other immunoglobulin providing the CDRs is called the “parent” or “acceptor” and the mouse antibody providing the framework changes is called the “donor.” Constant regions need not be present, but if they are, they are usually substantially identical to mouse antibody constant regions, i.e. at least about 85-90%, or at least about 95%, about 97%, about 98%, or about 99% or more identical to corresponding sequence of the mouse constant region. Hence, in some embodiments, a complete murinized human heavy or light chain immunoglobulin contains a mouse constant region, one or more human CDRs, and a substantially human framework that has a number of “murinizing” amino acid substitutions. Typically, a “murinized antibody” is an antibody comprising a murinized variable light chain and/or a murinized variable heavy chain. For example, a murinized antibody would not encompass a typical chimeric antibody, e.g., because the entire variable region of a chimeric antibody is non-mouse. A modified antibody that has been “murinized” by the process of “murinization” binds to the same antigen as the parent antibody that provides the CDRs and is usually less immunogenic in mice, as compared to the parent antibody.

As used herein, the term “heavy chain portion” includes amino acid sequences derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain portion comprises at least one of: a CH1 domain, a hinge (e.g., upper, middle, and/or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof. For example, a binding polypeptide of the invention can comprise a polypeptide containing a variable region(s) or portions of a variable region (e.g., one or more CDRs, such as the V_(H) CDR3), alone or in combination with a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, and a CH2 domain; a polypeptide chain comprising a CH1 domain and a CH3 domain; a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, and a CH3 domain, or a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, a CH2 domain, and a CH3 domain. In another embodiment, a polypeptide of the invention comprises a variable region(s) or portions of a variable region (e.g., one or more CDRs, such as, V_(H) CDR3) and a polypeptide chain comprising a CH3 domain. In a further embodiment, a polypeptide of the invention lacks at least a portion of a CH2 domain (e.g., all or part of a CH2 domain). As set forth herein, and as would be appreciated by one of ordinary skill in the art, the above heavy chain polypeptide domains (e.g., the heavy chain portions) can be modified such that they vary in amino acid sequence from the naturally occurring immunoglobulin molecule. Accordingly, the invention encompasses polypeptides comprising fragments, variants, and derivatives of the heavy chain portions of the invention.

According to some embodiments, the heavy chain portions of one polypeptide chain of an antibody (including antigen-binding fragments, variants, or derivatives thereof) are identical to those on a second polypeptide chain of the antibody. In alternative embodiments, the heavy chain portions of one polypeptide chain of an antibody (including antigen-binding fragments, variants, or derivatives thereof) are different from that on a second polypeptide chain of the antibody. Thus, each monomer component of an antibody of the invention can comprise a different target binding site, forming, for example, a bispecific antibody or diabody.

Antibody fragments of the invention, including single-chain antibodies, can comprise variable region(s) or portions of variable regions (e.g., one or more CDRs, such as, VH CDR3 or VL CDR3) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also encompassed by the invention are TDP-43-binding fragments that comprise any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. Antibodies (including immunospecific fragments thereof) of the invention can be derived from any animal origin including birds and mammals. In one embodiment, the antibodies are human, murine, donkey, rabbit, goat, guinea pig, camel, llama, horse, or chicken antibodies. In another embodiment, the variable region can be condricthoid in origin (e.g., from sharks).

In another embodiment, the antibodies disclosed herein are composed of a single polypeptide chain such as scFvs and are to be expressed intracellularly (intrabodies) for potential in vivo therapeutic and diagnostic applications.

The heavy chain portions or light chain portions of a binding polypeptide for use in the diagnostic and treatment methods disclosed herein can be derived from different immunoglobulin molecules. For example, a heavy chain portion of a polypeptide can comprise a CH1 domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule. In another example, a heavy chain portion can comprise a hinge region derived, in part, from an IgG1 molecule and, in part, from an IgG3 molecule. In another example, a heavy chain portion can comprise a chimeric hinge derived, in part, from an IgG1 molecule and, in part, from an IgG4 molecule.

As used herein, the term “light chain portion” includes amino acid sequences derived from an immunoglobulin light chain. In one embodiment, the light chain portion comprises at least one V_(L) or CL domain. As used herein, the term “light chain portion” includes amino acid sequences derived from an immunoglobulin light chain. A polypeptide comprising a light chain portion comprises at least a light chain variable region(s) or portions of a variable region (e.g., one or more CDRs, such as the VL CDR3). In some embodiments, the light chain portion includes a CH1 domain. In another embodiment, the light chain portion comprises at least one of a V_(L) or CL domain. Polypeptides comprising fragments, variants, and derivatives of these light chain portions are also encompassed by the invention.

The minimum size of a peptide or polypeptide epitope for an antibody is thought to be about four to five amino acids. Peptide or polypeptide epitopes can contain at least seven, at least nine, or between at least about 15 to about 30 amino acids. Since a CDR can recognize an antigenic peptide or polypeptide in its tertiary form, the amino acids comprising an epitope need not be contiguous, and in some cases, may not even be on the same peptide chain. According to one embodiment, a peptide or polypeptide epitope recognized by an antibody of the invention contains a sequence of at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25 contiguous or non-contiguous amino acids of TDP-43. In an additional embodiment, a peptide or polypeptide epitope recognized by an antibody of the invention contains between about 5 to about 30, about 10 to about 30, or 15 to about 30 contiguous or non-contiguous amino acids of TDP-43.

The terms “specifically binding” and “specifically recognizing” are used interchangeably herein and generally refer to a binding molecule (e.g., a polypeptide such as an antibody) that binds to an epitope or antigen more readily than it would bind to a random, unrelated epitope or antigen. As understood in the art, an antibody can specifically bind to, or specifically recognize an isolated polypeptide comprising, or consisting of, amino acid residues corresponding to a linear portion of a non-contiguous epitope. The term “specificity” is used herein to qualify the relative affinity by which a certain antibody binds to a certain epitope or antigen. For example, antibody “A” can be deemed to have a higher specificity for a given epitope than antibody “B,” or antibody “A” can be said to bind to epitope “C” with a higher specificity than it has for related epitope “D”. For example, antibody “A” can be deemed to have a higher specificity for a given epitope than antibody “B,” or antibody “A” can be said to bind to epitope “C” with a higher specificity than it has for related epitope “D.” Likewise, an antibody “A” can be deemed to have a higher specificity for a given antigen than antibody “B,” or antibody “A” can be said to bind to antigen “C” with a higher specificity than it has for related antigen “D.”

Where present, the term “immunological binding characteristics,” or other binding characteristics of an antibody with an antigen, in all of its grammatical forms, refers to the specificity, affinity, cross-reactivity, or other binding characteristics of an antibody.

By “preferentially binding”, it is meant that the binding molecule, e.g., antibody specifically binds to an epitope or antigen more readily than it would bind to a related, similar, homologous, or analogous epitope or antigen. Thus, an antibody which “preferentially binds” to a given epitope or antigen would more likely bind to that epitope or antigen than to a related epitope or antigen, even though such an antibody can cross-react with the related epitope or antigen.

By way of a non-limiting example, a binding molecule, e.g., an antibody can be considered to bind a first epitope or antigen preferentially if it binds said first epitope or antigen with a dissociation constant (K_(D)) that is less than the antibody's K_(D) for the second epitope or antigen. In another non-limiting example, an antibody can be considered to bind a first antigen preferentially if it binds the first epitope or antigen with an affinity that is at least one order of magnitude less than the antibody's K_(D) for the second epitope or antigen. In another non-limiting example, an antibody can be considered to bind a first epitope or antigen preferentially if it binds the first epitope or antigen with an affinity that is at least two orders of magnitude less than the antibody's K_(D) for the second epitope or antigen.

In another non-limiting example, a binding molecule, e.g., an antibody can be considered to bind a first epitope or antigen preferentially if it binds the first epitope or antigen with an off rate (k(off)) that is less than the antibody's k(off) for the second epitope or antigen. In another non-limiting example, an antibody can be considered to bind a first epitope or antigen preferentially if it binds the first epitope with an affinity that is at least one order of magnitude less than the antibody's k(off) for the second epitope or antigen. In another non-limiting example, an antibody can be considered to bind a first epitope or antigen preferentially if it binds the first epitope or antigen with an affinity that is at least two orders of magnitude less than the antibody's k(off) for the second epitope or antigen.

According to one embodiment, a TDP-43 binding molecule (e.g., an antibody, including an antigen-binding fragment or variant of an antibody or derivative thereof) binds TDP-43 or a fragment or variant thereof, with an off rate (k(off)) of less than or equal to 5×10⁻² sec⁻¹, 10⁻² sec⁻¹, 5×10⁻³ sec⁻¹ or 10⁻³ sec⁻¹. In another embodiment, a TDP-43 binding molecule binds TDP-43 or a fragment or variant thereof, with an off rate (k(off)) less than or equal to 5×10⁻⁴ sec⁻¹, 10⁻⁴ sec⁻¹, 5×10⁻⁵ sec⁻¹, or 10⁻⁵ sec⁻¹ 5×10⁻⁶ sec⁻¹, 10⁻⁶ sec⁻¹, 5×10⁻⁷ sec⁻¹ or 10⁻⁷ sec⁻¹.

According to another embodiment, a TDP-43 binding molecule (e.g., an antibody, including an antigen-binding fragment or variant of an antibody or derivative thereof) binds TDP-43 or a fragment or variant thereof, with an on rate (k(on)) of greater than or equal to 10³ M⁻¹ sec⁻¹, 5×10³ M⁻¹ sec⁻¹, 10⁴ M⁻¹ sec⁻¹ or 5×10⁴ M⁻¹ sec⁻¹. In an additional embodiment, a TDP-43 binding molecule of the invention binds TDP-43 or a fragment or variant thereof with an on rate (k(on)) greater than or equal to 10⁵ M⁻¹ sec⁻¹, 5×10⁵M⁻¹ sec⁻¹, 10⁶M⁻¹sec⁻¹, or 5×10⁶M⁻¹ sec⁻¹ or 10⁷M⁻¹ sec⁻¹.

The invention also encompasses a TDP-43 binding molecule that competes with one or more of the TDP-43 binding molecules of the invention for binding with TDP-43. For the purposes of this invention, a TDP-43 binding molecule (e.g., an antibody) is said to competitively inhibit binding of a reference TDP-43 binding molecule (e.g., antibody) to a given epitope or antigen if it preferentially binds to that epitope or antigen to the extent that it blocks, to some degree, binding of the reference antibody to the epitope or antigen. Competitive inhibition can be determined by any method known in the art, for example, competition ELISA assays. According to one embodiment, an a TDP-43 binding molecule (e.g., an antibody) competitively inhibits binding of a reference TDP-43 binding molecule (e.g., an antibody) to a given epitope or antigen by at least 90%, at least 80%, at least 70%, at least 60%, or at least 50%.

As used herein, the term “affinity” refers to a measure of the strength of the binding of an individual epitope or antigen with a TDP-43 binding molecule (e.g., an antibody, including fragments, variants, and derivatives thereof. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd ed. (1988) at pages 27-28. As used herein, the term “avidity” refers to the overall stability of the complex between a population of immunoglobulins and an antigen, that is, the functional combining strength of an immunoglobulin mixture with the antigen; see, e.g., Harlow at pages 29-34. Avidity is related to both the affinity of individual immunoglobulin molecules in the population with specific epitopes or antigens, and also the valencies of the immunoglobulins and the antigen. For example, the interaction between a bivalent monoclonal antibody and an antigen with a highly repeating epitope structure, such as a polymer, would be one of high avidity. The affinity or avidity of an antibody for an antigen can be determined experimentally using any suitable method; see, for example, Berzofsky et al., “Antibody-Antigen Interactions” In Fundamental Immunology, Paul, W. E., Ed., Raven Press New York, N.Y. (1984), Kuby, Janis Immunology, W. H. Freeman and Company New York, N.Y. (1992), and methods described herein. General techniques for measuring the affinity of an antibody for an antigen include ELISA, RIA, and surface plasmon resonance. The measured affinity of a particular antibody-antigen interaction can vary if measured under different conditions, e.g., salt concentration, pH. Thus, measurements of affinity and other antigen-binding parameters, e.g., K_(D), IC₅₀, are preferably made with standardized solutions of antibody and antigen, and a standardized buffer.

TDP-43 binding molecules (e.g., antibodies including antigen-binding fragments of antibodies and variants or derivatives thereof) of the invention are also described or specified in terms of their cross-reactivity. As used herein, the term “cross-reactivity” refers to the ability of an TDP-43 binding molecule (e.g., an antibody) specific for one antigen, to react with a second distinct antigen; a measure often reflective of the degree of relatedness between two different antigenic substances.

For example, certain antibodies have some degree of cross-reactivity, in that they bind related, but non-identical epitopes or antigens, e.g., epitopes with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods described herein or otherwise known in the art) to a reference epitope or antigen. An antibody can be deemed “highly specific” for a certain epitope, if it does not bind any other analog, ortholog, or homolog of that epitope or antigen. According to one embodiment TDP-43 binding molecules (e.g., antibodies including antigen-binding fragments of antibodies, and variants or derivatives thereof) do not bind epitopes with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods described herein or otherwise known in the art) to a reference epitope or antigen under physiological conditions.

TDP-43 binding molecules such as antibodies (including antigen-binding fragments of an antibody and variants or derivatives thereof) of the invention can also be described in terms of their binding affinity to TDP-43. According to one embodiment TDP-43 binding molecules (e.g., antibodies including antigen-binding fragments, variants or derivatives thereof) binding affinities include those with a dissociation constant or Kd of less than 5×10⁻² M, 10⁻²M, 5×10⁻³M, 10⁻³M, 5×10⁻⁴M, 10⁻⁴M, 5×10⁻⁵M, 10⁻⁵M, 5×10⁻⁶M, 10⁻⁶M, 5×10⁻⁷M, 10⁻⁷M, 5×10⁻⁸M, 10⁻⁸M, 5×10⁻⁹M, 10⁻⁹M, 5×10⁻¹⁰M, 10⁻¹⁰M, 5×10⁻¹¹M, 10⁻¹¹M, 5×10⁻¹²M, 10⁻¹²M, 5×10⁻¹³M, 10⁻¹³M, 5×10⁻¹⁴M, 10⁻¹⁴ M, 5×10⁻¹⁵M, or 10⁻¹⁵M.

The subunit structures and three dimensional configuration of the constant regions of the various immunoglobulin classes are well known. As used herein, the term “V_(H) domain” includes the amino terminal variable domain of an immunoglobulin heavy chain and the term “CH1 domain” includes the first (most amino terminal) constant region domain of an immunoglobulin heavy chain. The CH1 domain is adjacent to the V_(H) domain and is amino terminal to the hinge region of an immunoglobulin heavy chain molecule.

As used herein the term “CH2 domain” includes the portion of a heavy chain molecule that extends, e.g., from about residue 244 to residue 360 of an antibody using conventional numbering schemes (residues 244 to 360, Kabat numbering system; and residues 231-340, EU numbering system; see Kabat EA et al., op. cit). The CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG molecule. It is also well documented that the CH3 domain extends from the CH2 domain to the C-terminal of the IgG molecule and comprises approximately 108 residues.

As used herein, the term “hinge region” includes the portion of a heavy chain molecule that joins the CH1 domain to the CH2 domain. This hinge region comprises approximately 25 residues and is flexible, thus allowing the two N-terminal antigen-binding regions to move independently. Hinge regions can be subdivided into three distinct domains: upper, middle, and lower hinge domains; see Roux et al., J. Immunol. 161 (1998), 4083.

As used herein the term “disulfide bond” includes the covalent bond formed between two sulfur atoms. The amino acid cysteine comprises a thiol group that can form a disulfide bond or bridge with a second thiol group. In most naturally occurring IgG molecules, the CH1 and CL regions are linked by a disulfide bond and the two heavy chains are linked by two disulfide bonds at positions corresponding to 239 and 242 using the Kabat numbering system (position 226 or 229, EU numbering system).

As used herein, the terms “linked,” “fused” or “fusion” are used interchangeably.

These terms refer to the joining together of two more elements or components, by whatever means including chemical conjugation or recombinant means. An “in-frame fusion” refers to the joining of two or more polynucleotide open reading frames (ORFs) to form a continuous longer ORF, in a manner that maintains the correct translational reading frame of the original ORFs. Thus, a recombinant fusion protein is a single protein containing two or more segments that correspond to polypeptides encoded by the original ORFs (which segments are not normally so joined in nature). Although the reading frame is thus made continuous throughout the fused segments, the segments can be physically or spatially separated by, for example, in-frame linker sequence. For example, polynucleotides encoding the CDRs of an immunoglobulin variable region can be fused, in-frame, but be separated by a polynucleotide encoding at least one immunoglobulin framework region or additional CDR regions, as long as the “fused” CDRs are co-translated as part of a continuous polypeptide.

The term “expression” as used herein refers to a process by which a gene produces a biochemical, for example, an RNA or polypeptide. The process includes any manifestation of the functional presence of the gene within the cell including, without limitation, gene knockdown as well as both transient expression and stable expression. It includes without limitation transcription of the gene into messenger RNA (mRNA), transfer RNA (tRNA), small hairpin RNA (shRNA), small interfering RNA (siRNA) or any other RNA product, and the translation of such mRNA into polypeptide(s). If the final desired product is a biochemical, expression includes the creation of that biochemical and any precursors. Expression of a gene produces a “gene product.” As used herein, a gene product can be either a nucleic acid, e.g., a messenger RNA produced by transcription of a gene, or a polypeptide which is translated from a transcript. Gene products described herein further include nucleic acids with post transcriptional modifications, e.g., polyadenylation, or polypeptides with post translational modifications, e.g., methylation, glycosylation, the addition of lipids, association with other protein subunits, proteolytic cleavage, and the like.

As used herein, the term “sample” refers to any biological material obtained from a subject or patient. In one embodiment, a sample comprises blood, cerebrospinal fluid (“CSF”), or urine. In another embodiment a sample comprises whole blood, plasma, B cells enriched from blood samples, or cultured cells (e.g., B cells from a subject). In another embodiment a sample of the invention contains a biopsy or tissue sample including neural tissue. In a further embodiment, a sample of the invention comprises whole cells or a lysate of the cells. Samples of the invention, including blood samples and CSF samples can be collected using by methods known in the art.

As used herein, the terms “treat” or “treatment” refer to therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the development of dementia. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the manifestation of the condition or disorder is to be prevented.

By “subject” or “individual” or “animal” or “patient” or “mammal,” is meant any subject, particularly a mammalian subject, e.g., a human patient, for whom diagnosis, prognosis, prevention, or therapy is desired.

II. Antibodies

Antibodies that selectively bind TDP-43 are encompassed by the invention. As used herein, the term antibody or antibodies encompasses complete antibodies, as well as TDP-43-binding antibody fragments and variants and derivatives of these complete antibodies or antibody fragments that bind TDP-43. In one embodiment, an antibody of the invention demonstrates at least one, two, three, four, five or more of the structural characteristics (e.g., sequence), immunological binding characteristics (e.g., IC50, or epitope binding), and/or biological properties of the antibodies disclosed in the Examples and elsewhere in the specification.

According to some embodiments, the antibody of the invention is a completely human antibody. The invention also encompasses fragments, variants and derivatives of a completely human antibody. As disclosed in the Examples, the completely human antibodies disclosed herein were derived from a pool of samples from healthy subjects. Antibodies of potential interest were analyzed for class and light chain subclass determination, message from selected memory B cell cultures were transcribed by RT-PCR, cloned and combined into expression vectors for recombinant production; see the appended Examples. The completely human antibodies were then recombinantly expressed in HEK293 cells and subsequently characterized based on their binding specificities towards full-length TDP-43, truncated TDP-43 and a modified form of TDP-43 (FIGS. 2, 4-7, 10, and 11). This characterization confirmed that for the first time, human antibodies have been cloned that are highly specific for TDP-43 and recognize different epitopes within the TDP-43 protein.

Thus, according to one embodiment, the invention generally relates to an antibody that specifically recognizes TDP-43. In a further embodiment, the invention is directed to a human antibody that specifically recognizes TDP-43. In yet a further embodiment, the invention is directed to a total human antibody that specifically recognizes TDP-43. In additional embodiments, the invention encompasses a TDP-43 binding fragment, variant or derivative of a TDP-43 binding intact human (including completely human) antibody of the invention. In another embodiment, the antibodies of the invention specifically recognize full length, truncated, or pathologic human TDP-43 in a Western Blot. In a further embodiment, the antibodies of the invention selectively bind full length or pathologic TDP-43 in a Western Blot. In another embodiment, the antibodies of the invention specifically recognize full length, truncated, or pathologic human TDP-43 in an ELISA. In a further embodiment, the antibodies of the invention selectively bind full length or pathologic TDP-43 in an ELISA. In another embodiment, the antibodies of the invention specifically recognize any combination of full length, truncated, or pathologic human TDP-43 in an immunohistochemistry. In a further embodiment, the antibodies of the invention selectively bind full length or pathologic TDP-43 in an immunohistochemistry. In another embodiment, the antibodies of the invention specifically recognize any combination of full length, truncated, or pathologic human TDP-43 in an immunohistochemistry of the hippocampus. In a further embodiment, the antibodies of the invention selectively bind full length or pathologic TDP-43 in an immunohistochemistry of the hippocampus. In a further embodiment, the antibodies of the invention selectively bind to one or more of nuclear TDP-43, cytoplasmic TDP-43, axonal TDP-43, or neuritic TDP-43 in an immunohistochemistry of human FTLD-U hippocampus. In another embodiment, the antibodies of the invention selectively bind to one or more of cytoplasmic TDP-43 and neuritic TDP-43 in hippocampal granule cells in an immunohistochemistry of human FTLD-U hippocampus. According to one embodiment, the antibodies of the invention specifically recognize pathologic human-TDP-43.

In another embodiment, the invention encompasses an antibody (including an antigen-binding fragment, variant or derivatives thereof), that specifically binds to the same epitope of TDP-43 as a reference antibody having the heavy and light chain variable domain of an antibody selected from the group consisting of: NI-205.3F10, NI-205.51C1, NI-205.21G2, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, NI-205.87E7, NI-205.21G1, NI-205.68G5, NI-205.20A1, NI205.41D1, NI205.29E11, NI205.9E12, NI205.98H6, NI205.10D3, NI205.44B2, NI205.38H2, NI205.36D5, NI205.58E11, NI205.14H5, NI205.31D2, NI205.8F8, NI205.31C11, NI205.8C10, NI205.10H7, NI205.1A9, NI205.14W3, and NI205.19G5. In a further embodiment, the antibody (including an antigen-binding fragment, variant or derivatives thereof), specifically binds to the same epitope of TDP-43 as a reference antibody selected from the group consisting of: NI-205.3F10, NI-205.51C1, NI-205.21G2, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, NI-205.87E7, NI-205.21G1, NI-205.68G5, NI-205.20A1, NI205.41D1, NI205.29E11, NI205.9E12, NI205.98H6, NI205.10D3, NI205.44B2, NI205.38H2, NI205.36D5, NI205.58E11, NI205.14H5, NI205.31D2, NI205.8F8, NI205.31C11, NI205.8C10, NI205.10H7, NI205.1A9, NI205.14W3, and NI205.19G5.

In another embodiment, the invention encompasses an antibody (including an antigen-binding fragment, variant or derivatives thereof), that specifically binds to a TDP-43 polypeptide sequence selected from: QYGDVMDVFIP (SEQ ID NO: 123); AAIGWGSASNA (SEQ ID NO: 124); DMTEDELREFF (SEQ ID NO: 125), EDENDEP (SEQ ID NO: 126), VQVKKDL (SEQ ID NO: 127), KEYFSTF (SEQ ID NO: 128), IIKGISV (SEQ ID NO:315), NQSGPSG (SEQ ID NO:316), FNGGFGS (SEQ ID NO:317), FGNSRGGGAGL (SEQ ID NO:318), SNAGSGSGFNG (SEQ ID NO:319), QLERSGRFGGN (SEQ ID NO:320), EIPSEDD (SEQ ID NO:321), FNGGFGSSMDS (SEQ ID NO:322) and SINPAMMAAAQAALQSSWGMMGMLASQ (SEQ ID NO:323). In another embodiment, the invention encompasses an antibody (including an antigen-binding fragment, variant or derivatives thereof), that specifically binds to TDP-43 polypeptides FGNSRGGGAGL (SEQ ID NO:318) and SNAGSGSGFNG (SEQ ID NO:319). In another embodiment, the invention encompasses an antibody (including an antigen-binding fragment, variant or derivatives thereof), that specifically binds to TDP-43 polypeptide SINPAMMAAAQAALQSSWGMMGMLASQ (SEQ ID NO:323), but does not specifically bind to SINPGGGAAAQAALQSSWGMMGMLASQ (SEQ ID NO:314).

In a further embodiment, the invention encompasses an antibody (including an antigen-binding fragment, variant or derivatives thereof), that competitively inhibits the binding to TDP-43 by a reference antibody having the heavy and light chain variable domain of an antibody selected from the group consisting of: NI-205.3F10, NI-205.51C1, NI-205.21G2, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, NI-205.87E7, NI-205.21G1, NI-205.68G5, NI-205.20A1, NI205.41D1, NI205.29E11, NI205.9E12, NI205.98H6, NI205.10D3, NI205.44B2, NI205.38H2, NI205.36D5, NI205.58E11, NI205.14H5, NI205.31D2, NI205.8F8, NI205.31C11, NI205.8C10, NI205.10H7, NI205.1A9, NI205.14W3, and NI205.19G5.

In a further embodiment, the antibody (including an antigen-binding fragment, variant or derivatives thereof), competitively inhibits the binding to TDP-43 by a reference antibody selected from the group consisting of: NI-205.3F10, NI-205.51C1, NI-205.21G2, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, NI-205.87E7, NI-205.21G1, NI-205.68G5, NI-205.20A1, NI205.41D1, NI205.29E11, NI205.9E12, NI205.98H6, NI205.10D3, NI205.44B2, NI205.38H2, NI205.36D5, NI205.58E11, NI205.14H5, NI205.31D2, NI205.8F8, NI205.31C11, NI205.8C10, NI205.10H7, NI205.1A9, NI205.14W3, and NI205.19G5.

As illustrated in the Examples, the invention encompasses antibodies that bind to different portions and epitopes of TDP-43. According to some embodiments, an antibody of the invention binds a linear epitope of TDP-43. According to other embodiments, an antibody of the invention binds to a conformational epitope of TDP-43. In an additional embodiment an antibody of the invention selectively binds a TDP-43 domain selected from the group consisting of: TDP-43 domain I (amino acid residues 2-106 of SEQ ID NO:94), TDP-43 domain II (amino acid residues 99-204 of SEQ ID NO:94), TDP-43 domain III (amino acid residues 183-273 of SEQ ID NO:94), and TDP-43 domain IV (amino acid residues 258-414 of SEQ ID NO:94). In another embodiment, the anti-TDP-43 antibody does not recognize a truncated form of TDP-43. In an additional embodiment, the invention provides an anti-TDP-43 antibody which recognizes an N-terminal₁₋₂₅₉ fragment of TDP-43. In a further embodiment, the anti-TDP-43 antibody selectively binds pathologic TDP-43. In a further embodiment, an anti-TDP-43 antibody specifically binds TDP-43 domain IV (amino acid residues 258-414 of SEQ ID NO:94), but does not specifically binds TDP-43 domain IV comprising the A321G, M322G, and M323G substitutions.

The invention encompasses human anti-TDP-43 antibodies having different TPD-43 specificities, which are thus particularly useful for diagnostic and therapeutic purposes. The invention is also drawn to an antibody comprising an antigen-binding domain having an amino acid sequence selected from that present in a reference antibody selected from the group consisting of: NI-205.3F10, NI-205.51C1, NI-205.21G2, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, NI-205.87E7, NI-205.21G1, NI-205.68G5, NI-205.20A1, NI205.41D1, NI205.29E11, NI205.9E12, NI205.98H6, NI205.10D3, NI205.44B2, NI205.38H2, NI205.36D5, NI205.58E11, NI205.14H5, NI205.31D2, NI205.8F8, NI205.31C11, NI205.8C10, NI205.10H7, NI205.1A9, NI205.14W3, and NI205.19G5.

The examples and Figures disclose TDP-43 binding molecules that are characterized by containing in their binding domain at least one complementarity determining region (CDR) of the V_(H) and/or V_(L) variable region comprising any one of the amino acid sequences depicted in FIGS. 1A-1K and 3A-3R and listed in Table 2. The corresponding nucleotide sequences encoding these variable regions are set forth in Table 3. An exemplary set of CDRs of the above amino acid sequences of the V_(H) and/or V_(L) region is depicted in FIGS. 1A-1K and 3A-3R. However, as would be understood by a person of ordinary skill in the art, additional or alternative CDRs can be used, which specifically bind TDP-43, but which differ in their amino acid sequence from those set forth in FIGS. 1A-1K and 3A-3R by one, two, three or even more amino acids in case of CDR2 and CDR3.

TABLE 2 SEQ ID NOs of the V_(H) region, V_(H) CDR1, V_(H) CDR2, V_(H) CDR2, V_(L) region, V_(L) CDR2, V_(L) CDR2, and V_(L) CDR3 of TDP-43 specific antibodies. Antibody V_(H)/V_(L) CDR1 CDR2 CDR3 NI-205.3F10 V_(H) SEQ ID NO: 1 SEQ ID NO: 3 SEQ ID NO: 4 SEQ ID NO: 5 V_(L) SEQ ID NO: 6 SEQ ID NO: 7 SEQ ID NO: 8 SEQ ID NO: 9 NI-205.51C1 V_(H) SEQ ID NO: 10 SEQ ID NO: 11 SEQ ID NO: 12 SEQ ID NO: 13 V_(L) SEQ ID NO: 14 SEQ ID NO: 15 SEQ ID NO: 16 SEQ ID NO: 17 NI-205.21G2 V_(H) SEQ ID NO: 18 SEQ ID NO: 19 SEQ ID NO: 20 SEQ ID NO: 21 V_(L) SEQ ID NO: 22 SEQ ID NO: 23 SEQ ID NO: 24 SEQ ID NO: 25 NI-205.8A2 V_(H) SEQ ID NO: 26 SEQ ID NO: 28 SEQ ID NO: 29 SEQ ID NO: 30 V_(L) SEQ ID NO: 31 SEQ ID NO: 32 SEQ ID NO: 33 SEQ ID NO: 34 NI-205.15F12 V_(H) SEQ ID NO:: 35 SEQ ID NO: 37 SEQ ID NO: 38 SEQ ID NO: 39 V_(L) SEQ ID NO: 40 SEQ ID NO: 42 SEQ ID NO: 43 SEQ ID NO: 44 NI-205.113C4 V_(H) SEQ ID NO: 45 SEQ ID NO: 46 SEQ ID NO: 47 SEQ ID NO: 48 V_(L) SEQ ID NO: 49 SEQ ID NO: 50 SEQ ID NO: 51 SEQ ID NO: 52 NI-205.25F3 V_(H) SEQ ID NO: 53 SEQ ID NO: 54 SEQ ID NO: 55 SEQ ID NO: 56 V_(L) SEQ ID NO: 57 SEQ ID NO: 58 SEQ ID NO: 59 SEQ ID NO: 60 NI-205.87E7 V_(H) SEQ ID NO: 61 SEQ ID NO: 62 SEQ ID NO: 63 SEQ ID NO: 64 V_(L) SEQ ID NO: 65 SEQ ID NO: 66 SEQ ID NO: 67 SEQ ID NO: 68 NI-205.21G1 V_(H) SEQ ID NO: 69 SEQ ID NO: 70 SEQ ID NO: 71 SEQ ID NO: 72 V_(L) SEQ ID NO: 73 SEQ ID NO: 74 SEQ ID NO: 75 SEQ ID NO: 76 NI-205.68G5 V_(H) SEQ ID NO: 77 SEQ ID NO: 79 SEQ ID NO: 80 SEQ ID NO: 81 V_(L) SEQ ID NO: 82 SEQ ID NO: 84 SEQ ID NO: 85 SEQ ID NO: 86 NI-205.20A1 V_(H) SEQ ID NO: 87 SEQ ID NO: 88 SEQ ID NO: 89 SEQ ID NO: 90 V_(L) SEQ ID NO: 122 SEQ ID NO: 91 SEQ ID NO: 92 SEQ ID NO: 93 NI205.41D1 V_(H) SEQ ID NO: 130 SEQ ID NO: 131 SEQ ID NO: 132 SEQ ID NO: 133 V_(L) SEQ ID NO: 134 SEQ ID NO: 135 SEQ ID NO: 136 SEQ ID NO: 137 NI205.29E11 V_(H) SEQ ID NO: 138 SEQ ID NO: 139 SEQ ID NO: 140 SEQ ID NO: 141 V_(L) SEQ ID NO: 142 SEQ ID NO: 143 SEQ ID NO: 144 SEQ ID NO: 145 NI205.9E12 V_(H) SEQ ID NO: 146 SEQ ID NO: 147 SEQ ID NO: 148 SEQ ID NO: 149 V_(L) SEQ ID NO: 150 SEQ ID NO: 326 SEQ ID NO: 327 SEQ ID NO: 328 V_(L) SEQ ID NO: 151 SEQ ID NO: 152 SEQ ID NO: 153 SEQ ID NO: 154 NI205.98H6 V_(H) SEQ ID NO: 155 SEQ ID NO: 156 SEQ ID NO: 157 SEQ ID NO: 158 V_(L) SEQ ID NO: 159 SEQ ID NO: 160 SEQ ID NO: 161 SEQ ID NO: 162 NI205.10D3 V_(H) SEQ ID NO: 163 SEQ ID NO: 164 SEQ ID NO: 165 SEQ ID NO: 166 V_(L) SEQ ID NO: 167 SEQ ID NO: 168 SEQ ID NO: 169 SEQ ID NO: 170 NI205.44B22 V_(H) SEQ ID NO: 171 SEQ ID NO: 172 SEQ ID NO: 173 SEQ ID NO: 174 V_(L) SEQ ID NO: 175 SEQ ID NO: 176 SEQ ID NO: 177 SEQ ID NO: 178 NI205.38H2 V_(H) SEQ ID NO: 179 SEQ ID NO: 180 SEQ ID NO: 181 SEQ ID NO: 182 V_(L) SEQ ID NO: 183 SEQ ID NO: 184 SEQ ID NO: 185 SEQ ID NO: 186 NI205.36D5 V_(H) SEQ ID NO: 187 SEQ ID NO: 188 SEQ ID NO: 189 SEQ ID NO: 190 V_(L) SEQ ID NO: 191 SEQ ID NO: 192 SEQ ID NO: 193 SEQ ID NO: 194 NI205.58E11 V_(H) SEQ ID NO: 195 SEQ ID NO: 196 SEQ ID NO: 197 SEQ ID NO: 198 V_(L) SEQ ID NO: 199 SEQ ID NO: 200 SEQ ID NO: 201 SEQ ID NO: 202 NI205.14H5 V_(H) SEQ ID NO: 203 SEQ ID NO: 204 SEQ ID NO: 205 SEQ ID NO: 206 V_(L) SEQ ID NO: 207 SEQ ID NO: 208 SEQ ID NO: 209 SEQ ID NO: 210 NI205.31D2 V_(H) SEQ ID NO: 211 SEQ ID NO: 212 SEQ ID NO: 213 SEQ ID NO: 214 V_(L) SEQ ID NO: 215 SEQ ID NO: 216 SEQ ID NO: 217 SEQ ID NO: 218 NI205.8F8 V_(H) SEQ ID NO: 219 SEQ ID NO: 220 SEQ ID NO: 221 SEQ ID NO: 222 V_(L) SEQ ID NO: 223 SEQ ID NO: 224 SEQ ID NO: 225 SEQ ID NO: 226 NI205.31C11 V_(H) SEQ ID NO: 227 SEQ ID NO: 228 SEQ ID NO: 229 SEQ ID NO: 230 V_(L) SEQ ID NO: 231 SEQ ID NO: 232 SEQ ID NO: 233 SEQ ID NO: 234 NI205.8C10 V_(H) SEQ ID NO: 235 SEQ ID NO: 236 SEQ ID NO: 237 SEQ ID NO: 238 V_(L) SEQ ID NO: 239 SEQ ID NO: 240 SEQ ID NO: 241 SEQ ID NO: 242 NI205.10H7 V_(H) SEQ ID NO: 243 SEQ ID NO: 244 SEQ ID NO: 245 SEQ ID NO: 246 V_(L) SEQ ID NO: 247 SEQ ID NO: 248 SEQ ID NO: 249 SEQ ID NO: 250 NI205.1A9 V_(H) SEQ ID NO: 251 SEQ ID NO: 252 SEQ ID NO: 253 SEQ ID NO: 254 V_(L) SEQ ID NO: 255 SEQ ID NO: 256 SEQ ID NO: 257 SEQ ID NO: 258 NI205.14W3 V_(H) SEQ ID NO: 259 SEQ ID NO: 260 SEQ ID NO: 261 SEQ ID NO: 262 V_(L) SEQ ID NO: 263 SEQ ID NO: 264 SEQ ID NO: 265 SEQ ID NO: 266 NI205.19G5 V_(H) SEQ ID NO: 267 SEQ ID NO: 268 SEQ ID NO: 269 SEQ ID NO: 270 V_(L) SEQ ID NO: 271 SEQ ID NO: 272 SEQ ID NO: 273 SEQ ID NO: 274

In one embodiment, an antibody of the invention comprises at least one CDR comprising, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 3-5, 7-9, 11-13, 15-17, 19-21, 23-25, 28-30, 32-34, 37-39, 42-44, 46-48, 50-52, 54-56, 58-60, 62-64, 66-68, 70-72, 74-76, 79-81, 84-86, 88-93, 131-133, 135-137, 139-141, 143-145, 147-149, 152-154, 156-158, 160-162, 164-166, 168-170, 172-174, 176-178, 180-182, 184-186, 188-190, 192-194, 196-198, 200-202, 204-206, 208-210, 212-214, 216-218, 220-222, 224-226, 228-230, 232-234, 236-238, 240-242, 244-246, 248-250, 252-254, 256-258, 260-262, 264-266, 268-270, 272-274 and 326-328.

In one embodiment, an antibody of the invention comprises one, two, three, four, five or six CDRs comprising, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 3-5, 7-9, 11-13, 15-17, 19-21, 23-25, 28-30, 32-34, 37-39, 42-44, 46-48, 50-52, 54-56, 58-60, 62-64, 66-68, 70-72, 74-76, 79-81, 84-86, 88-93, 131-133, 135-137, 139-141, 143-145, 147-149, 152-154, 156-158, 160-162, 164-166, 168-170, 172-174, 176-178, 180-182, 184-186, 188-190, 192-194, 196-198, 200-202, 204-206, 208-210, 212-214, 216-218, 220-222, 224-226, 228-230, 232-234, 236-238, 240-242, 244-246, 248-250, 252-254, 256-258, 260-262, 264-266, 268-270, 272-274 and 326-328.

In one embodiment, an antibody of the invention comprises one, two, three, four, five or six CDRs comprising, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 3-5 and 7-9, 11-13 and 15-17, 19-21 and 23-25, 28-30 and 32-34, 37-39 and 42-44, 46-48 and 50-52, 54-56 and 58-60, 62-64 and 66-68, 70-72 and 74-76, 79-81 and 84-86, 88-93, 131-133 and 135-137, 139-141 and 143-145, 147-149 and 152-154, 156-158 and 160-162, 164-166 and 168-170, 172-174 and 176-178, 180-182 and 184-186, 188-190 and 192-194, 196-198 and 200-202, 204-206 and 208-210, 212-214 and 216-218, 220-222 and 224-226, 228-230 and 232-234, 236-238 and 240-242, 244-246 and 248-250, 252-254 and 256-258, 260-262 and 264-266, 268-270 and 272-274, and 147-149 and 326-328.

In one embodiment, an antibody of the invention comprises one, two, or three VH

CDRs comprising, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 3-5, 11-13, 19-21, 28-30, 37-39, 46-48, 54-56, 62-64, 70-72, 79-81, 88-90, 131-133, 139-141, 147-149, 156-158, 164-166, 172-174, 180-182, 188-190, 196-198, 204-206, 212-214, 220-222, 228-230, 236-238, 244-246, 252-254, 260-262, and 268-270.

In one embodiment, an antibody of the invention comprises one, two, or three VL CDRs comprising, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 7-9, 15-17, 23-25, 32-34, 42-44, 50-52, 58-60, 66-68, 74-76, 84-86, 91-93, 135-137, 143-145, 152-154, 160-162, 168-170, 176-178, 184-186, 192-194, 200-202, 208-210, 216-218, 224-226, 232-234, 240-242, 248-250, 256-258, 264-266, 272-274 and 326-328.

According to one embodiment, an antibody of the invention comprises a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 3, 11, 19, 28, 37, 46, 54, 62, 70, 79, 88, 131, 139, 147, 156, 164, 172, 180, 188, 196, 204, 212, 220, 228, 236, 244, 252, 260, or 268; a VH CDR2 of SEQ ID NO: 4, 12, 20, 29, 38, 47, 55, 63, 71, 80, 89, 132, 140, 148, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, or 269; or a VH CDR3 of SEQ ID NO: 5, 13, 21, 30, 39, 48, 56, 64, 72, 81, 90, 133, 141, 149, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, or 270. According to another embodiment, an antibody comprises a light chain variable region comprising a VL CDR1 of SEQ ID NO: 7, 15, 23, 32, 42, 50, 58, 66, 74, 84, 91, 135, 143, 152, 160, 168, 176, 184, 192, 200, 208, 216, 224, 232, 240, 248, 256, 264, 272 or 326; a VL CDR2 of SEQ ID NO: 8, 16, 24, 33, 43, 51, 59, 67, 75, 85, 92, 136, 144, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273 or 327; or a VL CDR3 of SEQ ID NO: 9, 17, 25, 34, 44, 52, 60, 68, 76, 86, 93, 137, 145, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274 or 328. In another embodiment, the antibody comprises a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 3, 11, 19, 28, 37, 46, 54, 62, 70, 79, 88, 131, 139, 147, 156, 164, 172, 180, 188, 196, 204, 212, 220, 228, 236, 244, 252, 260, or 268; a VH CDR2 of SEQ ID NO: 4, 12, 20, 29, 38, 47, 55, 63, 71, 80, 89, 132, 140, 148, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, or 269; or a VH CDR3 of SEQ ID NO: 5, 13, 21, 30, 39, 48, 56, 64, 72, 81, 90, 133, 141, 149, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, or 270, and further comprises a light chain variable region comprising a VL CDR1 of SEQ ID NO: 7, 15, 23, 32, 42, 50, 58, 66, 74, 84, 91, 135, 143, 152, 160, 168, 176, 184, 192, 200, 208, 216, 224, 232, 240, 248, 256, 264, 272 or 326; a VL CDR2 of SEQ ID NO: 8, 16, 24, 33, 43, 51, 59, 67, 75, 85, 92, 136, 144, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273 or 327; or a VL CDR3 of SEQ ID NO: 9, 17, 25, 34, 44, 52, 60, 68, 76, 86, 93, 137, 145, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274 or 328.

According to one embodiment, an antibody of the invention comprises a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 3, 11, 19, 28, 37, 46, 54, 62, 70, 79, 88, 131, 139, 147, 156, 164, 172, 180, 188, 196, 204, 212, 220, 228, 236, 244, 252, 260, or 268; a VH CDR2 of SEQ ID NO: 4, 12, 20, 29, 38, 47, 55, 63, 71, 80, 89, 132, 140, 148, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, or 269; and a VH CDR3 of SEQ ID NO: 5, 13, 21, 30, 39, 48, 56, 64, 72, 81, 90, 133, 141, 149, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, or 270. According to another embodiment, an antibody comprises a light chain variable region comprising a VL CDR1 of SEQ ID NO: 7, 15, 23, 32, 42, 50, 58, 66, 74, 84, 91, 135, 143, 152, 160, 168, 176, 184, 192, 200, 208, 216, 224, 232, 240, 248, 256, 264, 272 or 326; a VL CDR2 of SEQ ID NO: 8, 16, 24, 33, 43, 51, 59, 67, 75, 85, 92, 136, 144, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273 or 327; and a VL CDR3 of SEQ ID NO: 9, 17, 25, 34, 44, 52, 60, 68, 76, 86, 93, 137, 145, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274 or 328. In another embodiment, the antibody comprises a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 3, 11, 19, 28, 37, 46, 54, 62, 70, 79, 88, 131, 139, 147, 156, 164, 172, 180, 188, 196, 204, 212, 220, 228, 236, 244, 252, 260, or 268; a VH CDR2 of SEQ ID NO: 4, 12, 20, 29, 38, 47, 55, 63, 71, 80, 89, 132, 140, 148, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, or 269; and a VH CDR3 of SEQ ID NO: 5, 13, 21, 30, 39, 48, 56, 64, 72, 81, 90, 133, 141, 149, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, or 270, and further comprises a light chain variable region comprising a VL CDR1 of SEQ ID NO: 7, 15, 23, 32, 42, 50, 58, 66, 74, 84, 91, 135, 143, 152, 160, 168, 176, 184, 192, 200, 208, 216, 224, 232, 240, 248, 256, 264, 272 or 326; a VL CDR2 of SEQ ID NO: 8, 16, 24, 33, 43, 51, 59, 67, 75, 85, 92, 136, 144, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273 or 327; and a VL CDR3 of SEQ ID NO: 9, 17, 25, 34, 44, 52, 60, 68, 76, 86, 93, 137, 145, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274 or 328.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 3, a VH CDR2 of SEQ ID NO: 4, and VH CDR3 of SEQ ID NO: 5, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:7, a VL CDR2 of SEQ ID NO: 8, and a VL CDR3 of SEQ ID NO: 9.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 11, a VH CDR2 of SEQ ID NO: 12, and VH CDR3 of SEQ ID NO: 13, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:15, a VL CDR2 of SEQ ID NO: 16, and a VL CDR3 of SEQ ID NO: 17.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 19, a VH CDR2 of SEQ ID NO: 20, and VH CDR3 of SEQ ID NO: 21, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:23, a VL CDR2 of SEQ ID NO: 24, and a VL CDR3 of SEQ ID NO: 25.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 28, a VH CDR2 of SEQ ID NO: 29, and VH CDR3 of SEQ ID NO: 30, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:32, a VL CDR2 of SEQ ID NO: 33, and a VL CDR3 of SEQ ID NO: 34.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 37, a VH CDR2 of SEQ ID NO: 38, and VH CDR3 of SEQ ID NO: 39, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:42, a VL CDR2 of SEQ ID NO: 43, and a VL CDR3 of SEQ ID NO: 44.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 46, a VH CDR2 of SEQ ID NO: 47, and VH CDR3 of SEQ ID NO: 48, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:50, a VL CDR2 of SEQ ID NO: 51, and a VL CDR3 of SEQ ID NO: 52.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 54, a VH CDR2 of SEQ ID NO: 55, and VH CDR3 of SEQ ID NO: 56, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO: 58, a VL CDR2 of SEQ ID NO: 59, and a VL CDR3 of SEQ ID NO: 60.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 62, a VH CDR2 of SEQ ID NO: 63, and VH CDR3 of SEQ ID NO: 64, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:66, a VL CDR2 of SEQ ID NO: 67, and a VL CDR3 of SEQ ID NO: 68.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 70, a VH CDR2 of SEQ ID NO: 71, and VH CDR3 of SEQ ID NO: 72, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:74, a VL CDR2 of SEQ ID NO: 75, and a VL CDR3 of SEQ ID NO: 76.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 79, a VH CDR2 of SEQ ID NO: 80, and VH CDR3 of SEQ ID NO: 81, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:84, a VL CDR2 of SEQ ID NO: 85, and a VL CDR3 of SEQ ID NO: 86.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 88, a VH CDR2 of SEQ ID NO: 89, and VH CDR3 of SEQ ID NO: 90, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:91, a VL CDR2 of SEQ ID NO: 92, and a VL CDR3 of SEQ ID NO: 93.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 131, a VH CDR2 of SEQ ID NO: 132, and VH CDR3 of SEQ ID NO: 133, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:135, a VL CDR2 of SEQ ID NO: 136, and a VL CDR3 of SEQ ID NO: 137.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 147, a VH CDR2 of SEQ ID NO: 148, and VH CDR3 of SEQ ID NO: 149, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:152, a VL CDR2 of SEQ ID NO: 153, and a VL CDR3 of SEQ ID NO: 154.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 147, a VH CDR2 of SEQ ID NO: 148, and VH CDR3 of SEQ ID NO: 149, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:326, a VL CDR2 of SEQ ID NO: 327, and a VL CDR3 of SEQ ID NO: 328.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 156, a VH CDR2 of SEQ ID NO: 157, and VH CDR3 of SEQ ID NO: 158, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:160, a VL CDR2 of SEQ ID NO: 161, and a VL CDR3 of SEQ ID NO: 162.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 164, a VH CDR2 of SEQ ID NO: 165, and VH CDR3 of SEQ ID NO: 166, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:168, a VL CDR2 of SEQ ID NO: 169, and a VL CDR3 of SEQ ID NO: 170.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 172, a VH CDR2 of SEQ ID NO: 173, and VH CDR3 of SEQ ID NO: 174, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:176, a VL CDR2 of SEQ ID NO: 177, and a VL CDR3 of SEQ ID NO: 178.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 180, a VH CDR2 of SEQ ID NO: 181, and VH CDR3 of SEQ ID NO: 182, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:184, a VL CDR2 of SEQ ID NO: 185, and a VL CDR3 of SEQ ID NO: 186.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 188, a VH CDR2 of SEQ ID NO: 189, and VH CDR3 of SEQ ID NO: 190, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:192, a VL CDR2 of SEQ ID NO: 193, and a VL CDR3 of SEQ ID NO: 194.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 196, a VH CDR2 of SEQ ID NO: 197, and VH CDR3 of SEQ ID NO: 198, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:200, a VL CDR2 of SEQ ID NO: 201, and a VL CDR3 of SEQ ID NO: 202.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 204, a VH CDR2 of SEQ ID NO: 205, and VH CDR3 of SEQ ID NO: 206, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:208, a VL CDR2 of SEQ ID NO: 209, and a VL CDR3 of SEQ ID NO: 210.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 212, a VH CDR2 of SEQ ID NO: 213, and VH CDR3 of SEQ ID NO: 214, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:216, a VL CDR2 of SEQ ID NO: 217, and a VL CDR3 of SEQ ID NO: 218.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 220, a VH CDR2 of SEQ ID NO: 221, and VH CDR3 of SEQ ID NO: 222, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:224, a VL CDR2 of SEQ ID NO: 225, and a VL CDR3 of SEQ ID NO: 226.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 228, a VH CDR2 of SEQ ID NO: 229, and VH CDR3 of SEQ ID NO: 230, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:232, a VL CDR2 of SEQ ID NO: 233, and a VL CDR3 of SEQ ID NO: 234.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 236, a VH CDR2 of SEQ ID NO: 237, and VH CDR3 of SEQ ID NO: 238, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:240, a VL CDR2 of SEQ ID NO: 241, and a VL CDR3 of SEQ ID NO: 242.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 244, a VH CDR2 of SEQ ID NO: 245, and VH CDR3 of SEQ ID NO: 246, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:248, a VL CDR2 of SEQ ID NO: 249, and a VL CDR3 of SEQ ID NO: 250.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 252, a VH CDR2 of SEQ ID NO: 253, and VH CDR3 of SEQ ID NO: 254, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:256, a VL CDR2 of SEQ ID NO: 257, and a VL CDR3 of SEQ ID NO: 258.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 260, a VH CDR2 of SEQ ID NO: 261, and VH CDR3 of SEQ ID NO: 262, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:264, a VL CDR2 of SEQ ID NO: 265, and a VL CDR3 of SEQ ID NO: 266.

In one embodiment, an antibody of the invention can comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 268, a VH CDR2 of SEQ ID NO: 269, and VH CDR3 of SEQ ID NO: 270, and can further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO:272, a VL CDR2 of SEQ ID NO: 273, and a VL CDR3 of SEQ ID NO: 274.

In one embodiment, an antibody of the invention is an antibody comprising an amino acid sequence of the V_(H) and/or V_(L) region as depicted in FIGS. 1A-1K and 3A-3R.

In another embodiment, an antibody of the invention is characterized by the preservation of the cognate pairing of the heavy and light chain that is present in a human B-cell.

In one embodiment, an antibody of the invention comprises a heavy chain variable region (VH) comprising, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 10, 18, 26, 35, 45, 53, 61, 69, 77, 87, 130, 138, 146, 155, 163, 171, 179, 187, 195, 203, 211, 219, 227, 235, 243, 251, 259, and 267. In one embodiment, an antibody of the invention comprises a light chain variable region (VL) comprising, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 14, 22, 31, 40, 49, 57, 65, 73, 82, 122, 134, 142, 150, 151, 159, 167, 175, 183, 191, 199, 207, 215, 223, 231, 239, 247, 255, 263, and 271. In one embodiment, an antibody of the invention comprises a heavy chain variable region (VH) comprising, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 10, 18, 26, 35, 45, 53, 61, 69, 77, 87, 130, 138, 146, 155, 163, 171, 179, 187, 195, 203, 211, 219, 227, 235, 243, 251, 259, and 267, and further comprises a light chain variable region (VL) comprising, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 14, 22, 31, 40, 49, 57, 65, 73, 82, 122, 134, 142, 150, 151, 159, 167, 175, 183, 191, 199, 207, 215, 223, 231, 239, 247, 255, 263, and 271. In a specific embodiment, the antibody comprises a VH of SEQ ID NO: 1 and a VL of SEQ ID NO: 6; or a VH of SEQ ID NO: 10 and a VL of SEQ ID NO: 14; or a VH of SEQ ID NO: 18 and a VL of SEQ ID NO: 22; or a VH of SEQ ID NO: 26 and a VL of SEQ ID NO: 31; or a VH of SEQ ID NO: 35 and a VL of SEQ ID NO: 40, or a VH of SEQ ID NO:45 and a VL of SEQ ID NO: 49; or a VH of SEQ ID NO: 53 and a VL of SEQ ID NO: 57; or a VH of SEQ ID NO: 61 and a VL of SEQ ID NO: 65; or a VH of SEQ ID NO: 69 and a VL of SEQ ID NO: 73; or a VH of SEQ ID NO: 77 and a VL of SEQ ID NO: 82, or a VH of SEQ ID NO:87 and a VL of SEQ ID NO: 122, or a VH of SEQ ID NO:130 and a VL of SEQ ID NO: 134, or a VH of SEQ ID NO:138 and a VL of SEQ ID NO: 142, or a VH of SEQ ID NO:146 and a VL of SEQ ID NO: 150, or a VH of SEQ ID NO:146 and a VL of SEQ ID NO: 151, or a VH of SEQ ID NO:155 and a VL of SEQ ID NO: 159, or a VH of SEQ ID NO:163 and a VL of SEQ ID NO: 167, or a VH of SEQ ID NO:171 and a VL of SEQ ID NO: 175, or a VH of SEQ ID NO:179 and a VL of SEQ ID NO: 183, or a VH of SEQ ID NO:187 and a VL of SEQ ID NO: 191, or a VH of SEQ ID NO:195 and a VL of SEQ ID NO: 199, or a VH of SEQ ID NO:203 and a VL of SEQ ID NO: 207, or a VH of SEQ ID NO:211 and a VL of SEQ ID NO: 215, or a VH of SEQ ID NO:219 and a VL of SEQ ID NO: 223, or a VH of SEQ ID NO:227 and a VL of SEQ ID NO: 231, or a VH of SEQ ID NO:235 and a VL of SEQ ID NO: 239, or a VH of SEQ ID NO:243 and a VL of SEQ ID NO: 247, or a VH of SEQ ID NO:251 and a VL of SEQ ID NO: 255, or a VH of SEQ ID NO:259 and a VL of SEQ ID NO: 263, or a VH of SEQ ID NO:267 and a VL of SEQ ID NO: 271.

Alternatively, the TDP-binding molecule of the invention is a polypeptide such as an antibody (including an antigen-binding fragment of an antibody, or a derivative or variant thereof), which competes for binding to TDP-43, with at least one antibody having a VH and/or VL region as depicted in FIGS. 1A-1K and 3A-3R. Those antibodies can be human as well, in particular for therapeutic applications. Alternatively, the antibody is a murine, murinized or chimeric murine-human antibody, which is particularly useful for diagnostic methods and efficacy and safety studies in animals.

As discussed herein, the TDP-43 epitope of a completely human antibody is particularly relevant for diagnostic and therapeutic applications due to the fact that the antibody was initially generation as a result of a human immune response. Therefore, human completely human monoclonal antibodies of the invention recognize epitopes which are of particular physiological relevance and which might not be accessible or less immunogenic using conventional immunization and other antibody screening processes for the generation of for example, mouse monoclonal antibodies and antibodies derived from in vitro screening of phage display libraries. Therefore, the invention also extends generally to anti-TDP-43 antibodies and other TDP-43 binding molecules which compete with a human monoclonal antibody of the invention for specific binding to TDP-43. According to one embodiment, the antibody, or other TDP-43 binding molecule, competes with an antibody containing the variable domains disclosed in FIGS. 1A-1K and 3A-3R for binding with TDP-43. In another embodiment, the antibody or other TDP-43 binding molecule competes with a reference antibody selected from the group consisting of: NI-205.3F10, NI-205.51C1, NI-205.21G2, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, NI-205.87E7, NI-205.21G1, NI-205.68G5, NI-205.20A1, NI205.41D1, NI205.29E11, NI205.9E12, NI205.98H6, NI205.10D3, NI205.44B2, NI205.38H2, NI205.36D5, NI205.58E11, NI205.14H5, NI205.31D2, NI205.8F8, NI205.31C11, NI205.8C10, NI205.10H7, NI205.1A9, NI205.14W3, and NI205.19G5, for binding with TDP-43.

The invention also encompasses anti-TDP-43 antibodies and other TDP-43 binding molecules which bind to the same epitope of TDP-43 as a human monoclonal antibody of the invention. According to one embodiment, the antibody (including TDP-43 binding antibody fragments and variant or derivative thereof) or other TDP-43 binding molecule binds to the same epitope of TDP-43 as an antibody containing the variable domains disclosed in FIGS. 1A-1K and 3A-3R. In another embodiment, the antibody (including TDP-43 binding antibody fragments and variant or derivative thereof) or other TDP-43 binding molecule binds to the same epitope of TDP-43 as a reference antibody selected from the group consisting of: NI-205.3F10, NI-205.51C1, NI-205.21G2, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, NI-205.87E7, NI-205.21G1, NI-205.68G5, NI-205.20A1, NI205.41D1, NI205.29E11, NI205.9E12, NI205.98H6, NI205.10D3, NI205.44B2, NI205.38H2, NI205.36D5, NI205.58E11, NI205.14H5, NI205.31D2, NI205.8F8, NI205.31C11, NI205.8C10, NI205.10H7, NI205.1A9, NI205.14W3, and NI205.19G5.

In another embodiment, the invention encompasses an antibody (including an antigen-binding fragment, variant or derivatives thereof), that specifically binds to a TDP-43 polypeptide sequence selected from: QYGDVMDVFIP (SEQ ID NO: 123); AAIGWGSASNA (SEQ ID NO: 124); DMTEDELREFF (SEQ ID NO: 125), EDENDEP (SEQ ID NO: 126), VQVKKDL (SEQ ID NO: 127), KEYFSTF (SEQ ID NO: 128), IIKGISV (SEQ ID NO:315), NQSGPSG (SEQ ID NO:316), FNGGFGS (SEQ ID NO:317), FGNSRGGGAGL (SEQ ID NO:318), SNAGSGSGFNG (SEQ ID NO:319), QLERSGRFGGN (SEQ ID NO:320), EIPSEDD (SEQ ID NO:321), FNGGFGSSMDS (SEQ ID NO:322) and SINPAMMAAAQAALQSSWGMMGMLASQ (SEQ ID NO:323). In another embodiment, the invention encompasses an antibody (including an antigen-binding fragment, variant or derivatives thereof), that specifically binds to TDP-43 polypeptides FGNSRGGGAGL (SEQ ID NO:318) and SNAGSGSGFNG (SEQ ID NO:319). In another embodiment, the invention encompasses an antibody (including an antigen-binding fragment, variant or derivatives thereof), that specifically binds to TDP-43 polypeptide SINPAMMAAAQAALQSSWGMMGMLASQ (SEQ ID NO:323), but does not specifically bind to SINPGGGAAAQAALQSSWGMMGMLASQ (SEQ ID NO:314).

Competition between antibodies is determined by an assay in which the immunoglobulin under test inhibits specific binding of a reference antibody to a common antigen, such as TDP-43. Numerous types of competitive binding assays are known in the art and can routinely be applied or modified to test the ability of two compounds to compete for binding to an antigen, such as, solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay; see Stahli et al., Methods in Enzymology 9 (1983), 242-253; solid phase direct biotin-avidin EIA; see Kirkland et al., J. Immunol. 137 (1986), 3614-3619, and Cheung et al., Virology 176 (1990), 546-552; solid phase direct labeled assay, solid phase direct labeled sandwich assay; see Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press (1988); solid phase direct label RIA using I¹²⁵ label; see Morel et al, Molec. Immunol. 25 (1988), 7-15 and Moldenhauer et al., Scand. J. Immunol. 32 (1990), 77-82. Typically, such an assay involves the use of purified TDP-43 or aggregates thereof bound to a solid surface or cells bearing either of these, an unlabeled test immunoglobulin and a labeled reference immunoglobulin, e.g., a human monoclonal antibody of the invention. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test immunoglobulin. Usually the test immunoglobulin is present in excess. In one embodiment, the competitive binding assay is performed under conditions as described for the ELISA assay in the appended Examples. Antibodies identified by competition assay (competing antibodies) include antibodies binding to the same epitope as the reference antibody and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur. Usually, when a competing antibody is present in excess, it will inhibit specific binding of a reference antibody to a common antigen by at least 50% or 75%. Hence, the invention is further drawn to an antibody (e.g., an antigen-binding fragment of an antibody), where the antibody competitively inhibits binding to TDP-43 by a reference antibody selected from the group consisting of NI-205.3F10, NI-205.51C1, NI-205.21G2, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, NI-205.87E7, NI-205.21G1, NI-205.68G5, NI-205.20A1, NI205.41D1, NI205.29E11, NI205.9E12, NI205.98H6, NI205.10D3, NI205.44B2, NI205.38H2, NI205.36D5, NI205.58E11, NI205.14H5, NI205.31D2, NI205.8F8, NI205.31C11, NI205.8C10, NI205.10H7, NI205.1A9, NI205.14W3, and NI205.19G5.

The invention also provides antibodies that comprise, consist essentially of, or consist of, variants (including derivatives) of the antibody molecules (e.g., the V_(H) regions and/or VL regions) described herein, which antibodies immunospecifically bind to a TDP-43 polypeptide or fragment or variant thereof. Standard techniques known in the art can be used to introduce mutations in the nucleotide sequence encoding a molecule of the invention, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis which result in amino acid substitutions. Preferably, the variants (including derivatives) encode less than 50 amino acid substitutions, less than 40 amino acid substitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the reference V_(H) region, V_(H)CDR1, V_(H)CDR2, V_(H)CDR3, V_(L) region, V_(L)CDR1, V_(L)CDR2, or V_(L)CDR3.

According to one embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin heavy chain variable region (V_(H)), where at least one of V_(H)-CDRs of the heavy chain variable region or at least two of the V_(H)-CDRs of the heavy chain variable region are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to reference heavy chain V_(H)-CDR1, V_(H)-CDR2 or V_(H)-CDR3 amino acid sequences from the antibodies disclosed herein. Alternatively, the V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 regions of the V_(H) are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to reference heavy chain V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 amino acid sequences from the antibodies disclosed herein. Thus, according to this embodiment a heavy chain variable region of the invention has V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 polypeptide sequences related to the groups shown in FIGS. 1A-1K and 3A-3R. While FIGS. 1A-1K and 3A-3R shows V_(H)-CDRs defined by the Kabat system, other CDR definitions, e.g., V_(H)-CDRs defined by the Chothia system, are also included in the invention, and can be easily identified by a person of ordinary skill in the art using the data presented in FIGS. 1A-1K and 3A-3R. In one embodiment, the amino acid sequence of the reference VH CDR1 is SEQ ID NO: 3, 11, 19, 28, 37, 46, 54, 62, 70, 79, 88, 131, 139, 147, 156, 164, 172, 180, 188, 196, 204, 212, 220, 228, 236, 244, 252, 260, or 268; the amino acid sequence of the reference VH CDR2 is SEQ ID NO: 4, 12, 20, 29, 38, 47, 55, 63, 71, 80, 89, 132, 140, 148, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, or 269; and the amino acid sequence of the reference VH CDR3 is SEQ ID NO: 5, 13, 21, 30, 39, 48, 56, 64, 72, 81, 90, 133, 141, 149, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, or 270.

In another embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin heavy chain variable region (V_(H)) in which the V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 regions have polypeptide sequences which are identical to the V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 groups shown in FIGS. 1A-1K and 3A-3R. In one embodiment, the amino acid sequence of the VH CDR1 is SEQ ID NO: 3, 11, 19, 28, 37, 46, 54, 62, 70, 79, 88, 131, 139, 147, 156, 164, 172, 180, 188, 196, 204, 212, 220, 228, 236, 244, 252, 260, or 268; the amino acid sequence of the reference VH CDR2 is SEQ ID NO: 4, 12, 20, 29, 38, 47, 55, 63, 71, 80, 89, 132, 140, 148, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, or 269; and the amino acid sequence of the reference VH CDR3 is SEQ ID NO: 5, 13, 21, 30, 39, 48, 56, 64, 72, 81, 90, 133, 141, 149, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, or 270.

In another embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin heavy chain variable region (V_(H)) in which the V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 regions have polypeptide sequences which are identical to the V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 groups shown in FIGS. 1A-1K and 3A-3R, except for one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in any one V_(H)-CDR. In certain embodiments the amino acid substitutions are conservative. In one embodiment, the amino acid sequence of the VH CDR1 is SEQ ID NO: 3, 11, 19, 28, 37, 46, 54, 62, 70, 79, 88, 131, 139, 147, 156, 164, 172, 180, 188, 196, 204, 212, 220, 228, 236, 244, 252, 260, or 268; the amino acid sequence of the reference VH CDR2 is SEQ ID NO: 4, 12, 20, 29, 38, 47, 55, 63, 71, 80, 89, 132, 140, 148, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, or 269; and the amino acid sequence of the reference VH CDR3 is SEQ ID NO: 5, 13, 21, 30, 39, 48, 56, 64, 72, 81, 90, 133, 141, 149, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, or 270.

In another embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin light chain variable region (V_(L)), where at least one of the V_(L)-CDRs of the light chain variable region or at least two of the V_(L)-CDRs of the light chain variable region are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to reference light chain V_(L)-CDR1, V_(L)-CDR2 or V_(L)-CDR3 amino acid sequences from antibodies disclosed herein. Alternatively, the V_(L)-CDR1, V_(L)-CDR2 and V_(L)-CDR3 regions of the VL are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to reference light chain V_(L)-CDR1, V_(L)-CDR2 and V_(L)-CDR3 amino acid sequences from antibodies disclosed herein. Thus, according to this embodiment a light chain variable region of the invention has V_(L)-CDR1, V_(L)-CDR2 and V_(L)-CDR3 polypeptide sequences related to the polypeptides shown in FIGS. 1A-1K and 3A-3R. While FIGS. 1A-1K and 3A-3R show V_(L)-CDRs defined by the Kabat system, other CDR definitions, e.g., V_(L)-CDRs defined by the Chothia system, are also included in the invention. In one embodiment, the amino acid sequence of the reference VL CDR1 is SEQ ID NO: 7, 15, 23, 32, 42, 50, 58, 66, 74, 84, 91, 135, 143, 152, 160, 168, 176, 184, 192, 200, 208, 216, 224, 232, 240, 248, 256, 264, 272 or 326; the amino acid sequence of the reference VL CDR2 is SEQ ID NO: 8, 16, 24, 33, 43, 51, 59, 67, 75, 85, 92, 136, 144, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273 or 327; and the amino acid sequence of the reference VL CDR3 is SEQ ID NO: 9, 17, 25, 34, 44, 52, 60, 68, 76, 86, 93, 137, 145, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274 or 328.

In another embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin light chain variable region (V_(L)) in which the V_(L)-CDR1, V_(L)-CDR2 and V_(L)-CDR3 regions have polypeptide sequences which are identical to the V_(L)-CDR1, V_(L)-CDR2 and V_(L)-CDR3 groups shown in FIGS. 1A-1K and 3A-3R. In one embodiment, the amino acid sequence of the VL CDR1 is SEQ ID NO: 7, 15, 23, 32, 42, 50, 58, 66, 74, 84, 91, 135, 143, 152, 160, 168, 176, 184, 192, 200, 208, 216, 224, 232, 240, 248, 256, 264, 272 or 326; the amino acid sequence of the VL CDR2 is SEQ ID NO: 8, 16, 24, 33, 43, 51, 59, 67, 75, 85, 92, 136, 144, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273 or 327; and the amino acid sequence of the VL CDR3 is SEQ ID NO: 9, 17, 25, 34, 44, 52, 60, 68, 76, 86, 93, 137, 145, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274 or 328.

In another embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin heavy chain variable region (V_(H)) in which the V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 regions have polypeptide sequences which are identical to the V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 groups shown in FIGS. 1A-1K and 3A-3R, except for one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in any one V_(L)-CDR. In certain embodiments the amino acid substitutions are conservative. In one embodiment, the amino acid sequence of the VL CDR1 is SEQ ID NO: 7, 15, 23, 32, 42, 50, 58, 66, 74, 84, 91, 135, 143, 152, 160, 168, 176, 184, 192, 200, 208, 216, 224, 232, 240, 248, 256, 264, 272 or 326; the amino acid sequence of the VL CDR2 is SEQ ID NO: 8, 16, 24, 33, 43, 51, 59, 67, 75, 85, 92, 136, 144, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273 or 327; and the amino acid sequence of the VL CDR3 is SEQ ID NO: 9, 17, 25, 34, 44, 52, 60, 68, 76, 86, 93, 137, 145, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274 or 328.

According to one embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin heavy chain variable region (VH) at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference heavy chain variable region (VH) amino acid sequence from the antibodies disclosed herein. Thus, according to this embodiment a heavy chain variable region of the invention has a polypeptide sequence related to the heavy chain variable regions shown in FIGS. 1A-1K and 3A-3R. In one embodiment, the amino acid sequence of the reference heavy chain variable region (V_(H)) is SEQ ID NO: 1, 10, 18, 26, 35, 45, 53, 61, 69, 77, 87, 130, 138, 146, 155, 163, 171, 179, 187, 195, 203, 211, 219, 227, 235, 243, 251, 259, or 267.

In another embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin heavy chain variable region (V_(H)) which is identical to a reference heavy chain variable region shown in FIGS. 1A-1K and 3A-3R. In one embodiment, the amino acid sequence of the reference heavy chain variable region is SEQ ID NO: 1, 10, 18, 26, 35, 45, 53, 61, 69, 77, 87, 130, 138, 146, 155, 163, 171, 179, 187, 195, 203, 211, 219, 227, 235, 243, 251, 259, and 267.

In another embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin heavy chain variable region (V_(H)) having a polypeptide sequence which is identical to a reference heavy chain variable region (V_(H)) sequence shown in FIGS. 1A-1K and 3A-3R, except for one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions. In certain embodiments the amino acid substitutions are conservative. In one embodiment, the amino acid sequence of the reference heavy chain variable region sequence is SEQ ID NO: 1, 10, 18, 26, 35, 45, 53, 61, 69, 77, 87, 130, 138, 146, 155, 163, 171, 179, 187, 195, 203, 211, 219, 227, 235, 243, 251, 259, or 267.

According to one embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin light chain variable region (V_(L)) at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference light chain variable region (V_(L)) amino acid sequence from the antibodies disclosed herein. Thus, according to this embodiment a light chain variable region of the invention has a polypeptide sequence related to the light chain variable regions shown in FIGS. 1A-1K and 3A-3R. In one embodiment, the amino acid sequence of the reference light chain variable region (V_(L)) is SEQ ID NO: 6, 14, 22, 31, 40, 49, 57, 65, 73, 82, 122, 134, 142, 150, 151, 159, 167, 175, 183, 191, 199, 207, 215, 223, 231, 239, 247, 255, 263, and 271.

In another embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin light chain variable region (V_(L)) which is identical to a reference light chain variable region shown in FIGS. 1A-1K and 3A-3R. In one embodiment, the amino acid sequence of the reference light chain variable region is SEQ ID NO: 6, 14, 22, 31, 40, 49, 57, 65, 73, 82, 122, 134, 142, 150, 151, 159, 167, 175, 183, 191, 199, 207, 215, 223, 231, 239, 247, 255, 263, and 271.

In another embodiment, the invention provides an isolated polypeptide comprising, consisting essentially of, or consisting of an immunoglobulin light chain variable region (V_(L)) having a polypeptide sequence which is identical to a reference light chain variable region (V_(L)) sequence shown in FIGS. 1A-1K and 3A-3R, except for one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions. In certain embodiments the amino acid substitutions are conservative. In one embodiment, the amino acid sequence of the reference light chain variable region sequence is SEQ ID NO: 6, 14, 22, 31, 40, 49, 57, 65, 73, 82, 122, 134, 142, 150, 151, 159, 167, 175, 183, 191, 199, 207, 215, 223, 231, 239, 247, 255, 263, and 271.

An immunoglobulin or its encoding nucleic acid (e.g., a cDNA) can be further modified. Thus, in a further embodiment the method of the invention comprises any one of the step(s) of producing a chimeric antibody, murinized antibody, single-chain antibody, Fab-fragment, bi-specific antibody, fusion antibody, labeled antibody or an analog of any one of those. Corresponding methods are known in the art and are described, e.g., in Harlow and Lane “Antibodies, A Laboratory Manual”, CSH Press, Cold Spring Harbor (1988). When derivatives of said antibodies are obtained by for example, the phage display technique, surface plasmon resonance as employed in the BIAcore system can be used to increase the efficiency of phage antibodies which bind to the same epitope as that of any one of the antibodies described herein (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13). The production of chimeric antibodies is described, for example, in International Application Publication No. WO89/09622. Methods for the production of humanized antibodies are described in, e.g., European application EP-A1 0 239 400 and International Application WO90/07861. A further source of antibodies to be utilized in accordance with the invention is so-called xenogeneic antibodies. The general principle for the production of xenogeneic antibodies such as human-like antibodies in mice is described in, e.g., International Application Publication Nos. WO91/10741, WO94/02602, WO96/34096 and WO 96/33735. As discussed above, the antibody of the invention can exist in a variety of forms besides complete antibodies; including, for example, Fv, Fab and F(ab)₂, as well as in single chains; see, e.g., International Application Publication No. WO88/09344.

The antibodies of the invention or their corresponding immunoglobulin chain(s) can be further modified using conventional techniques known in the art, for example, by using amino acid deletion(s), insertion(s), substitution(s), addition(s), and/or recombination(s) and/or any other modification(s) known in the art either alone or in combination. Methods for introducing such modifications in the nucleic acid sequence encoding the amino acid sequence of an immunoglobulin chain are well known to a person of ordinary skill in the art; see, e.g., Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1994). Modifications of the antibody of the invention include chemical and/or enzymatic derivatizations at one or more constituent amino acids, including side chain modifications, backbone modifications, and N- and C-terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. Likewise, the invention encompasses the production of chimeric proteins (i.e., fusion proteins) which comprise the TDP-43 binding polypeptides of the invention such as antibodies, at the amino terminus fused to heterologous molecule such as an immunostimulatory ligand at the carboxyl terminus; see, e.g., International Application Publication No. WO00/30680 for corresponding technical details.

Additionally, the invention encompasses peptides and polypeptides that specifically bind TDP-43. For example containing the CDR3 region of the variable region of any one of the mentioned antibodies, in particular CDR3 of the heavy chain since it has frequently been observed that heavy chain CDR3 (HCDR3) is the region having a greater degree of variability and a predominant participation in antigen-antibody interaction. Such peptides and polypeptides can readily be synthesized or produced by recombinant means to produce a TDP-43 binding molecule of the invention. Such methods are known to those of ordinary skill in the art. Peptides can be synthesized for example, using automated peptide synthesizers which are commercially available. The peptides can also be produced by recombinant techniques by incorporating the DNA expressing the peptide into an expression vector and transforming cells with the expression vector to produce the peptide. Accordingly, the invention relates to TDP-43 binding molecules such as, antibodies (e.g., a TDP-43 binding fragment of an antibody) that display one or more properties of the TDP-43 binding molecules described herein. For example, such antibodies and binding molecules can be tested for their binding specificity and affinity by for example, ELISA or Western Blot and immunohistochemistry as described herein; see, e.g., the Examples. As disclosed in Example 2, the half maximal effective concentration (EC₅₀) of NI-205.3F10, NI-205.51C1, NI-205.21G2, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, NI-205.87E7, NI-205.21G1, NI-205.68G5, NI-205.20A1, NI205.41D1, NI205.29E11, NI205.9E12, NI205.98H6, NI205.10D3, NI205.44B2, NI205.38H2, NI205.36D5, NI205.58E11, NI205.14H5, NI205.31D2, NI205.8F8, NI205.31C11, NI205.8C10, NI205.10H7, NI205.1A9, NI205.14W3, and NI205.19G5, was determined for human TDP-43 by direct ELISA to bind human TDP-43 with high affinity at a sub-mid nanomolar EC₅₀ (0.18-17.2 nM).

As an alternative to obtaining immunoglobulins directly from the culture of immortalized B cells or B memory cells, the immortalized cells can be used as a source of rearranged heavy chain and light chain loci for subsequent expression and/or genetic manipulation. Rearranged antibody genes can be reverse transcribed from appropriate mRNAs to produce cDNA. If desired, the heavy chain constant region can be exchanged for that of a different isotype or eliminated altogether. The variable regions can be linked to encode single chain Fv regions. Multiple Fv regions can be linked to confer binding ability to more than one target or chimeric heavy and light chain combinations can be employed. Once the genetic material is available, design of analogs which retain the ability to bind a desired target is straightforward. Methods for cloning antibody variable regions and generation of recombinant antibodies are known in the art and are described, for example, in Gilliland et al., Tissue Antigens 47 (1996), 1-20; Doenecke et al., Leukemia 11 (1997), 1787-1792.

Once the appropriate genetic material is obtained and, if desired, modified to encode an analog, the coding sequences, including those that encode, at a minimum, the variable regions of the heavy and light chain, can be inserted into expression systems contained on vectors which can be transfected into standard recombinant host cells. A variety of such host cells can be used; for efficient processing, however, mammalian cells can be considered. Mammalian cell lines useful for this purpose include, but are not limited to, CHO cells, HEK 293 cells, or NSO cells.

The production of the antibody or analog is then undertaken by culturing the modified recombinant host under culture conditions appropriate for the growth of the host cells and the expression of the coding sequences. The antibodies are then recovered by isolating them from the culture. The expression systems are designed to include signal peptides so that the resulting antibodies are secreted into the medium; however, intracellular production is also possible.

In accordance with the above, the invention also relates to a polynucleotide encoding the antibody or equivalent binding molecule of the invention. In one embodiment, the polynucleotide encodes at least a variable region of an immunoglobulin chain of the antibody described above. Typically, said variable region encoded by the polynucleotide comprises at least one complementarity determining region (CDR) of the V_(H) and/or V_(L) of the variable region of said antibody.

The person of ordinary skill in the art will readily appreciate that the variable domain of the antibody having the above-described variable domain can be used for the construction of other polypeptides or antibodies of desired specificity and biological function. Thus, the invention also encompasses polypeptides and antibodies comprising at least one CDR of the above-described variable domain and which advantageously have substantially the same or similar binding properties as the antibody described in the appended examples. As generally understood in the art, binding affinity can be enhanced by making amino acid substitutions within the CDRs or within the hypervariable loops (Chothia and Lesk, J. Mol. Biol. 196 (1987), 901-917) which partially overlap with the CDRs as defined by Kabat; see, e.g., Riechmann, et al, Nature 332 (1988), 323-327. Thus, the invention also relates to antibodies wherein one or more of the mentioned CDRs comprise one or more, or not more than two amino acid substitutions. In one embodiment, the antibody of the invention comprises in one or both of its immunoglobulin chains two or all three CDRs of the variable regions as set forth in FIGS. 1A-1K and 3A-3R.

Binding molecules such as antibodies (including antigen-binding fragments, variants, or derivatives thereof) of the invention, can comprise a constant region which mediates one or more effector functions. For example, binding of the Cl component of complement to an antibody constant region can activate the complement system. Activation of complement is important in the opsonization and lysis of cell pathogens. The activation of complement also stimulates the inflammatory response and can also be involved in autoimmune hypersensitivity. Further, antibodies bind to receptors on various cells via the Fc region, with a Fc receptor binding site on the antibody Fc region binding to a Fc receptor (FcR) on a cell. There are a number of Fc receptors which are specific for different classes of antibody, including IgG (gamma receptors), IgE (epsilon receptors), IgA (alpha receptors) and IgM (mu receptors). Binding of antibody to Fc receptors on cell surfaces triggers a number of important and diverse biological responses including engulfment and destruction of antibody-coated particles, clearance of immune complexes, lysis of antibody-coated target cells by killer cells (called antibody-dependent cell-mediated cytotoxicity, or ADCC), release of inflammatory mediators, placental transfer and control of immunoglobulin production.

Accordingly, certain embodiments of the invention include an antibody (including an antibody antigen-binding fragment, variant, or derivative thereof), in which at least a fraction of one or more of the constant region domains has been substituted, deleted or otherwise altered so as to provide desired biochemical characteristics such as reduced effector functions, the ability to non-covalently dimerize, increased ability to localize at the site of TDP-43 aggregation and deposition, reduced serum half-life, or increased serum half-life when compared with a whole, unaltered antibody of approximately the same immunogenicity. For example, certain antibodies for use in the diagnostic and treatment methods described herein are domain deleted antibodies which comprise a polypeptide chain similar to an immunoglobulin heavy chain, but which lack at least a portion of one or more heavy chain domains. For instance, in certain embodiments an antibody of the invention is missing an entire domain of the constant region of the modified antibody, such as, all or part of the CH2 domain. In other embodiments, antibodies of the invention useful for example in diagnostic or therapeutic methods have a constant region, e.g., an IgG heavy chain constant region, which is altered to eliminate glycosylation, referred to elsewhere herein as aglycosylated or “agly” antibodies. Such “agly” antibodies can be prepared enzymatically or by other techniques known in the art including for example, by engineering the consensus glycosylation site(s) in the constant region. While not being bound by theory, it is believed that “agly” antibodies can have an improved safety and stability profile in vivo. Methods of producing aglycosylated antibodies, having desired effector function are found for example in International Application Publication No. WO2005/018572, which is herein incorporated by reference in its entirety.

In certain antibodies, including antigen-binding antibody fragments and variants described herein, the Fc portion can be mutated to decrease effector function using techniques known in the art. For example, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating modified antibody thereby increasing TDP-43 localization. In other cases it can be that constant region modifications consistent with the instant invention moderate complement binding and thus reduce the serum half-life and nonspecific association of a conjugated cytotoxin. Yet other modifications of the constant region can be used to modify disulfide linkages or oligosaccharide moieties that allow for enhanced localization due to increased antigen specificity or antibody flexibility. The resulting physiological profile, bioavailability and other biochemical effects of the modifications, such as TDP-43 localization, biodistribution and serum half-life, can routinely be measured using techniques known in the art.

In certain embodiments, the Fc portion of antibodies of the invention are mutated or exchanged for alternative protein sequences to increase the cellular uptake of antibodies by way of example, by enhancing receptor-mediated endocytosis of antibodies via Fcγ receptors, LRP, or Thy1 receptors or by ‘SuperAntibody Technology’, which is said to enable antibodies to be shuttled into living cells without harming them (Muller, S., et al., Expert Opin. Biol. Ther. (2005), 237-241). For example, the generation of fusion proteins of the antibody binding region and the cognate protein ligands of cell surface receptors or bispecific or multi-specific antibodies with a specific sequences binding to TDP-43 as well as a cell surface receptor can be engineered using techniques known in the art.

In certain antibodies, including antigen-binding antibody fragments and variants described herein, the Fc portion can be mutated or exchanged for alternative protein sequences or the antibody can be chemically modified to increase its blood brain barrier penetration.

Modified forms of antibodies (e.g., antigen-binding fragments of antibodies and variants, or derivatives thereof) of the invention can be made from whole precursor or parent antibodies using techniques known in the art. Exemplary techniques are discussed in more detail herein. Antibodies of the invention, including antigen-binding antibody fragments and variants described herein, can routinely be made or manufactured using techniques known in the art. In certain embodiments, antibodies (including antibody fragments and derivatives) are “recombinantly produced,” i.e., are produced using recombinant DNA technology. Exemplary techniques for making antibodies are discussed in more detail elsewhere herein.

Antibodies (including antigen-binding fragments of antibodies and variants, and derivatives thereof) of the invention also include derivatives that are modified, e.g., by the covalent attachment of any type of molecule to the antibody such that the covalent attachment does not prevent the antibody from specifically binding to its cognate epitope. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications can be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative can contain one or more non-classical amino acids.

In particular embodiments the TDP-43 binding molecules of the invention, are polypeptides such as antibodies (including antigen-binding fragments, variants, or derivatives thereof) do not elicit a deleterious immune response in the animal to be treated, e.g., in a human. In certain embodiments, binding molecules, e.g., antibodies (including antigen-binding fragments of antibodies) of the invention are derived from a patient, e.g., a human patient, and are subsequently used in the same species from which they are derived, e.g., human, thus, alleviating or minimizing the occurrence of deleterious immune responses.

De-immunization can also be used to decrease the immunogenicity of an antibody. As used herein, the term “de-immunization” includes alteration of an antibody to modify T cell epitopes; see, e.g., International Application Publication Nos. WO98/52976 and WO00/34317. For example, V_(H) and V_(L) sequences from the starting antibody are analyzed and a human T cell epitope “map” from each V region showing the location of epitopes in relation to complementarity determining regions (CDRs) and other key residues within the sequence. Individual T cell epitopes from the T cell epitope map are analyzed in order to identify alternative amino acid substitutions with a low risk of altering activity of the final antibody. A range of alternative V_(H) and V_(L) sequences are designed comprising combinations of amino acid substitutions and these sequences are subsequently incorporated into a range of binding polypeptides, e.g., TDP-43-specific antibodies, including immunospecific fragments thereof, for use in the diagnostic and treatment methods disclosed herein, which are then tested for function. Typically, between 12 and 24 variant antibodies are generated and tested. Complete heavy and light chain genes comprising modified V and human C regions are then cloned into expression vectors and the subsequent plasmids introduced into cell lines for the production of whole antibody. The antibodies are then compared in appropriate biochemical and biological assays, and the optimal variant is identified.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd ed. (1988); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas Elsevier, N.Y., 563-681 (1981), each of which references are herein incorporated by reference in their entireties. The term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology. The term “monoclonal antibody” refers to an antibody that is derived from a single isolated clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Thus, the term “monoclonal antibody” is not limited to antibodies produced through hybridoma technology. In certain embodiments, antibodies of the invention are derived from human B cells which have been immortalized via transformation with Epstein-Barr virus, as described herein. For clarity, the term “monoclonal antibody” as used herein, does not encompass an endogenous antibody that can be isolated from the plasma of a host organism.

In the well known hybridoma process (Kohler et al., Nature 256 (1975), 495) the relatively short-lived, or mortal, lymphocytes from a mammal, e.g., B cells derived from a human subject as described herein, are fused with an immortal tumor cell line (e.g., a myeloma cell line), thus, producing hybrid cells or “hybridomas” which are both immortal and capable of producing the genetically coded antibody of the B cell. The resulting hybrids are segregated into single genetic strains by selection, dilution, and re-growth with each individual strain comprising specific genes for the formation of a single antibody. The selected hybridomas produce antibodies, which are homogeneous against a desired antigen and, in reference to their pure genetic parentage, are termed “monoclonal”.

Hybridoma cells thus prepared are seeded and grown in a suitable culture medium that contain one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. Reagents, cell lines and methods for forming, selecting and growing of hybridomas are known in the art. Generally, culture medium in which the hybridoma cells are growing is assayed for production of monoclonal antibodies against the desired antigen. The binding specificity of the monoclonal antibodies produced by hybridoma cells is determined by in vitro assays such as immunoprecipitation, radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA) as described herein. After hybridoma cells are identified that produce antibodies of the desired specificity, affinity and/or activity, the clones can be subcloned by limiting dilution procedures and grown by standard methods; see, e.g., Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, pp. 59-103 (1986). It will further be appreciated that the monoclonal antibodies secreted by the hybridoma subclones can be separated from culture medium, ascites fluid or serum by conventional purification procedures such as, for example, protein-A, hydroxylapatite chromatography, gel electrophoresis, dialysis or affinity chromatography.

In another embodiment, lymphocytes are selected by micromanipulation and the variable genes isolated. For example, peripheral blood mononuclear cells can be isolated from an immunized or naturally immune mammal, e.g., a human, and cultured for about 7 days in vitro. The PBMC cultures are then screened for specific IgGs that meet the screening criteria and the cells from positive wells are isolated. Individual Ig-producing B cells can be isolated by FACS or by identifying them in a complement-mediated hemolytic plaque assay. Ig-producing B cells can be micromanipulated into a tube and the V_(H) and V_(L) genes can be amplified using, e.g., RT-PCR. The V_(H) and V_(L) genes can be cloned into an antibody expression vector and transfected into cells (e.g., eukaryotic or prokaryotic cells) for expression.

Alternatively, antibody-producing cell lines can be selected and cultured using or routinely modifying techniques known in the art. Such techniques are described in a variety of laboratory manuals and primary publications. In this respect, techniques suitable for use in the invention as described below are described in Current Protocols in Immunology, Coligan et al., Eds., Green Publishing Associates and Wiley-Interscience, John Wiley and Sons, New York (1991) which is herein incorporated by reference in its entirety, including supplements.

Antibody fragments that recognize specific antigens and/or epitopes can be generated using techniques known in the art. For example, Fab and F(ab′)₂ fragments can be produced recombinantly or by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab′)₂ fragments). F(ab′)₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain. Such fragments are sufficient for use, for example, in immunodiagnostic procedures involving coupling the immunospecific portions of immunoglobulins to detecting reagents such as radioisotopes.

Completely human antibodies, such as those described herein, are particularly desirable for therapeutic treatment of human patients. Human antibodies of the invention are isolated, e.g., from elderly healthy subjects who because of their age can be suspected to be at risk of developing a disorder, e.g., amyotrophic lateral sclerosis and/or frontotemporal lobar degeneration, or a patient with the disorder but with an unusually stable disease course. However, though it is prudent to expect that elderly healthy and symptom-free subjects, respectively, more regularly will have developed protective anti-TDP-43 antibodies than younger subjects, the latter can be used as well as a source for obtaining a human antibody of the invention. This is particularly true for younger patients who are predisposed to develop a familial form of a TDP-43 proteinopathies but remain symptom-free since their immune system and immune response functions more efficiently than that in older adults.

Antibodies of the invention can be produced by any method known in the art for synthesis of antibodies, including in particular, chemical synthesis or recombinant expression techniques as described herein.

In one embodiment, an antibody, or antigen-binding fragment, variant, or derivative thereof of the invention comprises a synthetic constant region wherein one or more domains are partially or entirely deleted (“domain-deleted antibodies”). In certain embodiments compatible modified antibodies will comprise domain deleted constructs or variants wherein the entire CH2 domain has been removed (ΔCH2 constructs). For other embodiments a short connecting peptide can be substituted for the deleted domain to provide flexibility and freedom of movement for the variable region. Those of ordinary skill in the art will appreciate that such constructs can be desirable due to the regulatory properties of the CH2 domain on the catabolic rate of the antibody. Domain deleted constructs can be derived using a vector encoding an IgG₁ human constant domain; see, e.g., International Applications WO02/060955 and WO02/096948A2. This vector is engineered to delete the CH2 domain and provide a synthetic vector expressing a domain deleted IgG₁ constant region.

In certain embodiments the antibodies (including antigen-binding fragments, variants, or derivatives thereof) of the invention are minibodies. Minibodies can be made using methods known in the art; see, e.g., U.S. Pat. No. 5,837,821 or International Application Publication No. WO 94/09817.

In one embodiment, an antibody (e.g., antigen-binding fragment, variant, or derivative thereof of an antibody) of the invention comprises an immunoglobulin heavy chain having deletion or substitution of a few or even a single amino acid as long as it permits association between the monomeric subunits. For example, the mutation of a single amino acid in selected areas of the CH2 domain can be enough to substantially reduce Fc binding and thereby increase TDP-43 localization. Similarly, it can be desirable to simply delete that part of one or more constant region domains that control the effector function (e.g., complement binding) to be modulated. Such partial deletions of the constant regions can improve selected characteristics of the antibody (serum half-life) while leaving other desirable functions associated with the subject constant region domain intact. Moreover, as alluded to above, the constant regions of the disclosed antibodies can be synthetic through the mutation or substitution of one or more amino acids that enhances the profile of the resulting construct. In this respect it can be possible to disrupt the activity provided by a conserved binding site (e.g. Fc binding) while substantially maintaining the configuration and immunogenic profile of the modified antibody. Yet other embodiments comprise the addition of one or more amino acids to the constant region to enhance desirable characteristics such as effector function or provide for more cytotoxin or carbohydrate attachment. In such embodiments it can be desirable to insert or replicate specific sequences derived from selected constant region domains.

The invention also provides antibodies that comprise, consist essentially of, or consist of, variants (including derivatives) of antibodies (e.g., the V_(H) regions and/or V_(L) regions) described herein, which antibodies (inducing antibody fragments), immunospecifically bind to TDP-43. Standard techniques known to those of skill in the art can be used to introduce mutations in the nucleotide sequence encoding an antibody, including, but not limited to, site-directed mutagenesis and PCR-mediated mutagenesis which result in amino acid substitutions. In one embodiment, the variants (including derivatives) encode less than 50 amino acid substitutions, less than 40 amino acid substitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the reference V_(H) region, V_(H)-CDR1, V_(H)-CDR2, V_(H)-CDR3, V_(L) region, V_(L)-CDR1, V_(L)-CDR2, or V_(L)-CDR3. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues having side chains with similar charges have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity (e.g., the ability to bind TDP-43).

For example, it is possible to introduce mutations only in framework regions or only in CDR regions of an antibody. Introduced mutations can be silent or neutral missense mutations, e.g., have no, or little, effect on an antibody's ability to bind antigen, indeed some such mutations do not alter the amino acid sequence whatsoever. These types of mutations can be useful to optimize codon usage, or improve a hybridoma's antibody production. Alternatively, non-neutral missense mutations can alter an antibody's ability to bind antigen. The location of most silent and neutral missense mutations is likely to be in the framework regions, while the location of most non-neutral missense mutations is likely to be in a CDR, though this is not an absolute requirement. A person of ordinary skill in the art is able to design and test altered molecules for desired properties including for example, improvements in antigen-binding activity or change in antibody specificity. Following mutagenesis, proteins displaying the desired properties can routinely be expressed and the functional and/or biological activity of the encoded protein, (e.g., ability to immunospecifically bind at least one epitope of TDP-43) can be determined using or routinely modifying techniques known in the art.

Anti-TDP-43 antibodies of the present invention can be characterized using any in vivo or in vitro models of TDP-43 proteinopathies. A skilled artisan readily understands that an anti-TDP-43 antibody of the invention can be characterized in a mouse model for TDP-43 proteinopathies, for example, but not limited to, any one of the animal models for TDP-43 proteinopathies described in Example 5. Wegorzewska et al., Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 18809-14; Gurney et al., Science 264 (1994), 1772-75; Shan et al., Neuropharmacol. Letters 458 (2009), 70-74; Wils et al., Proc. Natl. Acad. Sci. USA. 106 (2010), 3858-63; Duchen and Strich, J. Neurol. Neurosurg. Psychiatry 31 (1968), 535-42; Dennis and Citron, Neuroscience 185 (2009), 745-50; Swamp et al., Brain 134 (2011), 2610-2626; Igaz et al., J Clin Invest. 121(2):726-38 (2011); Caccamo et al., Am J Pathol. 180(1):293-302 (2012), Cannon et al., Acta Neuropathol. 123(6):807-23 (2012), Custer et al., Hum Mol Genet. 19(9):1741-55 (2010); and Tatom et al., Mol. Ther. 17 (2009), 607-613.

A skilled artisan understands that an experimental model of TDP-43 proteinopathy can be used in a preventative setting or it can be used in a therapeutic setting. In a preventative setting, the dosing of animals starts prior to the onset of the TDP-43 proteinopathy or symptoms thereof. In preventative settings, an anti-TDP-43 antibody of the invention is evaluated for its ability to prevent, reduce or delay the onset of TDP-43 proteinopathy or symptoms thereof. In a therapeutic setting, the dosing of animals start after the onset of TDP-43 proteinopathy or a symptom thereof. In a therapeutic setting, an anti-TDP-43 antibody of the invention is evaluated for its ability to treat, reduce or alleviate the TDP-43 proteinopathy or a symptom thereof. Symptoms of the TDP-43 proteinopathies include, but are not limited to, accumulation of pathological TDP-43 deposits, pathological TDP-43 distribution, phosphorylated TDP-43, or insoluble TDP-43 fractions in the neurons, brain, spinal cord, cerebrospinal fluid or serum of the experimental object. A skilled artisan understands that a positive preventative or therapeutic outcome in any animal model of TDP-43 proteinopathies indicates that the particular anti-TDP-43 antibody can be used for preventative or therapeutic purposes in a subject other than the experimental model organism, for example, it can be used to treat TDP-43 proteinopathies in a human subject in need thereof.

In one embodiment, an anti-TDP-43 antibody of the invention can be administered to a TDP-43 proteinopathy mouse model and corresponding control wild type mice. The antibody administered can be a murinized antibody of the present invention or a human-murine chimera of an antibody of the present invention. The anti-TDP-43 antibody can be administered by any means known in the art, for example, by intraperitoneal, intracranial, intramuscular, intravenous, subcutaneous, oral, and aerosol administration. Experimental animals can be given one, two, three, four, five or more doses of the anti-TDP-43 antibody or a control composition, such as PBS. In one embodiment, experimental animals will be administered one or two doses of an anti-TDP-43 antibody. In another embodiment, the animals are chronically dosed with the anti-TDP-43 antibody over several weeks or months. A skilled artisan can readily design a dosing regimen that fits the experimental purpose, for example, dosing regimen for acute studies, dosing regimen for chronic studies, dosing regimen for toxicity studies, dosing regimen for preventative or therapeutic studies. The presence of the anti-TDP-43 antibody in a particular tissue compartment of the experimental animals, for example, but not limited to, serum, blood, cerebrospinal fluid, brain tissue, can be established using well know methods of the art. In one embodiment, an anti-TDP-43 antibody of the invention is capable to penetrate the blood brain barrier. In another embodiment, an anti-TDP-43 antibody of the invention is capable to enter neurons. A skilled artisan understands that by adjusting the anti-TDP-43 antibody dose and the dosing frequency, a desired anti-TDP-43 antibody concentration can be maintained in the experimental animals. Any effect of an anti-TDP-43 antibody of the present invention in the TDP-43 proteinopathy models can be assessed by comparing the level, biochemical characteristics or distribution of TDP-43 in the treated and control animals. In one embodiment, an antibody of the present invention is capable of reducing the level, amount or concentration of TDP-43 inclusions in the brain or spinal cord in an animal model. The antibody can reduce the level, amount or concentration of TDP-43 inclusions by at least about 5%, 10%, 20%, 30%, 50%, 70%, 90% or more. In another embodiment, an antibody of the present invention is capable of reducing the number or frequency of TDP-43 inclusion-positive neurons in the brain or spinal cord in an animal model, for example, by at least about 5%, 10%, 20%, 30%, 50%, 70%, 90% or more. The effect of an antibody of the present invention can also be assessed by examining the distribution and biochemical properties of TDP-43 following antibody administration. In one embodiment, an antibody of the present invention is capable of reducing the amount or concentration of cytoplasmic TDP-43 protein in the brain or spinal cord of an animal model, for example, by at least about 5%, 10%, 20%, 30%, 50%, 70%, 90% or more. In another embodiment, an antibody of the present invention is capable of reducing the amount or concentration of neuritic TDP-43 protein in the brain or spinal cord of an animal model, for example, by at least about 5%, 10%, 20%, 30%, 50%, 70%, 90% or more. In a further embodiment, an antibody of the present invention can reduce the amount or concentration of phosphorylated TDP-43 protein in the brain or spinal cord in an animal model, for example, by at least about 5%, 10%, 20%, 30%, 50%, 70%, 90% or more. Phosphorylated TDP-43 can be detected using antibodies specific for pathologically phosphorylated forms of TDP-43, such as p403/p404 and p409/p410. Hasegawa et al., Ann Neurol, 64(1):60-70 (2008) An antibody of the present invention can also alter, for example, reduce or increase TDP-43 concentration in the blood, serum or cerebrospinal fluid of an animal model, for example, by at least about 5%, 10%, 20%, 30%, 50%, 70%, 90% or more. In one embodiment, the % reduction or increase is relative compared to the level, number, frequency, amount or concentration that existed before treatment, or to the level, number, frequency, amount or concentration that exist in an untreated/control treated subject.

In one embodiment, an antibody of the present invention can prevent or delay the onset of at least one symptom of a TDP-43 proteinopathy in a subject. In one embodiment, an antibody of the present invention can reduce or eliminate at least one symptom of a TDP-43 proteinopathy in a subject. The symptom can be the formation of pathological TDP-43 deposits, phosphorylated TDP-43 deposits, or insoluble TDP-43 deposits. The symptom can also be the presence, or elevated concentration or amount, of TDP-43 in the serum, blood, urine or cerebrospinal fluid, wherein elevated concentration amount is compared to a healthy subject. The symptom can be a neurological symptom, for example, altered conditioned taste aversion, altered contextual fear conditioning, memory impairment, loss of motor function. In one embodiment, memory impairment is assessed using a two-trial Y-maze task. In one embodiment, the at least one symptom is reduced by at least about 5%, 10%, 15%, 20%, 30%, 50%, 70%, or 90%. In another embodiment, the two-trial Y-maze task ratio is significantly higher in an antibody treated subject than in a control subject. In a specific embodiment, the two-trial Y-maze task ratio is increased by at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In another embodiment, the two-trial Y-maze task ratio is at least about two times, three times, four times, five times, ten times, or twenty times higher. The present invention also provides a method of preventing or delaying the onset of at least one symptom of a TDP-43 proteinopathy in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TDP-43 antibody described herein. The present invention further provides a method of reducing or eliminating least one symptom of a TDP-43 proteinopathy in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TDP-43 antibody described herein. In one embodiment, the subject is an experimental organism, such as, but not limited to, transgenic mouse. In one embodiment, the subject is a human.

III. Polynucleotides Encoding Antibodies

A polynucleotide encoding an antibody, or antigen-binding fragment, variant, or derivative thereof can be composed of any polyribonucleotide or polydeoxribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA. For example, a polynucleotide encoding an antibody, or antigen-binding fragment, variant, or derivative thereof can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that can be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, a polynucleotide encoding an antibody, or antigen-binding fragment, variant, or derivative thereof can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide encoding an antibody (including an antigen-binding fragment of an antibody, or a variant, or derivative thereof) can also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically, or metabolically modified forms.

An isolated polynucleotide encoding a non-natural variant of a polypeptide derived from an immunoglobulin (e.g., an immunoglobulin heavy chain portion or light chain portion) can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence encoding the immunoglobulin such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. In one embodiment, conservative amino acid substitutions are made at one or more amino acid residue positions that are non-essential.

RNA can be isolated from the original B cells, hybridoma cells or from other transformed cells by standard techniques, such as guanidinium isothiocyanate extraction and precipitation followed by centrifugation or chromatography. Where desirable, mRNA can be isolated from total RNA using standard techniques such as, chromatography on oligo dT cellulose. Suitable techniques are familiar in the art. In one embodiment, cDNAs that encode the light and the heavy chains of the antibody can be made, either simultaneously or separately, using reverse transcriptase and DNA polymerase in accordance with known methods. PCR can be initiated by consensus constant region primers or by more specific primers based on the published heavy and light chain DNA and amino acid sequences. As discussed above, PCR also can be used to isolate DNA clones encoding the antibody light and heavy chains. In this case the libraries can be screened by consensus primers or larger homologous probes, such as human constant region probes.

DNA, typically plasmid DNA, can be isolated from the cells using techniques known in the art, restriction mapped and sequenced in accordance with standard, known techniques set forth in detail, e.g., in the foregoing references relating to recombinant DNA techniques. Of course, the DNA can be synthetic according to the invention at any point during the isolation process or subsequent analysis.

In one embodiment, the invention provides an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin heavy chain variable region (V_(H)), where at least one of the CDRs of the heavy chain variable region or at least two of the V_(H)-CDRs of the heavy chain variable region are at least 80%, 85%, 90%, 95%, 96%, 98%, or 99% identical to reference heavy chain V_(H)-CDR1, V_(H)-CDR2, or V_(H)-CDR3 amino acid sequences from the antibodies disclosed herein. Alternatively, the V_(H)-CDR1, V_(H)-CDR2, or V_(H)-CDR3 regions of the V_(H) are at least 80%, 85%, 90%, 95%, 96%, 98%, or 99% identical to reference heavy chain V_(H)-CDR1, V_(H)-CDR2, and V_(H)-CDR3 amino acid sequences from the antibodies disclosed herein. Thus, according to this embodiment a heavy chain variable region of the invention has V_(H)-CDR1, V_(H)-CDR2, or V_(H)-CDR3 polypeptide sequences related to the polypeptide sequences shown in FIGS. 1A-1K and 3A-3R. In one embodiment, the amino acid sequence of the reference VH CDR1 is SEQ ID NO: 3, 11, 19, 28, 37, 46, 54, 62, 70, 79, 88, 131, 139, 147, 156, 164, 172, 180, 188, 196, 204, 212, 220, 228, 236, 244, 252, 260, or 268; the amino acid sequence of the reference VH CDR2 is SEQ ID NO: 4, 12, 20, 29, 38, 47, 55, 63, 71, 80, 89, 132, 140, 148, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, or 269; and the amino acid sequence of the reference VH CDR3 is SEQ ID NO: 5, 13, 21, 30, 39, 48, 56, 64, 72, 81, 90, 133, 141, 149, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, or 270. In one embodiment, the invention provides an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin heavy chain variable region (V_(H)), in which the V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 regions have the polypeptide sequences of the V_(H)-CDR1, V_(H)-CDR2 and V_(H)-CDR3 groups shown in FIGS. 1A-1K and 3A-3R, except for one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in any one V_(H)-CDR. In certain embodiments the amino acid substitutions are conservative. In one embodiment, the amino acid sequence of the VH CDR1 is SEQ ID NO: 3, 11, 19, 28, 37, 46, 54, 62, 70, 79, 88, 131, 139, 147, 156, 164, 172, 180, 188, 196, 204, 212, 220, 228, 236, 244, 252, 260, or 268; the amino acid sequence of the VH CDR2 is SEQ ID NO: 4, 12, 20, 29, 38, 47, 55, 63, 71, 80, 89, 132, 140, 148, 157, 165, 173, 181, 189, 197, 205, 213, 221, 229, 237, 245, 253, 261, or 269; and the amino acid sequence of the VH CDR3 is SEQ ID NO: SEQ ID NO: 5, 13, 21, 30, 39, 48, 56, 64, 72, 81, 90, 133, 141, 149, 158, 166, 174, 182, 190, 198, 206, 214, 222, 230, 238, 246, 254, 262, or 270.

In another embodiment, the invention provides an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin light chain variable region (V_(L)), where at least one of the V_(L)-CDRs of the light chain variable region or at least two of the V_(L)-CDRs of the light chain variable region are at least 80%, 85%, 90%, 95%, 96%, 98%, or 99% identical to reference light chain V_(L)-CDR1, V_(L)-CDR2, or V_(L)-CDR3 amino acid sequences from the antibodies disclosed herein. Alternatively, the V_(L)-CDR1, V_(L)-CDR2, or V_(L)-CDR3 regions of the VL are at least 80%, 85%, 90%, 95%, 96%, 98%, or 99% identical to reference light chain V_(L)-CDR1, V_(L)-CDR2, and V_(L)-CDR3 amino acid sequences from the antibodies disclosed herein. Thus, according to this embodiment a light chain variable region of the invention has V_(L)-CDR1, V_(L)-CDR2, or V_(L)-CDR3 polypeptide sequences related to the polypeptide sequences shown in FIGS. 1A-1K and 3A-3R. In one embodiment, the amino acid sequence of the reference VL CDR1 is SEQ ID NO: 7, 15, 23, 32, 42, 50, 58, 66, 74, 84, 91, 135, 143, 152, 160, 168, 176, 184, 192, 200, 208, 216, 224, 232, 240, 248, 256, 264, 272 or 326; the amino acid sequence of the reference VL CDR2 is SEQ ID NO: 8, 16, 24, 33, 43, 51, 59, 67, 75, 85, 92, 136, 144, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273 or 327; and the amino acid sequence of the reference VL CDR3 is SEQ ID NO: 9, 17, 25, 34, 44, 52, 60, 68, 76, 86, 93, 137, 145, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274 or 328.

In another embodiment, the invention provides an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin light chain variable region (V_(L)) in which the V_(L)-CDR1, V_(L)-CDR2 and V_(L)-CDR3 regions have the polypeptide sequences of the V_(L)-CDR1, V_(L)-CDR2 and V_(L)-CDR3 groups shown in FIGS. 1A-1K and 3A-3R, except for one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in any one V_(L)-CDR. In certain embodiments the amino acid substitutions are conservative. In one embodiment, the amino acid sequence of the VL CDR1 is SEQ ID NO: 7, 15, 23, 32, 42, 50, 58, 66, 74, 84, 91, 135, 143, 152, 160, 168, 176, 184, 192, 200, 208, 216, 224, 232, 240, 248, 256, 264, 272 or 326; the amino acid sequence of the VL CDR2 is SEQ ID NO: 8, 16, 24, 33, 43, 51, 59, 67, 75, 85, 92, 136, 144, 153, 161, 169, 177, 185, 193, 201, 209, 217, 225, 233, 241, 249, 257, 265, 273 or 327; and the amino acid sequence of the VL CDR3 is SEQ ID NO: 9, 17, 25, 34, 44, 52, 60, 68, 76, 86, 93, 137, 145, 154, 162, 170, 178, 186, 194, 202, 210, 218, 226, 234, 242, 250, 258, 266, 274 or 328.

As known in the art, “sequence identity” between two polypeptides or two polynucleotides is determined by comparing the amino acid or nucleic acid sequence of one polypeptide or polynucleotide to the sequence of a second polypeptide or polynucleotide. When discussed herein, whether any particular polypeptide is at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% identical to another polypeptide can be determined using methods and computer programs/software known in the art such as, but not limited to, the BESTFIT program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711). BESTFIT uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2 (1981), 482-489, to find the best segment of homology between two sequences. When using BESTFIT or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference sequence according to the invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference polypeptide sequence and that gaps in homology of up to 5% of the total number of amino acids in the reference sequence are allowed.

In one embodiment of the invention, the polynucleotide comprises, consists essentially of, or consists of a nucleic acid having a polynucleotide sequence of the V_(H)or V_(L) region of an TDP-43 binding antibody as listed in Table 3. In this respect, a person of ordinary skill in the art will readily appreciate that the polynucleotides encoding at least the variable domain of the light and/or heavy chain can encode the variable domain of both immunoglobulin chains or only one.

TABLE 3 Nucleotide sequences of the V_(H) and V_(L) region of TDP-43 specific antibodies. Nucleotide sequences of variable heavy (VH) Antibody and variable light (VL) chains NI-205.3F10 V_(H) SEQ ID NO: 95 V_(L) SEQ ID NO: 96 NI-205.51C1 V_(H) SEQ ID NO: 97 V_(L) SEQ ID NO: 98 NI-205.21G2 V_(H) SEQ ID NO: 99 V_(L) SEQ ID NO: 100 NI-205.8A2 V_(H) SEQ ID NO: 101 V_(L) SEQ ID NO: 102 NI-205.15F12 V_(H) SEQ ID NO: 103 V_(L) SEQ ID NO: 104 NI-205.113C4 V_(H) SEQ ID NO: 105 V_(L) SEQ ID NO: 106 NI-205.25F3 V_(H) SEQ ID NO: 107 V_(L) SEQ ID NO: 108 NI-205.87E7 V_(H) SEQ ID NO: 109 V_(L) SEQ ID NO: 110 NI-205.21G1 V_(H) SEQ ID NO: 111 V_(L) SEQ ID NO: 112 NI-205.68G5 V_(H) SEQ ID NO: 113 V_(L) SEQ ID NO: 114 NI-205.20A1 V_(H) SEQ ID NO: 115 V_(L) SEQ ID NO: 116 NI205.41D1 V_(H) SEQ. ID. NO: 275 V_(L) SEQ. ID. NO: 276 NI205.29E11 V_(H) SEQ. ID. NO: 277 V_(L) SEQ. ID. NO: 278 NI205.9E12 V_(H) SEQ. ID. NO: 279 V_(L) SEQ. ID. NO: 280 V_(L) SEQ. ID. NO: 281 NI205.98H6 V_(H) SEQ. ID. NO: 282 V_(L) SEQ. ID. NO: 283 NI205.10D3 V_(H) SEQ. ID. NO: 284 V_(L) SEQ. ID. NO: 285 NI205.44B22 V_(H) SEQ. ID. NO: 286 V_(L) SEQ. ID. NO: 287 NI205.38H2 V_(H) SEQ. ID. NO: 288 V_(L) SEQ. ID. NO: 289 NI205.36D5 V_(H) SEQ. ID. NO: 290 V_(L) SEQ. ID. NO: 291 NI205.58E11 V_(H) SEQ. ID. NO: 292 V_(L) SEQ. ID. NO: 293 NI205.14H5 V_(H) SEQ. ID. NO: 294 V_(L) SEQ. ID. NO: 295 NI205.31D2 V_(H) SEQ. ID. NO: 296 V_(L) SEQ. ID. NO: 297 NI205.8F8 V_(H) SEQ. ID. NO: 298 V_(L) SEQ. ID. NO: 299 NI205.31C11 V_(H) SEQ. ID. NO: 300 V_(L) SEQ. ID. NO: 301 NI205.8C10 V_(H) SEQ. ID. NO: 302 V_(L) SEQ. ID. NO: 303 NI205.10H7 V_(H) SEQ. ID. NO: 304 V_(L) SEQ. ID. NO: 305 NI205.1A9 V_(H) SEQ. ID. NO: 306 V_(L) SEQ. ID. NO: 307 NI205.14W3 V_(H) SEQ. ID. NO: 308 V_(L) SEQ. ID. NO: 309 NI205.19G5 V_(H) SEQ. ID. NO: 310 V_(L) SEQ. ID. NO: 310

In one embodiment, the invention provides an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin heavy chain variable region at least 80%, 85%, 90%, 95%, 96%, 98%, or 99% or 95% identical to reference heavy chain VH. In one embodiment, the amino acid sequence of the reference heavy chain variable region is SEQ ID NO: 1, 10, 18, 26, 35, 45, 53, 61, 69, 77, 87, 130, 138, 146, 155, 163, 171, 179, 187, 195, 203, 211, 219, 227, 235, 243, 251, 259, or 267.

In one embodiment, the invention provides an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin light chain variable region at least 80%, 85%, 90%, 95%, 96%, 98%, or 99% or 95% identical to reference light chain VL. In one embodiment, the amino acid sequence of the reference light chain variable region is SEQ ID NO: 6, 14, 22, 31, 40, 49, 57, 65 ,73, 82, 122, 134, 142, 150, 151, 159, 167, 175, 183, 191, 199, 207, 215, 223, 231, 239, 247, 255, 263, or 271.

The invention also includes fragments of the polynucleotides of the invention. Preferably the polynucleotides encode a polypeptide that binds TDP-43. Additionally polynucleotides which encode fusion polynucleotides, Fab fragments, and other derivatives, as described herein, are also contemplated by the invention.

The polynucleotides can be produced or manufactured by any appropriate method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody can be assembled from chemically synthesized oligonucleotides, e.g., as described in Kutmeier et al., BioTechniques 17 (1994), 242, which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody (including an antigen-binding fragment of an antibody, or variant or derivative thereof) can be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody is known, a nucleic acid encoding the antibody can be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably polyA⁺ RNA, isolated from, any tissue or cells expressing the TDP-43-specific antibody, such as hybridoma cells selected to express an antibody) by PCR amplification using synthetic primers hybridizable to the 3′ and 5′ ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR can then be cloned into replicable cloning vectors using any method known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the antibody, or antigen-binding fragment, variant, or derivative thereof is determined, its nucleotide sequence can be manipulated using methods known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1990) and Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley & Sons, NY (1998), the contents of both of which are herein incorporated by reference in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

IV. Expression of Antibody Polypeptides

Following manipulation of the isolated genetic material to provide an antibody (including an antigen-binding fragment of an antibody, or variant or derivative thereof) of the invention, the polynucleotide encoding the antibody is typically inserted in an expression vector for introduction into host cells that can be used to produce the desired quantity of antibody. Recombinant expression of an antibody, or fragment, derivative or analog thereof, e.g., a heavy or light chain of an antibody which binds to a target molecule is described herein. Once a polynucleotide encoding an antibody or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody can be produced by recombinant DNA technology using techniques known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are known to those of ordinary skill in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors can include the nucleotide sequence encoding the constant region of the antibody (see, e.g., International Application Publication No. WO 86/05807 and U.S. Pat. No. 5,122,464) and the variable domain of the antibody can be cloned into such a vector for expression of the entire heavy or light chain.

The term “vector” or “expression vector” is used herein to mean vectors used in accordance with the invention as a vehicle for introducing into and expressing a desired gene in a host cell. As known in the art, such vectors can readily be selected from the group consisting of plasmids, phages, viruses and retroviruses. In general, vectors compatible with the instant invention will comprise a selection marker, appropriate restriction sites to facilitate cloning of the desired gene and the ability to enter and/or replicate in eukaryotic or prokaryotic cells. Numerous expression vector systems can be employed for the purposes of this invention. For example, one class of vector utilizes DNA elements which are derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (RSV, MMTV or MOMLV) or SV40 virus. Others involve the use of polycistronic systems with internal ribosome binding sites. Additionally, cells which have integrated the DNA into their chromosomes can be selected by introducing one or more markers which allow selection of transfected host cells. The marker can provide for prototrophy to an auxotrophic host, biocide resistance (e.g., antibiotics) or resistance to heavy metals such as copper. The selectable marker gene can either be directly linked to the DNA sequences to be expressed, or introduced into the same cell by co-transformation. Additional elements can also be needed for optimal synthesis of mRNA. These elements can include signal sequences, splice signals, as well as transcriptional promoters, enhancers, and termination signals.

In particular embodiments the cloned variable region genes are inserted into an expression vector along with the heavy and light chain constant region coding sequences (e.g., human heavy or light chain constant region genes) as discussed above. In one embodiment, this is effected using a proprietary expression vector of Biogen IDEC, Inc., referred to as NEOSPLA, disclosed in U.S. Pat. No. 6,159,730. This vector contains the cytomegalovirus promoter/enhancer, the mouse beta globin major promoter, the SV40 origin of replication, the bovine growth hormone polyadenylation sequence, neomycin phosphotransferase exon 1 and exon 2, the dihydrofolate reductase gene and leader sequence. This vector has been found to result in very high level expression of antibodies upon incorporation of variable and constant region genes, transfection in CHO cells, followed by selection in G418 containing medium and methotrexate amplification. Of course, any expression vector which is capable of eliciting expression in eukaryotic cells can be used in the invention. Examples of suitable vectors include, but are not limited to plasmids pcDNA3, pHCMV/Zeo, pCR3.1, pEF1/His, pIND/GS, pRc/HCMV2, pSV40/Zeo2, pTRACER-HCMV, pUB6N5-His, pVAX1, and pZeoSV2 (available from Invitrogen, San Diego, Calif.), and plasmid pCI (available from Promega, Madison, Wis.). In general, screening large numbers of transformed cells for those which express suitably high levels if immunoglobulin heavy and light chains is routine experimentation which can be carried out, for example, by robotic systems. Vector systems are also taught in U.S. Pat. Nos. 5,736,137 and 5,658,570, each of which is herein incorporated by reference in its entirety. This system provides for high expression levels, e.g., >30 pg/cell/day. Other exemplary vector systems are disclosed e.g., in U.S. Pat. No. 6,413,777.

In other embodiments the antibodies (e.g., antigen-binding fragments of antibodies and variants or derivatives thereof) of the invention can be expressed using polycistronic constructs such as those disclosed in U.S. Patent Application Publication No. 2003-0157641 A1 and herein incorporated by reference in its entirety. In these expression systems, multiple gene products of interest such as heavy and light chains of antibodies can be produced from a single polycistronic construct. These systems advantageously use an internal ribosome entry site (IRES) to provide relatively high levels of antibodies. Compatible IRES sequences are disclosed in U.S. Pat. No. 6,193,980 which is also incorporated herein. Those ordinary skill in the art will appreciate that such expression systems can be used to effectively produce the full range of antibodies disclosed in the application.

More generally, once the vector or DNA sequence encoding a monomeric subunit of the antibody has been prepared, the expression vector can be introduced into an appropriate host cell. Introduction of the plasmid into the host cell can be accomplished by various techniques known to those in the art. These include, but are not limited to, transfection including lipotransfection using, e.g., Fugene or lipofectamine, protoplast fusion, calcium phosphate precipitation, cell fusion with enveloped DNA, microinjection, and infection with intact virus. Typically, plasmid introduction into the host is via standard methods known in the art, such as, calcium phosphate co-precipitation method. The host cells harboring the expression construct are grown under conditions appropriate to the production of the light chains and heavy chains, and assayed for heavy and/or light chain protein synthesis. Non-limiting exemplary assay techniques include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), or fluorescence-activated cell sorter analysis (FACS), and immunohistochemistry.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody for use in the methods described herein. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, operably linked to a heterologous promoter. In particular embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains can be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

The host cell can be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors can contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector can be used which encodes both heavy and light chain polypeptides. In such situations, the light chain is advantageously placed before the heavy chain to avoid an excess of toxic free heavy chain; see Proudfoot, Nature 322 (1986), 52; Kohler, Proc. Natl. Acad. Sci. USA 77 (1980), 2197. The coding sequences for the heavy and light chains can comprise cDNA or genomic DNA.

As used herein, “host cells” refers to cells which harbor vectors constructed using recombinant DNA techniques and encoding at least one heterologous gene. In descriptions of processes for isolation of antibodies from recombinant hosts, the terms “cell” and “cell culture” are used interchangeably to denote the source of an antibody unless it is clearly specified otherwise. In other words, recovery of polypeptide from the “cells” can mean either from spun down whole cells, or from the cell culture containing both the medium and the suspended cells.

A variety of host-expression vector systems can be utilized to express antibodies for use in methods described herein. Such host-expression systems represent vehicles by which the coding sequences of interest can be produced and subsequently purified, but also represent cells which can, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, NSO, BLK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). In one embodiment, bacterial cells such as Escherichia coli, and eukaryotic cells, especially for the expression of whole recombinant antibody, are used for the expression of a recombinant antibody. For example, mammalian cells such as Chinese Hamster Ovary (CHO) cells, in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies; see, e.g., Foecking et al., Gene 45 (1986), 101; Cockett et al., Bio/Technology 8 (1990), 2.

The host cell lines used for protein expression of the TDP-43 binding molecules of the invention include, for example cells of mammalian origin; those of ordinary skill in the art are credited with ability to determine particular host cell lines which are best suited for the desired gene product to be expressed therein. Exemplary host cell lines include, but are not limited to, CHO (Chinese Hamster Ovary), DG44 and DUXB11 (Chinese Hamster Ovary lines, DHFR minus), HELA (human cervical carcinoma), CVI (monkey kidney line), COS (a derivative of CVI with SV40 T antigen), VERY, BHK (baby hamster kidney), MDCK, WI38, R1610 (Chinese hamster fibroblast) BALBC/3T3 (mouse fibroblast), HAK (hamster kidney line), SP2/O (mouse myeloma), P3×63-Ag3.653 (mouse myeloma), BFA-1c1BPT (bovine endothelial cells), RAJI (human lymphocyte) and 293 (human kidney). In a specific embodiment, host cell lines are CHO or 293 cells. Host cell lines are readily available and are typically available from commercial services, including for example, the American Tissue Culture Collection or from published literature.

In addition, a host cell strain can be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products can be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells can be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which stably express the antibody.

A number of selection systems can be used according to the present invention, including but not limited to, the herpes simplex virus thymidine kinase (Wigler et al., Cell 11 (1977), 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48 (1992), 202), and adenine phosphoribosyltransferase (Lowy et al., Cell 22 (1980), 817) genes can be employed in tk-, hgprt- or aprt-cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77 (1980), 357; O'Hare et al., Proc. Natl. Acad. Sci. USA 78 (1981), 1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78 (1981), 2072); neo, which confers resistance to the aminoglycoside G-418 Goldspiel et al., Clinical Pharmacy 12 (1993), 488-505; Wu and Wu, Biotherapy 3 (1991), 87-95; Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32 (1993), 573-596; Mulligan, Science 260 (1993), 926-932; and Morgan and Anderson, Ann. Rev. Biochem. 62 (1993), 191-217; TIB TECH 11 (1993), 155-215; and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30 (1984), 147. Methods known in the art of recombinant DNA technology which can be used are described in Ausubel et al., (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al., (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), each of which are herein incorporated by reference in their entireties.

The expression levels of an antibody can be increased using techniques known in the art, including for example, by vector amplification, see e.g., Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Academic Press, New York, Vol. 3. (1987). When a marker in the vector system expressing an antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase; see Crouse et al., Mol. Cell. Biol. 3 (1983), 257.

In vitro production allows scale-up to give large amounts of the desired polypeptides. Techniques for mammalian cell cultivation under tissue culture conditions are known in the art and include homogeneous suspension culture, e.g. in an airlift reactor or in a continuous stirrer reactor, or immobilized or entrapped cell culture, e.g. in hollow fibers, microcapsules, on agarose microbeads or ceramic cartridges. If necessary and/or desired, the solutions of polypeptides can be purified by the customary chromatography methods, for example gel filtration, ion-exchange chromatography, chromatography over DEAE-cellulose or (immuno-)affinity chromatography, e.g., after preferential biosynthesis of a synthetic hinge region polypeptide or prior to or subsequent to the HIC chromatography step described herein.

Genes encoding antibodies (including for example, antigen-binding fragments of antibodies and variants, or derivatives thereof) of the invention can also be expressed in non-mammalian cells such as bacteria or insect or yeast or plant cells. Bacteria which readily take up nucleic acids include members of the enterobacteriaceae, such as strains of Escherichia coli or Salmonella; Bacillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus, and Haemophilus influenzae. It will further be appreciated that, when expressed in bacteria, the heterologous polypeptides typically become part of inclusion bodies. The heterologous polypeptides must be isolated, purified and then assembled into functional molecules. Where tetravalent forms of antibodies are desired, the subunits will then self-assemble into tetravalent antibodies; see, e.g., International Application Publication No. WO02/096948.

In bacterial systems, a number of expression vectors can be advantageously selected depending upon the use intended for the antibody being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody, vectors which direct the expression of high levels of fusion protein products that are readily purified can be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., EMBO J. 2 (1983), 1791), in which the antibody coding sequence can be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13 (1985), 3101-3109; Van Heeke & Schuster, J. Biol. Chem. 24 (1989), 5503-5509); and the like. pGEX vectors can also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to a matrix of glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In addition to prokaryotes, eukaryotic microbes can also be used. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among eukaryotic microorganisms although a number of other strains are commonly available, e.g., Pichia pastoris. For expression in Saccharomyces, the plasmid YRp7, for example, (Stinchcomb et al., Nature 282 (1979), 39; Kingsman et al., Gene 7 (1979), 141; Tschemper et al., Gene 10 (1980), 157) is commonly used. This plasmid already contains the TRP 1 gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC No. 44076 or PEP4-1 (Jones, Genetics 85 (1977), 12). The presence of the trpl lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.

In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is typically used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. The antibody coding sequence can be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

Once an antibody of the invention has been recombinantly expressed, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the invention, can be purified according to standard procedures of the art, including for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, e.g. ammonium sulfate precipitation, or by any other standard technique for the purification of proteins; see, e.g., Scopes, “Protein Purification”, Springer Verlag, N.Y. (1982). Alternatively, another method for increasing the affinity of antibodies of the invention is disclosed in U.S. Patent Publication No. 2002-0123057 A1.

V. Fusion Proteins and Conjugates

In certain embodiments, the antibody polypeptide comprises an amino acid sequence or one or more moieties not normally associated with an antibody. Exemplary modifications are described in more detail below. For example, a single-chain AT antibody fragment of the invention can comprise a flexible linker sequence, or can be modified to add a functional moiety (e.g., PEG, a drug, a toxin, or a label such as a fluorescent, radioactive, enzyme, nuclear magnetic, heavy metal and the like)

An antibody polypeptide of the invention can comprise, consist essentially of, or consist of a fusion protein. Fusion proteins are chimeric molecules which comprise, for example, an immunoglobulin TDP-43-binding domain with at least one target binding site, and at least one heterologous portion, i.e., a portion with which it is not naturally linked in nature. The amino acid sequences can normally exist in separate proteins that are brought together in the fusion polypeptide or they can normally exist in the same protein but are placed in a new arrangement in the fusion polypeptide. Fusion proteins can be created, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship.

The term “heterologous” as applied to a polynucleotide or a polypeptide, means that the polynucleotide or polypeptide is derived from a distinct entity from that of the rest of the entity to which it is being compared. For instance, as used herein, a “heterologous polypeptide” to be fused to an antibody, or an antigen-binding fragment, variant, or analog thereof is derived from a non-immunoglobulin polypeptide of the same species, or an immunoglobulin or non-immunoglobulin polypeptide of a different species.

As discussed in more detail elsewhere herein, antibodies, (e.g., antigen-binding fragments of antibodies and variants or derivatives thereof) or antigen-binding fragments, variants, or derivatives thereof of the invention can further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalent and non-covalent conjugations) to polypeptides or other compositions. For example, antibodies can be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins; see, e.g., International Application Publication Nos. WO92/08495; WO91/14438; WO89/12624; U.S. Pat. No. 5,314,995; and European Patent Application No. EP 0 396 387.

Antibodies (e.g., antigen-binding fragments of antibodies and variants, or derivatives thereof) of the invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and can contain amino acids other than the 20 gene-encoded amino acids. Antibodies can be modified by natural processes, such as posttranslational processing, or by chemical modification techniques which are known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in the antibody, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini, or on moieties such as carbohydrates. It will be appreciated that the same type of modification can be present in the same or varying degrees at several sites in a given antibody. Also, a given antibody can contain many types of modifications. Antibodies can be branched, for example, as a result of ubiquitination, and they can be cyclic, with or without branching. Cyclic, branched, and branched cyclic antibodies can result from posttranslation natural processes or can be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination; see, e.g., Proteins—Structure And Molecular Properties, T. E. Creighton, W. H. Freeman and Company, New York 2nd Ed., (1993); Posttranslational Covalent Modification Of Proteins, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182 (1990), 626-646; Rattan et al., Ann. NY Acad. Sci. 663 (1992), 48-62).

The invention also provides for fusion proteins comprising an antibody, or antigen-binding fragment, variant, or derivative thereof, and a heterologous polypeptide. In one embodiment, a fusion protein of the invention comprises, consists essentially of, or consists of, a polypeptide having the amino acid sequence of any one or more of the V_(H) regions of an antibody of the invention or the amino acid sequence of any one or more of the V_(L) regions of an antibody of the invention or fragments or variants thereof, and a heterologous polypeptide sequence. In another embodiment, a fusion protein for use in the diagnostic and treatment methods disclosed herein comprises, consists essentially of, or consists of a polypeptide having the amino acid sequence of any one, two, three of the V_(H)-CDRs of an antibody, or fragments, variants, or derivatives thereof, or the amino acid sequence of any one, two, three of the V_(L)-CDRs of an antibody, or fragments, variants, or derivatives thereof, and a heterologous polypeptide sequence. In one embodiment, the fusion protein comprises a polypeptide having the amino acid sequence of a V_(H)-CDR3 of an antibody of the invention, or fragment, derivative, or variant thereof, and a heterologous polypeptide sequence, which fusion protein specifically binds to TDP-43. In another embodiment, a fusion protein comprises a polypeptide having the amino acid sequence of at least one V_(H) region of an antibody of the invention and the amino acid sequence of at least one V_(L) region of an antibody of the invention or fragments, derivatives or variants thereof, and a heterologous polypeptide sequence. In one embodiment, the V_(H) and V_(L) regions of the fusion protein correspond to a single source antibody (or scFv or Fab fragment) which specifically binds TDP-43. In yet another embodiment, a fusion protein for use in the diagnostic and treatment methods disclosed herein comprises a polypeptide having the amino acid sequence of any one, two, three or more of the V_(H) CDRs of an antibody and the amino acid sequence of any one, two, three or more of the VL CDRs of an antibody, or fragments or variants thereof, and a heterologous polypeptide sequence. In one embodiment, two, three, four, five, six, or more of the V_(H)-CDR(s) or V_(L)-CDR(s) correspond to single source antibody (or scFv or Fab fragment) of the invention. Nucleic acid molecules encoding these fusion proteins are also encompassed by the invention.

Exemplary fusion proteins reported in the literature include fusions of the T cell receptor (Gascoigne et al., Proc. Natl. Acad. Sci. USA 84 (1987), 2936-2940; CD4 (Capon et al., Nature 337 (1989), 525-531; Traunecker et al., Nature 339 (1989), 68-70; Zettmeissl et al., DNA Cell. Biol. USA 9 (1990), 347-353; and Byrn et al., Nature 344 (1990), 667-670); L-selectin (homing receptor) (Watson et al., J. Cell. Biol. 110 (1990), 2221-2229; and Watson et al., Nature 349 (1991), 164-167); CD44 (Aruffo et al., Cell 61 (1990), 1303-1313); CD28 and B7 (Linsley et al., J. Exp. Med. 173 (1991),721-730); CTLA-4 (Lisley et al., J. Exp. Med. 174 (1991), 561-569); CD22 (Stamenkovic et al., Cell 66 (1991), 1133-1144); TNF receptor (Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88 (1991), 10535-10539; Lesslauer et al., Eur. J. Immunol. 27 (1991), 2883-2886; and Peppel et al., J. Exp. Med. 174 (1991), 1483-1489 (1991); and IgE receptor a (Ridgway and Gorman, J. Cell. Biol. 115 (1991), Abstract No. 1448).

As discussed elsewhere herein, antibodies, (e.g., intact antibodies, and antigen-binding fragments of antibodies and variants, or derivatives thereof) of the invention can be fused to heterologous polypeptides to increase the in vivo half-life of the polypeptides or for use in immunoassays using methods known in the art. For example, in one embodiment, PEG can be conjugated to the antibodies of the invention to increase their half-life in vivo; see, e.g., Leong et al., Cytokine 16 (2001), 106-119; Adv. in Drug Deliv. Rev. 54 (2002), 531; or Weir et al., Biochem. Soc. Transactions 30 (2002), 512.

Moreover, antibodies (e.g., intact antibodies, and antigen-binding fragments of antibodies and variants, or derivatives thereof) of the invention can be fused to marker sequences, such as a peptide to facilitate their purification or detection. In particular embodiments, the marker amino acid sequence is a hexa-histidine peptide (HIS), such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif., 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86 (1989), 821-824, for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the “HA” tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37 (1984), 767) and the “flag” tag.

Fusion proteins can be prepared using methods that are well known in the art; see for example U.S. Pat. Nos. 5,116,964 and 5,225,538. The precise site at which the fusion is made can be selected empirically to optimize the secretion or binding characteristics of the fusion protein. DNA encoding the fusion protein is then transfected into a host cell for expression.

Antibodies of the invention can be used in non-conjugated form or can be conjugated to at least one of a variety of molecules, e.g., to improve the therapeutic properties of the molecule, to facilitate target detection, or for imaging or therapy of the patient. Antibodies (e.g., intact antibodies, and antigen-binding fragments of antibodies and variants, or derivatives thereof) of the invention can be labeled or conjugated either before or after purification, when purification is performed. In particular, antibodies of the invention can be conjugated to therapeutic agents, prodrugs, peptides, proteins, enzymes, viruses, lipids, biological response modifiers, pharmaceutical agents, or PEG.

Conjugates that are immunotoxins including conventional antibodies have been widely described in the art. The toxins can be coupled to the antibodies by conventional coupling techniques or immunotoxins containing protein toxin portions can be produced as fusion proteins. The antibodies of the invention can be used in a corresponding way to obtain such immunotoxins. Illustrative of such immunotoxins are those described by Byers, Seminars Cell. Biol. 2 (1991), 59-70 and by Fanger, Immunol. Today 12 (1991), 51-54.

Those of ordinary skill in the art will appreciate that conjugates can also be assembled using a variety of techniques depending on the selected agent to be conjugated. For example, conjugates with biotin are prepared e.g. by reacting an TDP-43 binding polypeptide with an activated ester of biotin such as the biotin N-hydroxysuccinimide ester. Similarly, conjugates with a fluorescent marker can be prepared in the presence of a coupling agent, e.g. those listed herein, or by reaction with an isothiocyanate, or fluorescein-isothiocyanate. Conjugates of the of the invention are prepared in an analogous manner.

The invention further encompasses antibodies (e.g., intact antibodies, and antigen-binding fragments of antibodies and variants, or derivatives thereof) of the invention conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, demonstrate presence of a neurological disease, to indicate the risk of getting a neurological disease, to monitor the development or progression of a neurological disease, i.e. TDP-43 proteinopathy as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment and/or prevention regimen. Detection can be facilitated by coupling the antibody, or antigen-binding fragment, variant, or derivative thereof to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions; see, e.g., U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include 125I, ¹³¹I, ¹¹¹In or ⁹⁹Tc.

An antibody, or antigen-binding fragment, variant, or derivative thereof also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

One of the ways in which an antibody, or antigen-binding fragment, variant, or derivative thereof can be detectably labeled is by linking the same to an enzyme and using the linked product in an enzyme immunoassay (EIA) (Voller, A., “The Enzyme Linked Immunosorbent Assay (ELISA)” Microbiological Associates Quarterly Publication, Walkersville, Md., Diagnostic Horizons 2 (1978), 1-7); Voller et al., J. Clin. Pathol. 31 (1978), 507-520; Butler, Meth. Enzymol. 73 (1981), 482-523; Maggio, E. (ed.), Enzyme Immunoassay, CRC Press, Boca Raton, Fla., (1980); Ishikawa, E. et al., (eds.), Enzyme Immunoassay, Kgaku Shoin, Tokyo (1981). The enzyme, which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. Additionally, the detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection can also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

Detection can also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibody, or antigen-binding fragment, variant, or derivative thereof, it is possible to detect the antibody through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, (March, 1986)), which is herein incorporated by reference in its entirety). The radioactive isotope can be detected by means including, but not limited to, a gamma counter, a scintillation counter, or autoradiography.

An antibody, or antigen-binding fragment, variant, or derivative thereof can also be detectably labeled using fluorescence emitting metals such as ¹⁵²Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

Techniques for conjugating various moieties to an antibody, or antigen-binding fragment, variant, or derivative thereof are known; see, e.g., Arnon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al., (eds.), pp. 243-56 (Alan R. Liss, Inc. (1985); Hellstrom et al., “Antibodies For Drug Delivery”, in Controlled Drug Delivery (2nd Ed.), Robinson et al., (eds.), Marcel Dekker, Inc., pp. 623-53 (1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al., (eds.), pp. 475-506 (1985); “Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al., (eds.), Academic Press pp. 303-16 (1985), and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev. 62 (1982), 119-158.

As mentioned, in certain embodiments, a moiety that enhances the stability or efficacy of a binding molecule, e.g., a binding polypeptide, e.g., an antibody or immunospecific fragment thereof can be conjugated. For example, in one embodiment, PEG can be conjugated to the binding molecules of the invention to increase their half-life in vivo. Leong et al., Cytokine 16 (2001), 106; Adv. in Drug Deliv. Rev. 54 (2002), 531; or Weir et al., Biochem. Soc. Transactions 30 (2002), 512.

VI. Compositions and Methods of Use

The invention relates to compositions comprising the aforementioned TDP-43 binding molecule, e.g., antibody or antigen-binding fragment thereof of the invention or derivative or variant thereof, or the polynucleotide, vector or cell of the invention. The composition of the invention can further comprise a pharmaceutically acceptable carrier. Furthermore, the pharmaceutical composition of the invention can comprise further agents such as interleukins or interferons depending on the intended use of the pharmaceutical composition. For example, for use in the treatment of TDP-43 proteinopathy the additional agent can be selected from the group consisting of small organic molecules, anti-TDP-43 antibodies, and combinations thereof. Hence, in a particular embodiment the invention relates to the use of the TDP-43 binding molecule, e.g., antibody or antigen-binding fragment thereof of the invention or of a binding molecule having substantially the same binding specificities of any one thereof, the polynucleotide, the vector or the cell of the invention for the preparation of a pharmaceutical or diagnostic composition for prophylactic and therapeutic treatment of a TDP-43 proteinopathy, monitoring the progression of a TDP-43 proteinopathy or a response to a TDP-43 proteinopathy treatment in a subject or for determining a subject's risk for developing a TDP-43 proteinopathy.

Hence, in one embodiment the invention relates to a method of treating a neurological disorder characterized by abnormal accumulation and/or deposition of TDP-43 in the brain and the central nervous system, respectively, which method comprises administering to a subject in need thereof a therapeutically effective amount of any one of the afore-described TDP-43 binding molecules, antibodies, polynucleotides, vectors or cells of the instant invention. The term “TDP-43 proteinopathy” includes but is not limited to TDP-43 proteinopathies such as argyrophilic grain disease, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), ALS-Parkinsonism dementia complex of Guam, corticobasal degeneration, Dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration (FTLD), frontotemporal dementia, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, Parkinson's disease dementia, Parkinson-dementia complex in Kii peninsula and Pick's disease as well as other movement disorders, neurodegenerative diseases and disease of the central nervous system (CNS) in general. Unless stated otherwise, the terms neurodegenerative, neurological or neuropsychiatric are used interchangeably herein.

A particular advantage of the therapeutic approach of the invention lies in the fact that the antibodies of the invention are derived from B cells or B memory cells from healthy human subjects with no signs of ALS and/or FTLD and thus are, with a certain probability, capable of preventing a clinically manifest TDP-43 proteinopathies, or of diminishing the risk of the occurrence of the clinically manifest disease, or of delaying the onset of the clinically manifest disease. Typically, the antibodies of the invention also have already successfully gone through somatic maturation, i.e. the optimization with respect to target selectivity and effectiveness in the high affinity binding to the target TDP-43 molecule by means of somatic variation of the variable regions of the antibody.

The knowledge that such cells in vivo, e.g., in a human, have not been activated by means of related or other physiological proteins or cell structures in the sense of an autoimmunological or allergic reaction is also of great medical importance since this signifies a considerably increased chance of successfully living through the clinical test phases. So to speak, efficiency, acceptability and tolerability have already been demonstrated before the preclinical and clinical development of the prophylactic or therapeutic antibody in at least one human subject. It can thus be expected that the human anti-TDP-43 antibodies of the invention, both its target structure-specific efficiency as therapeutic agent and its decreased probability of side effects significantly increase its clinical probability of success.

The invention also provides a pharmaceutical and diagnostic, respectively, pack or kit comprising one or more containers filled with one or more of the above described ingredients, e.g. anti-TDP-43 antibody, binding fragment, derivative or variant thereof, polynucleotide, vector or cell of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition or alternatively the kit comprises reagents and/or instructions for use in appropriate diagnostic assays. The composition, e.g. kit of the invention is of course particularly suitable for the risk assessment, diagnosis, prevention and treatment of a disorder which is accompanied with the presence of TDP-43, and in particular applicable for the treatment of neurodegenerative diseases, TDP-43 proteinopathies, argyrophilic grain disease, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), ALS-Parkinsonism dementia complex of Guam, corticobasal degeneration, Dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration (FTLD), frontotemporal dementia, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, Parkinson's disease dementia, Parkinson-dementia complex in Kii peninsula and Pick's disease.

In a specific embodiment, the composition of invention is in a sterile aqueous solution. In another embodiment, one or more of the components of a composition of the invention have been lyophilized. In an additional embodiment, the composition of the invention does not contain serum. In a further embodiment, one or more antibodies contained in a composition of the invention are recombinantly produced. In another embodiment, the population of antibodies of the invention in the composition constitutes at least 10% of the immunoglobulin population in the composition.

The pharmaceutical compositions of the invention can be formulated according to methods known in the art; see for example Remington: The Science and Practice of Pharmacy (2000) by the University of Sciences in Philadelphia, ISBN 0-683-306472. Examples of suitable pharmaceutical carriers are known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions can be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration. Aerosol formulations such as nasal spray formulations include purified aqueous or other solutions of the active agent with preservative agents and isotonic agents. Such formulations are adjusted to a pH and isotonic state compatible with the nasal mucous membranes. Formulations for rectal or vaginal ad-ministration can be presented as a suppository with a suitable carrier.

More particularly, pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In such cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and will preferably be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.

Furthermore, whereas the invention includes the now standard (though fortunately infrequent) procedure of drilling a small hole in the skull to administer a drug of the invention, in one aspect, the binding molecule, especially antibody or antibody based drug of the invention can cross the blood-brain barrier, which allows for intravenous or oral administration.

The dosage regimen will be determined by the attending physician and clinical factors. As is known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. A typical dose can be, for example, in the range of 0.001 to 1000 μg (or of nucleic acid for expression or for inhibition of expression in this range); however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. Generally, the dosage can range, e.g., from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg (e.g., 0.02 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 0.75 mg/kg, 1 mg/kg, 2 mg/kg, etc.), of the host body weight. For example dosages can be 1 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg, or at least 1 mg/kg. Doses intermediate in the above ranges are also intended to be within the scope of the invention. Subjects can be administered such doses daily, on alternative days, weekly or according to any other schedule determined by empirical analysis. An exemplary treatment entails administration in multiple dosages over a prolonged period, for example, of at least six months. Additional exemplary treatment regimens entail administration once per every two weeks or once a month or once every 3 to 6 months. Exemplary dosage schedules include 1-10 mg/kg or 15 mg/kg on consecutive days, 30 mg/kg on alternate days or 60 mg/kg weekly. In some methods, two or more monoclonal antibodies with different binding specificities are administered simultaneously, in which case the dosage of each antibody administered falls within the ranges indicated. Progress can be monitored by periodic assessment.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives can also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. Furthermore, the pharmaceutical composition of the invention can comprise further agents such as dopamine or psychopharmacologic drugs, depending on the intended use of the pharmaceutical composition.

Furthermore, in a particular embodiment of the invention the pharmaceutical composition can be formulated as a vaccine, for example, if the pharmaceutical composition of the invention comprises an anti-TDP-43 antibody or binding fragment, derivative or variant thereof for passive immunization. It is prudent to expect that the human anti TDP-43 antibodies and equivalent TDP-43 binding molecules of the invention are particularly useful as a vaccine for the prevention or amelioration of TDP-43 proteinopathies such as amyotrophic lateral sclerosis (ALS) argyrophilic grain disease, Alzheimer's disease, ALS-Parkinsonism dementia complex of Guam, corticobasal degeneration, Dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration (FTLD), frontotemporal dementia, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, Parkinson's disease dementia, Parkinson-dementia complex in Kii peninsula, Pick's disease, Machado-Joseph disease and the like.

In one embodiment, it can be beneficial to use recombinant Fab (rFab) and single chain fragments (scFvs) of the antibody of the invention, which might more readily penetrate a cell membrane. For example, Robert et al., Protein Eng. Des. Sel. (2008) October 16; S1741-0134, published online ahead, describe the use of chimeric recombinant Fab (rFab) and single chain fragments (scFvs) of monoclonal antibody WO-2 which recognizes an epitope in the N-terminal region of Aβ. The engineered fragments were able to (i) prevent amyloid fibrillization, (ii) disaggregate preformed Aβ1-42 fibrils and (iii) inhibit Aβ1-42 oligomer-mediated neurotoxicity in vitro as efficiently as the whole IgG molecule. The perceived advantages of using small Fab and scFv engineered antibody formats which lack the effector function include more efficient passage across the blood-brain barrier and minimizing the risk of triggering inflammatory side reactions. Furthermore, besides scFv and single-domain antibodies retain the binding specificity of full-length antibodies, they can be expressed as single genes and intracellularly in mammalian cells as intrabodies, with the potential for alteration of the folding, interactions, modifications, or subcellular localization of their targets; see for review, e.g., Miller and Messer, Molecular Therapy 12 (2005), 394-401.

In a different approach Muller et al., Expert Opin. Biol. Ther. (2005), 237-241, describe a technology platform, so-called ‘SuperAntibody Technology’, which is said to enable antibodies to be shuttled into living cells without harming them. Such cell-penetrating antibodies open new diagnostic and therapeutic windows. The term ‘TransMabs’ has been coined for these antibodies.

In a further embodiment, co-administration or sequential administration of other neuroprotective agents useful for treating a TDP-43 proteinopathy can be desirable. In one embodiment, the additional agent is comprised in the pharmaceutical composition of the invention. Examples of neuroprotective agents which can be used to treat a subject include, but are not limited to, an acetylcholinesterase inhibitor, a glutamatergic receptor antagonist, kinase inhibitors, HDAC inhibitors, anti-inflammatory agents, divalproex sodium, or any combination thereof. Examples of other neuroprotective agents that can be used concomitant with pharmaceutical composition of the invention are described in the art; see, e.g. International Application Publication No. WO2007/011907. In one embodiment, the additional agent is dopamine or a dopamine receptor agonist.

A therapeutically effective dose or amount refers to that amount of the active ingredient sufficient to ameliorate the symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD₅₀/ED₅₀. In one embodiment, the therapeutic agent in the composition is present in an amount sufficient to restore or preserve normal behavior and/or cognitive properties in case of ALS and/or FTLD or other TDP-43 proteinopathies.

From the foregoing, it is evident that the invention encompasses any use of an TDP-43 binding molecule comprising at least one CDR of the above described antibody, in particular for diagnosing and/or treatment of a TDP-43 proteinopathies as mentioned above, particularly amyotrophic lateral sclerosis and/or frontotemporal lobar degeneration. In one embodiment, said binding molecule is an antibody of the invention or an immunoglobulin chain thereof. In addition, the invention relates to anti-idiotypic antibodies of any one of the mentioned antibodies described hereinbefore. Anti-idiotypic antibodies are antibodies or other binding molecules which bind to the unique antigenic peptide sequence located on an antibody's variable region near the antigen-binding site and are useful, e.g., for the detection of anti-TDP-43 antibodies in sample of a subject.

In another embodiment the invention relates to a diagnostic composition comprising any one of the above described TDP-43 binding molecules, antibodies, antigen-binding fragments, polynucleotides, vectors or cells of the invention and optionally suitable means for detection such as reagents conventionally used in immuno or nucleic acid based diagnostic methods. The antibodies of the invention are, for example, suited for use in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier. Examples of immunoassays which can utilize the antibody of the invention are competitive and non-competitive immunoassays in either a direct or indirect format. Examples of such immunoassays are the radioimmunoassay (RIA), the sandwich (immunometric assay), flow cytometry and the Western blot assay. The antigens and antibodies of the invention can be bound to many different carriers and used to isolate cells specifically bound thereto. Examples of known carriers include glass, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble or insoluble for the purposes of the invention. There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the invention include enzymes, radioisotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds, and bioluminescent compounds; see also the embodiments discussed hereinabove.

By a further embodiment, the TDP-43 binding molecules, in particular antibodies of the invention can also be used in a method for the diagnosis of a disorder in an individual by obtaining a body fluid sample from the tested individual which can be a blood sample, a lymph sample or any other body fluid sample and contacting the body fluid sample with an antibody of the instant invention under conditions enabling the formation of antibody-antigen complexes. The level of such complexes is then determined by methods known in the art, a level significantly higher than that formed in a control sample indicating the disease in the tested individual. In the same manner, the specific antigen bound by the antibodies of the invention can also be used. Thus, the invention relates to an in vitro immunoassay comprising the binding molecule, e.g., antibody or antigen-binding fragment thereof of the invention.

In this context, the invention also relates to means specifically designed for this purpose. For example, an antibody-based array can be used, which is for example loaded with antibodies or equivalent antigen-binding molecules of the invention which specifically recognize TDP-43. Design of microarray immunoassays is summarized in Kusnezow et al., Mol. Cell Proteomics 5 (2006), 1681-1696. Accordingly, the invention also relates to microarrays loaded with TDP-43 binding molecules identified in accordance with the invention.

In one embodiment, the invention relates to a method of diagnosing a TDP-43 proteinopathy in a subject, the method comprising:

-   -   (a) assessing the level of TDP-43 in a sample from the subject         to be diagnosed with an antibody of the invention, an TDP-43         binding fragment thereof or an TDP-43 binding molecule having         substantially the same binding specificities of any one thereof;         and     -   (b) Comparing the level of the TDP-43 to a reference standard         that indicates the level of the TDP-43 in one or more control         subjects,     -   Wherein a difference or similarity between the level of the         TDP-43 and the reference standard indicates that the subject         suffers from a TDP-43 proteinopathy.

The subject to be diagnosed can be asymptomatic or preclinical for the disease. In one embodiment, the control subject has a TDP-43 proteinopathy, for example ALS or FTLD, wherein a similarity between the level of TDP-43 and the reference standard indicates that the subject to be diagnosed has a TDP-43 proteinopathy. Alternatively, or in addition as a second control the control subject does not have a TDP-43 proteinopathy, wherein a difference between the level of TDP-43 and the reference standard indicates that the subject to be diagnosed has a TDP-43 proteinopathy. I, the subject to be diagnosed and the control subject(s) are age-matched. The sample to be analyzed can be any body fluid suspected to contain TDP-43, for example a blood, CSF, or urine sample.

The level of TDP-43 can be assessed by any suitable method known in the art comprising, e.g., analyzing TDP-43 by one or more techniques chosen from Western blot, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescent activated cell sorting (FACS), two-dimensional gel electrophoresis, mass spectroscopy (MS), matrix-assisted laser desorption/ionization-time of flight-MS (MALDI-TOF), surface-enhanced laser desorption ionization-time of flight (SELDI-TOF), high performance liquid chromatography (HPLC), fast protein liquid chromatography (FPLC), multidimensional liquid chromatography (LC) followed by tandem mass spectrometry (MS/MS), and laser densitometry. In one embodiment, said in vivo imaging of TDP-43 comprises positron emission tomography (PET), single photon emission tomography (SPECT), near infrared (NIR) optical imaging or magnetic resonance imaging (MRI).

Methods of diagnosing a neurodegenerative disease such as AD, Parkinson's disease, ALS, Huntington's disease, Dementia with Lewy bodies or FTLD for monitoring a TDP-43 proteinopathy progression, and monitoring a TDP-43 proteinopathy treatment using antibodies and related means which can be adapted in accordance with the invention are also described in International Application Publication Nos. WO 2010/111587 and WO2007/011907, which is herein incorporated by reference in its entirety. Those methods can be applied as described but with an TDP-43 specific antibody, binding fragment, derivative or variant of the invention.

These and other embodiments are disclosed and encompassed by the description and examples of the invention. Further literature concerning any one of the materials, methods, uses and compounds to be employed in accordance with the invention can be retrieved from public libraries and databases, using for example electronic devices. For example the public database “Medline” can be utilized, which is hosted by the National Center for Biotechnology Information and/or the National Library of Medicine at the National Institutes of Health. Further databases and web addresses, such as those of the European Bioinformatics Institute (EBI), which is part of the European Molecular Biology Laboratory (EMBL) are known to the person of ordinary skill in the art and can also be obtained using internet search engines. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness are given in Berks, TIBTECH 12 (1994), 352-364.

The above disclosure generally describes the invention. Unless otherwise stated, a term as used herein is given the definition as provided in the Oxford Dictionary of Biochemistry and Molecular Biology, Oxford University Press, 1997, revised 2000 and reprinted 2003, ISBN 0 19 850673 2. Several documents are cited throughout the text of this specification. Full bibliographic citations can be found at the end of the specification immediately preceding the claims. The contents of all cited references (including literature references, issued patents, published patent applications as cited throughout this application and manufacturer's specifications, instructions, etc.) are hereby incorporated by reference in their entireties; however, there is no admission that any document cited is indeed prior art as to the invention.

A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only and are not intended to limit the scope of the invention.

EXAMPLES Material and Methods

Detailed descriptions of conventional methods, such as those employed herein can be found in the cited literature. Unless indicated otherwise below, identification of TDP-43-specific B cells and molecular cloning of TDP-43 antibodies displaying specificity of interest as well as their recombinant expression and functional characterization has been or can be performed as described in the Examples and Supplementary Methods section of International Application PCT/EP2008/000053 published as WO2008/081008, each of which are herein incorporated by reference in its entirety.

Human TDP-43 Antibody Screening ELISA

96 well half area microplates (Corning) were coated with either:

-   -   (a) recombinant full-length His-tagged human TDP-43 (Biogen         Idec, USA); or     -   (b) a synthetic peptide consisting of residues 390-414 of the         C-terminal domain of TDP-43 with phosphorylation modification at         residues 409 and 410 (Shafer-N, DK)     -   at a concentration of 5 μg/ml and 3.3 μg/ml, respectively, in         carbonate ELISA coating buffer (pH 9.6) overnight at 4° C.

Plates were washed in PBS-Tween (pH 7.6) and non-specific binding sites were blocked for 1 hr. at room temperature with PBS-T containing 2% BSA (Sigma, Buchs, Switzerland). B cell conditioned medium was transferred from memory B cell culture plates to ELISA plates and incubated for 1 hr. at room temperature. ELISA plates were washed in PBS-T and then incubated with horse radish peroxidase (HRP)-conjugated anti-human immunoglobulins polyclonal antibodies (Jackson ImmunoResearch, USA). After washing with PBS-T, binding of human antibodies was determined by measurement of HRP activity in a standard colorimetric assay.

MSD

Standard 96 well 10-Spot MULTI-SPOT plates (Meso Scale Discovery, USA) were coated with a mixture of TDP-43 protein fragments corresponding to amino acids 1-259, 260 to 277 and 350-366 (Abcam plc, UK), respectively. 10 μg/ml of each peptide was used and formulated in PBS. Non-specific binding sites were blocked for 1 hr. at room temperature with PBS-T containing 3% BSA followed by incubation with B cell conditioned medium for 1 hr. at room temperature. Plates were washed in PBS-T and then incubated with SULFO-Tag conjugated anti-human polyclonal antibody (Mesoscale Discovery, USA). After washing with PBS-T, bound antibody was detected by electrochemiluminescence measurement using a SECTOR Imager 6000 (Meso Scale Discovery, USA).

Molecular Cloning of Human TDP-43 Antibodies

Samples containing memory B cells were obtained from healthy human subjects. Living B cells of selected memory B cell cultures were harvested, mRNA was isolated and cDNA was prepared by Reverse Transcriptase (Clontech, USA). Immunoglobulin heavy and light chain sequences were then obtained using a nested PCR approach.

A combination of primers representing all sequence families of the human immunoglobulin germline repertoire are used for the amplifications of leader peptides, V-segments and J-segments. The first round amplification is performed using leader peptide-specific primers in 5′-end and constant region-specific primers in 3′-end (Smith et al., Nat Protoc. 4 (2009), 372-384). For heavy chains and kappa light chains, the second round amplification is performed using V-segment-specific primers at the 5′-end and J-segment-specific primers at the 3′ end. For lambda light chains, the second round amplification is performed using V-segment-specific primers at the 5′-end and a C-region-specific primer at the 3′end (Marks et al., Mol. Biol. 222 (1991), 581-597; de Haard et al., J. Biol. Chem. 26 (1999), 18218-18230).

Identification of the antibody clone with the desired specificity is performed by re-screening on ELISA upon recombinant expression of complete antibodies. Recombinant expression of complete human IgG1 antibodies or chimeric IgG2a antibodies is achieved upon insertion of the variable heavy and light chain sequences “in the correct reading frame” into expression vectors that complement the variable region sequence with a sequence encoding a leader peptide at the 5′-end and with a sequence encoding the appropriate constant domain(s) at the 3′-end. To that end the primers contained restriction sites designed to facilitate cloning of the variable heavy and light chain sequences into antibody expression vectors. Heavy chain immunoglobulins are expressed by inserting the immunoglobulin heavy chain RT-PCR product in frame into a heavy chain expression vector bearing a signal peptide and the constant domains of human immunoglobulin gamma 1 or mouse immunoglobulin gamma 2a. Kappa light chain immunoglobulins are expressed by inserting the kappa light chain RT-PCR-product in frame into a light chain expression vector providing a signal peptide and the constant domain of human kappa light chain immunoglobulin. Lambda light chain immunoglobulins are expressed by inserting the lambda light chain RT-PCR-product in frame into a lambda light chain expression vector providing a signal peptide and the constant domain of human or mouse lambda light chain immunoglobulin.

Functional recombinant monoclonal antibodies are obtained upon co-transfection into HEK293 or CHO cells (or any other appropriate recipient cell line of human or mouse origin) of an Ig-heavy-chain expression vector and a kappa or lambda Ig-light-chain expression vector. Recombinant human monoclonal antibody is subsequently purified from the conditioned medium using a standard Protein A column purification. Recombinant human monoclonal antibody can be produced in unlimited quantities using either transiently or stably transfected cells. Cell lines producing recombinant human monoclonal antibody can be established either by using the Ig-expression vectors directly or by re-cloning of Ig-variable regions into different expression vectors. Derivatives such as F(ab), F(ab)₂ and scFv can also be generated from these Ig-variable regions.

Purification and Characterization of His-Tagged TDP-43

An expression vector for 6× His-tagged TDP-43 (pCGB026) was generated by cloning the TDP-43 sequence into the pRSET A expression vector (Invitrogen). BL21 Star (DE3)pLysS E. coli cells (Invitrogen) were transformed with pCGB026. Following growth at 37° C. to approximately 1 OD in a 1 L shake flask containing LB broth, IPTG was added to 0.5 mM and the cells were grown overnight at 18° C. Cells were pelleted by low-speed centrifugation, the supernatant was decanted and the cell pellets were frozen for storage at −20° C.

Cell pellets were equilibrated to room temperature and resuspended in 50 mL of 50 mM Tris-HCl pH 7.5, 20 mM imidazole, 150 mM NaCl, containing protease inhibitors (PI) (final concentration PI: 1 mM PMSF, 5 μM pepstatin A, 1 mM benzamide, 10 μM bestatin, 10 μM E64, 20 μM leupeptin, 1.5 μM aprotinin). Following homogenization for 5 min. to break up large particles, the cells were disrupted under high pressure using a Microfluidizer (Microfluidics, Inc.). The cell lysate was centrifuged for 30 min. at 10,000 rpm at 4° C. The pellet, containing insoluble his-tagged TDP-43, was resuspended in 5 mL B-PER solution (Thermo Scientific) containing 2 mM MgCl₂, Complete EDTA-free PI tablets (Roche), 100 μg/mL lysozyme, 5 U/mL DNase (Thermo Scientific) and incubated for 15 min. at room temperature. Additional B-PER/2 mM MgCl₂/PI tablet solution was added to a final volume of 50 mL and the mixture was centrifuged for 10 min. at 10,000 rpm. The isolated pellet was washed twice in 20 mL of 50 mM Tris-HCl pH 7.5, 20 mM imidazole, 150 mM NaCl, PI buffer, followed by centrifugation for 10 min. at 10,000 rpm. The isolated pellet was then resuspended in 8 M urea, 20 mM sodium phosphate pH 7.8 containing PI, mixed for 5 min. by homogenization and centrifuged at 10,000 rpm for 10 min.

The supernatant was isolated, filtered through a 0.45 μm filter, combined with 4 mL of Ni-NTA resin (Invitrogen) equilibrated in 8 M urea, 20 mM sodium phosphate pH 7.8, 0.5 M NaCl, with PI, and incubated while rocking overnight at 4° C. The flow-through was collected and the resin was washed with 10 column volumes of 8 M urea, 20 mM sodium phosphate pH 5.3, 0.5 M NaCl. His-tagged TDP-43 was eluted in 0.5 column volume fractions with 8 M urea, 20 mM sodium phosphate pH 4, 0.5 M sodium chloride. Peak fractions were pooled, and protein concentration was determined using UV spectrometry. The total purified yield was ˜8 mg/L culture.

SDS-PAGE analysis of the purified protein showed a major band at ˜47 kDa (data not provided), consistent with the predicted molecular mass of 46.5 kDa. Intact mass spectrometry on the purified protein indicated a major peak at 46538 Da, consistent with the predicted mass of 46529.9 Da. The ability of known commercially available antibodies against TDP-43 to bind the purified protein was determined by ELISA. Mouse monoclonal antibody 2E2-D3, recognizing amino acids 205-222 (Zhang, H.-X. et al., 2008, Neuroscience Lett., 434, 170-74), and rabbit polyclonal antibodies A260 and G400, recognizing sequences around amino acids Ala-260 and Gly-400, respectively, all bound to the purified His-tagged TDP-43 (data not provided).

Recombinant Expression of Human TDP-43 Domains

The human TDP-43 domain coding sequences were amplified by PCR from the full length cDNA sequence (Q13148, TARDBP HUMAN) and cloned into the expression vector pRSET-A (Invitrogen, USA). The four expression vectors (His-huTDP-43 domain I, His-huTDP-43 domain II, His-huTDP-43 domain III and His-huTDP-43 domain IV) are coding for the four TDP-43 domains: the N-terminal domain (amino acid residues 2-106 of SEQ ID NO:94), the RNA binding domain 1 (amino acid residues 99-204 of SEQ ID NO:94), the RNA binding domain 2 (amino acid residues 183-273 of SEQ ID NO:94) and the Glycine-rich domain (amino acid residues 258-414 of SEQ ID NO:94), respectively. DNA constructs comprising the cDNA encoding the TDP-43 domains under the control of the T7 promoter were used to transform an appropriate Escherichia coli strain such as BL21(DE3) (New England Biolabs, USA) and expression of 15 ml cell culture was induced by the addition of 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG). Cells were harvested after 4 hrs. induction at 37° C. and then resuspended in 1 ml 100 mM KCl, 50 mM HEPES, 2 mM EGTA, 1 mM MgCl₂, 1 mM Dithiothreitol, 0.1 mM PMSF, 10% glycerol and 0.1 mg/ml lysozyme , pH 7.5, followed by sonification. Soluble and insoluble fractions were collected after centrifugation at 9000 rpm at 4° C. for 45 min. Similarly, 9000 g supernatant from mock Escherichia coli was collected. When required (TDP-43 domain IV), insoluble fraction was solubilized in 1 ml 8M Urea, 20 mM Tris, 200 mM KCl and 1 mM β-Mercaptoethanol. Soluble and solubilized fractions were loaded onto Ni-NTA Superflow Columns (Qiagen, USA) and His-TDP-43 domains were purified according to manufacturer's protocol. Purity grade of recombinant proteins was estimated by SDS-PAGE and Coomassie staining. Concentration of purified proteins was determined by 280 nM absorbance measurement.

Direct ELISA

96 well microplates (Corning) were coated with human full length TDP-43, TDP-43 domain I (amino acid residues 2-106 of SEQ ID NO:94), TDP-43 domain II (amino acid residues 99-204 of SEQ ID NO:94), TDP-43 domain III (amino acid residues 183-273 of SEQ ID NO:94), TDP-43 domain IV (amino acid residues 258-414 of SEQ ID NO:94) or with a synthetic peptide covering residues 390 to 414 of the C-terminal domain of TDP-43 (see, SEQ ID NO:94) with phosphorylation modification at residues 409/410 (Schafer-N, DK) diluted to a concentration of 6.6 μg/ml or 3.3 μg/ml, respectively, in carbonate ELISA coating buffer (pH 9.6) overnight at 4° C. Non-specific binding sites were blocked for 1 hr. at room temperature with PBST containing 2% BSA (Sigma, Buchs, Switzerland). Antibodies were incubated 1 hr. at room temperature. Binding was determined using either a donkey anti-human IgGγ-specific antibody conjugated with HRP (Jackson ImmunoResearch, USA) or a goat-anti mouse IgG (H+L)-specific secondary antibody conjugated with HRP (Jackson ImmunoResearch, USA)., followed by measurement of HRP activity in a standard colorimetric assay.

Western Blot Analysis

Recombinant full length TDP-43, TDP-43 domain I (amino acid residues 2-106 of SEQ ID NO:94), TDP-43 domain II (amino acid residues 99-204 of SEQ ID NO:94), TDP-43 domain III (amino acid residues 183-273 of SEQ ID NO:94), TDP-43 domain IV (amino acid residues 258-414 of SEQ ID NO:94), 300 ng of each, were resolved by SDS-PAGE (NuPAGE 12% Bis-Tris Gel; Invitrogen, Basel, Switzerland) followed by electroblotting on nitrocellulose membranes. Non-specific binding sites were blocked for 1 hr. at room temperature with PBST containing 2% BSA (Sigma, Buchs, Switzerland). Blots were incubated overnight with primary antibodies (10 nM) followed by either a donkey anti-human IgGγ-specific secondary antibody conjugated with HRP (Jackson ImmunoResearch, USA) or a goat-anti mouse IgG (H+L)-specific secondary antibody conjugated with HRP (Jackson ImmunoResearch, USA). Blots were developed using ECL and ImageQuant 350 detection (GE Healthcare, Otelfingen, Switzerland).

Two-Trial Y-Maze Task

Improvement of working memory in antibody treated TDP-43 proteinopathy mouse model can be tested using a two-trial Y-maze task (e.g., Pennanen, Genes Brain Behav. 5 (2006), 369-79, which is herein incorporated by reference in its entirety). The three arms of the maze are 22 cm long, 5 cm wide and 15 cm deep. Black and white abstractive clues are placed on a black curtain surrounding the maze. Experiments are conducted with an ambient light level of 6 lux during the dark phase. Each experiment comprises a training session and an observation session. During the training session, a mouse is assigned to two of the three arms (the start arm and the second arm), which can be freely explored during 4 min, with no access to the third arm (the novel arm). The mouse is then removed from the maze and kept in a holding cage for 1.5-5 min, while the maze is thoroughly cleaned with 70% ethanol to remove any olfactory clues. The mouse is then put back again in the maze for observation with all three arms accessible for 4 min. The sequence of entries, the number of entry to each arm and the time spent in each arm is recorded. From that the ratio of time spent in the novel third arm over the average of time spent in the other two arms (start arm and second arm) is calculated and compared among different treatment groups in tauopathy mouse model and corresponding control wild type mice. Rodents typically prefer to investigate a new arm of the maze rather than returning to one that was previously visited. Effects of the antibodies can be monitored in regard of regaining this preference by treated TDP-43 proteinopathy model mice in comparison to non-discriminative behavior of untreated mice due to their disorder-related working memory impairment. Therefore, a ratio close to 1 indicates impaired working memory. A higher ratio indicates better working memory. Impaired working memory in a TDP-43 proteinopathy model mice is considered to be due to TDP-43 pathology resulting from the overexpression of human TDP-43. Therefore a significantly higher ratio observed in anti-TDP-43 antibody treated mice than in the control mice will indicate that the anti-TDP-43 antibody has therapeutic effect on TDP-43 pathology.

Pole Test

Mice are tested at the beginning of the dark phase when they are most active. The pole is made of a wooden stick with 50 cm length and 1 cm width covered with cloth to facilitate climbing. The base of the pole is placed in the home cage of the mouse. The mouse is placed on the top of the pole and the time to orient downwards and time to climb down to the home cage is recorded over 5 trials with 30 min intertrial intervals. The best performance trial is analyzed.

Elevated Plus Maze Test

Mice are tested at the beginning of the dark phase when they are most active.

Testing is performed in dim light (40 lux). The elevated plus maze consists of two open and two closed arms (arm length: 30 cm; width: 5 cm). Open arms have a small 1 cm edge and the closed arms are bordered by a 15 cm wall. At the beginning of the task, mice are placed in the center of the elevated plus maze facing an open arm. Mice are video-tracked while exploring the maze for 5 min. The time spent in the open and closed arms and the distance covered are measured and analyzed.

EXAMPLE 1 Human TDP-43 Antibody Binding Analysis by ELISA and Western Blotting Direct ELISAs

96 well microplates (Corning) were coated with polypeptides comprising TDP-43 amino acid residues 2-106 of SEQ ID NO:94 (TDP-43 domain I), residues 99-204 of SEQ ID NO:94 (TDP-43 domain II), residues 183-273 of SEQ ID NO:94 (TDP-43 domain III), residues 258-414 of SEQ ID NO:94 (TDP-43 domain IV), residues 2-414 of SEQ ID NO:94 (full-length TDP-43) and a synthetic polypeptide containing residues 390-414 with phosphorylation modification at residues 409/410 of SEQ ID NO:94. The polypeptides were coated onto ELISA plates at equal coating concentration of 6.6 μg/ml (recombinant TDP-43 and TDP-43 fragments) or 3.3 μg/ml (synthetic peptides). Binding of the human-derived antibodies was determined by direct ELISA.

Antibodies NI-205.51C1 (FIG. 2A) and NI-205.3F10 (FIG. 2C) bound specifically to TDP-43 domain III (amino acid residues 183-273 of SEQ ID NO:94). Antibodies NI-205.8A2 (FIG. 2D), NI-205.15F12 (FIG. 2E), NI-205.25F3 (FIG. 2G) and NI-205.21G1 (FIG. 2I) bound specifically to TDP-43 domain IV (amino acid residues 258-414 of SEQ ID NO:94). Antibody NI-205.87E7 (FIG. 2H) bound specifically to TDP-43 domain I (amino acid residues 2-106 of SEQ ID NO:94). Antibodies NI-205.21G2 (FIG. 2B) and NI-205.113C4 (FIG. 2F) bound specifically to TDP-43 domain II (amino acid residues 99-204 of SEQ ID NO:94). All human derived TDP-43 specific antibodies specifically recognized full-length TDP-43. To control for coating efficiency, of the different TDP-43 domains, commercially available antibodies binding to full-length TDP-43 and a specific TDP-43 domain were used: Ab50930 (Abcam, UK), TDP-43 domain-1; TARDBP monoclonal antibody (MO1), clone 2E2-D3 (Abnova, Taiwan), TDP-43 domain III, and Ab82695 (Abcam, US), TDP-43 domain IV. Control antibodies bound to full-length TDP-43 and their specific TDP-43 domain.

Binding to Distinct TDP-43 Domains by Western Blot

Recombinant full length TDP-43, TDP-43 domain I (amino acid residues 2-106 of SEQ ID NO:94), TDP-43 domain II (amino acid residues 99-204 of SEQ ID NO:94), TDP-43 domain III (amino acid residues 183-273 of SEQ ID NO:94), and TDP-43 domain IV (amino acid residues 258-414 of SEQ ID NO:94) were resolved by SDS-PAGE. Commercially available TDP-43 specific antibody TARDBP (MO1), clone 2E2-D3 (Abnova, Taiwan) was used as positive control for human TDP-43 detection whereas, an anti-human IgG Fcγ-specific antibody was used as a negative control. Binding of the human-derived antibodies to specific TDP-43 domains was determined by Western Blot analysis.

Western blotting indicated that antibodies: (a) NI-205.51C1 and NI-205.3F10 antibodies bound specifically to TDP-43 domain III (amino acid residues 183-273 of SEQ ID NO:94); (b) NI-205.8A2 and NI-205.21G1 bound specifically to TDP-43 domain IV (amino acid residues 258-414 of SEQ ID NO:94); (c) NI-205.21G2 specifically recognized TDP-43 domain II (amino acid residues 99-204 of SEQ ID NO:94); (d) NI-205.51C1, NI-205.3F10, NI-205.8A2, NI-205.21G1, NI-205.21G2, recognized full length human TDP-43 in addition to a domain of TDP-43; and (e) human-derived antibodies NI-205.25F3, NI-205.15F12 and NI-205.87E7 recognized full length TDP-43 but did not appear to bind a specific TDP-43 domain (data not provided). Additionally, the antibodies NI-205.68G5 and NI-205.20A1, that preferentially or exclusively bound the phospho-TDP-43 C-terminal peptide (see Example 2), did not appear to recognize recombinant full length TDP-43 or any of its fragments(data not provided).

Example 2 EC50 Determination for Human TDP-43 Binding Antibodies Determination of Half Maximal Effective Concentration (EC₅₀)

To determine the half maximal effective concentration (EC₅₀) of the human-derived TDP-43-specific antibodies for human TDP-43 and to evaluate target-specificity, 96 well microplates (Corning) were coated with recombinant full length TDP-43 (Biogen Idec, USA), Escherichia coli extract and BSA (Sigma, Buchs, Switzerland), diluted to a concentration of 5 μg/ml in carbonate ELISA coating buffer (pH 9.6) overnight at 4° C. Alternatively, 96 well half area microplates (Corning) were coated with a synthetic peptide covering residues 390 to 414 of the C-terminal domain of TDP-43 with phosphorylation modification at residues 409/410 (Schafer-N, DK) and BSA (Sigma, Buchs, Switzerland), diluted to a concentration of 3.3 μg/ml in carbonate ELISA coating buffer (pH 9.6) overnight at 4° C. Non-specific binding sites were blocked for 1 hr. at room temperature with PBS containing 2% BSA (Sigma, Buchs, Switzerland). Human TDP-43-specific antibodies were diluted to the indicated concentrations and incubated 1 hr. at room temperature. Binding was determined using a donkey anti-human IgGγ-specific secondary antibody conjugated with HRP (Jackson ImmunoResearch, USA), followed by measurement of HRP activity in a standard colorimetric assay. EC₅₀ values were estimated by a non-linear regression using GraphPad Prism software (San Diego, USA).

As disclosed in Table 4, antibodies NI-205.51C1 and NI-205.21G2 bind to human TDP-43 with high affinity at subnanomolar EC₅₀ of 180 pM and 240 pM, respectively. No binding was observed to the phospho-TDP-43 C-terminal peptide for these antibodies. Antibodies NI-205.3F10, NI-205.8A2, NI-205.15F12, NI-205.113C4, NI-205.25F3, and NI-205.87E7 bound to human TDP-43, but not to the phospho-TDP-43 C-terminal peptide. The EC₅₀ values of these antibodies for human TDP-43 proteins ranged from 1 to 18 nM. NI-205.21G1 bound to full-length TDP-43 at 4.1nM EC₅₀ and recognized phosphor-TDP-43 C-terminal peptide with lower affinity at 49.5 nM EC₅₀. Antibodies NI-205.68G5 and NI-205.20A1 showed preferential or exclusive binding to the phosphor-TDP-43 C-terminal peptide at 16.9 and 15.8 nM EC₅₀, respectively, suggesting that phosphorylation of serine at position 409 and/or serine at position 410 of TDP-43 is required for the binding by NI-205.68G5 and NI-205.20A1.

TABLE 4 Antibody Affinity for TDP-43 and phosphorylated TDP-43 Full-length TDP-43 Phospho-TDP-43 Peptide Antibody EC₅₀ (nM)] EC₅₀ (nM) NI-205.51C1 0.18 N.A. NI-205.21G2 0.24 N.A. NI-205.3F10 1.4-2.8 N.A. NI-205.8A2 7.2 N.A. NI-205.15F12 7.2 N.A. NI-205.113C4 13.2 N.A. NI-205.25F3 13.3 N.A. NI-205.87E7 17.2 N.A. NI-205.21G1 4.1 49.5 NI-205.68G5 >100 16.9 NI-205.20A1 N.A. 15.8 Table 4: EC₅₀ binding of human derived TDP-43 binding antibodies to recombinant TDP-43 and phosphor-TDP-43 peptide.

Example 3 Epitope Mapping with Synthetic Peptides (PepSpotting)

Scans of overlapping peptides were used to map the epitopes within the human

TDP-43 protein that are recognized by the human-derived TDP-43 specific antibodies. Pepscan membranes (PepSpots, JPT Peptide Technologies, Berlin, Germany) with 101 linear 15 mer peptides of 11 amino acid overlapping sequences that collectively represent the entire sequence of human TDP-43 (Q13148, TARDBP_HUMAN). The peptides were spotted onto nitrocellulose membranes that were then activated for 5 min. in methanol and subsequently washed at room temperature in TBS for 10 min. Non-specific binding sites were blocked for 2 hours at room temperature with Roti®-Block (Carl Roth GmbH Co. KG, Karlsruhe, Germany). Human-derived TDP-43 specific antibodies (1 μg/ml) were incubated for 3 hours at room temperature in Roti®-Block. Binding of primary antibody was determined using HRP conjugated donkey-anti human IgGγ-specific secondary antibody (Jackson ImmunoResearch, USA). Blots were developed using ECL and ImageQuant 350 detection (GE Healthcare, Otelfingen, Switzerland).

Table 4 summarizes the identified binding epitopes for the different human-derived TDP-43-specific antibodies identified using PepSpot.

TABLE 5 Identified binding epitopes within the human TDP-43 protein sequence Antibody Binding epitope NI-205.3F10 213-QYGDVMDVFIP-223 (SEQ ID NO: 123) NI-205.8A2 381-AAIGWGSASNA-391 (SEQ ID NO: 124) NI-205.51C1 201-DMTEDELREFF-211 (SEQ ID NO: 125) NI-205.87E7 9-EDENDEP-15 (SEQ ID NO: 126) NI-205.113C4 133-VQVKKDL-139 (SEQ ID NO: 127) NI-205.21G2 121-KEYFSTF-127 (SEQ ID NO: 128)

Example 4 Binding of Human Recombinant TDP-43 Antibodies to Pathologic Forms of TDP-43 in Human Spinal Cord and Brain Tissue

For validation of TDP-43 antibody-binding capacity, spinal cord and brain sections derived from human ALS patients or patients with FTLD were used. Antibody binding to TDP-43 pathology was assessed by immunohistochemical staining. Binding of human recombinant TDP-43 antibodies was characterized on human FTLD-TDP-43 case tissue (10 patient cases, 7 control cases). Immunohistochemistry was performed on Sum thick paraffin embedded sections, and included the use of EDTA-based epitope retrieval prior to conducting otherwise standard immunoperoxidase procedures with Elite ABC kits (Vector Laboratories) with DAB (Pierce). The following primary antibodies were used: mouse monoclonal antibody 2E2-D3 raised against human TDP-43 (Abnova) as a positive control; recombinant human TDP-43 antibodies described here/above NI205.3F10, NI205.51C1, NI205.21G2, NI205.8A2, NI205.15F12, NI205.25F3, NI205.87E7, NI205.21G1, NI205.68G5, NI205.20A1. Sections were counterstained with Haematoxylin to reveal cell nuclei.

The antibodies NI205.8A2, NI205.3F10, NI205.21G2, and NI205.21G1 preferentially bound to cytoplasmic TDP-43 (i.e., pathologic forms of TDP-43) over nuclear TDP-43. By contrast, the commercially available positive control antibody, 2E2 (Abnova, Taiwan) was observed to bind both nuclear and cytoplasmic TDP-43. Interestingly, the binding of the antibody NI205.21G1 demonstrated very specific binding that appears to be comparable to the binding observed for control antibodies that recognize phosphorylated TDP-43 (FIGS. 11E and H).

Example 5 In Vivo Validation of TDP-43 Antibody

Experiments for preclinical validation of the TDP-43 antibodies are performed in mouse models of TDP-43 proteinopathy. Human TDP-43 antibodies are administered by peripheral injection or intraventricular brain infusion via osmotic minipumps. Treatment effects are monitored by analysis of blood and CSF samples, and analysis of body weight, general clinical impression and signs of motor or cognitive impairment as seen through for example, though behavioral tests including open field, Y-maze, elevated plus maze, novel object recognition, grip strength, paw grip strength endurance, pole test, challenging beam walk, rotarod, or otherwise known in the art.

Upon completion of the treatment studies, changes in TDP-43 levels in collected blood and CSF are measured and brain and spinal cord tissues are evaluated by quantitative immunohistochemical and biochemical techniques for brain and spinal cord content of physiological and pathological TDP-43 and general neuropathology.

Preclinical models useful for validating the antibodies and other TDP-43 binding molecules of the invention include the TDP-43-A315T mouse model system as described by Wegorzewska et al., Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 18809-14. The A315T mouse is a transgenic model of TDP-43 proteinopathy, wherein the phenotype of the mice shows features of both ALS and frontotemporal lobar degeneration with ubiquitin aggregates (FTLD-U).

Further suitable models include the B6.Cg-Tg (SOD1*G93A)]Gur/J mouse model system as described by Gurney et al., Science 264 (1994), 1772-75. This mouse line expresses the G93A mutant form of the human superoxide dismutase 1 and develops signs of motor neuron disease followed by progression to death within 6 to 8 months. These mice show a characteristic redistribution of TDP-43 to the cytoplasm of motor neurons and the occurrence of TDP-43 immunoreactive inclusions and are therefore a suitable model to study pharmacological interventions targeting TDP-43; see e.g., Shan et al., Neuropharmacol. Letters 458 (2009), 70-74.

Further experiments for validating the TDP-43 antibodies are performed in the TDP43WT mouse model system as described by Wils et al., Proc. Natl. Acad. Sci. USA. 106 (2010), 3858-63. This mouse line expresses wild type human TDP-43 and develops degeneration of cortical and spinal motor neurons and development of spastic quadriplegia reminiscent of ALS. A dose-dependent degeneration of nonmotor cortical and subcortical neurons characteristic of FTLD is also observed in this mouse line. Neurons in the affected spinal cord and brain regions show accumulation of TDP-43 nuclear and cytoplasmic aggregates that are both ubiquitinated and phosphorylated as observed in ALS/FTLD patients.

Further experiments for validating the TDP-43 antibodies are performed in an independent model of motor neuron disease, the Wobbler mouse model (B6.B-Vps54wr/J, available from the Jackson Laboratories) as described by Duchen and Strich, J. Neurol. Neurosurg. Psychiatry 31 (1968), 535-42. This mouse model was reported to display extensive intracellular ubiquitin inclusions and abnormal cytoplasmic distribution of TDP-43 reminiscent to sporadic ALS, see e.g., Dennis and Citron, Neuroscience 185 (2009), 745-50.

Further experiments for validating the TDP-43 antibodies are performed in recently characterized TDP-43_G348C transgenic mice overexpressing human genomic TDP-43_G348C under the control of the endogenous promoter. Swarup et al., Brain 134 (2011), 2610-2626.

Further experiments for validating the TDP-43 antibodies are performed in model systems, including transgenic cell lines and transgenic animals, that express or overexpress TDP-43, TDP-43 mutants, such as C-terminal truncations of TDP-43, TDP-43 mutations seen in a patient population, or mutants that effect cellular localization, e.g. nuclear localization of TDP-43. TDP-43 model systems, e.g., cell lines and animal models, for validating the TDP-43 antibodies further include systems with demonstrated TDP-43 upregulation or accumulation resulting from the changes in the expression of a different gene, e.g. the Wobbler mouse and models with down-regulation of progranulin. In one embodiment, experiments for validating the TDP-43 antibodies are performed in mice expressing human TDP-43 with a defective nuclear localization signal in the forebrain (Igaz et al., J Clin Invest. 121(2):726-38 (2011)); transgenic mice that selectively express 25-kDa C-terminal fragment of TDP-43 in neurons (Caccamo et al., Am J Pathol. 180(1):293-302 (2012)), transgenic mice that conditionally express wild-type human TDP-43 (hTDP-43) in the forebrain (Cannon et al., Acta Neuropathol. 123(6):807-23 (2012)), and transgenic mice with ubiquitous expression of wild-type and disease-causing versions of human VCP/p97 (Custer et al., Hum Mol Genet. 19(9):1741-55 (2010)). In another embodiment, experiments for validating the TDP-43 antibodies are performed in mice transfected with an AAV vector encoding wild type TDP-43, nuclear localization signal defective TDP-43, or a truncated C-terminal fragment of TDP-43 comprising residues 220-414 of SEQ ID NO: 94. Tatom et al., Mol. Ther. 17 (2009), 607-613.

Chronic efficacy study: To assess the pharmacological effects of the human anti-TDP-43 antibodies disclosed herein, TDP-43_G348C transgenic mice (Swamp et al., Brain 134 (2011), 2610-2626) are treated weekly with 10 mg/kg i.p. injection of a human anti-TDP-43 antibody or vehicle control for a period of 16-24 weeks. After 12 weeks of treatment, blood samples are collected by tail vein bleeding. The serum anti-TDP-43 antibody levels are determined by ELISA. After 12 weeks and 22 weeks of treatment, neurological and cognitive/motor behavior is evaluated using open field test, Y-maze test, elevated plus maze test, novel object recognition test, grip strength test, paw grip strength endurance (PAGE) test, pole test, challenging beam walk test, or rotarod test. The neurological and cognitive/motor behavior test results for antibody treated and control animals are compared. Improved performance of antibody treated animals indicates therapeutic efficacy of the anti-TDP-43 antibody.

Acute efficacy study: TDP-43_G348C transgenic mice (Swarup et al., Brain 134 (2011), 2610-2626) are treated with 1-4 i.p. injections of up to 50 mg/kg anti-TDP-43 antibody or or vehicle control within a period of one week. At the end of the treatment period, blood samples are collected by tail vein bleeding. The serum anti-TDP-43 antibody levels are determined by ELISA. At the end of the 1-week treatment period, neurological and cognitive/motor behavior is evaluated using open field test, Y-maze test, elevated plus maze test, novel object recognition test, grip strength test, paw grip strength endurance (PAGE) test, pole test, challenging beam walk test, or rotarod test. The neurological and cognitive/motor behavior test results for antibody treated and control animals are compared. Improved performance of antibody treated animals indicates therapeutic efficacy of the anti-TDP-43 antibody.

Example 6 Determination of Binding Affinity (EC₅₀) for Human TDP-43 Antibodies by Direct ELISA

The half maximal effective concentration (EC₅₀) of the human-derived TDP-43-specific antibodies for human TDP-43 and their target target-specificity was determined substantially as described in Example 2 above. Briefly, 96 well microplates (Corning) were coated with recombinant full length TDP-43 (Biogen Idec, USA), Escherichia coli extract and BSA (Sigma, Buchs, Switzerland), diluted to a concentration of 5 μg/ml in carbonate ELISA coating buffer (pH 9.6) overnight at 4° C. Alternatively, 96 well half area microplates (Corning) were coated with a synthetic peptide covering residues 390 to 414 of the C-terminal domain of TDP-43 with phosphorylation modification at residues 409/410 (Schafer-N, DK) and BSA (Sigma, Buchs, Switzerland), diluted to a concentration of 3.3 μg/ml in carbonate ELISA coating buffer (pH 9.6) overnight at 4° C. Non-specific binding sites were blocked for 1 hr. at room temperature with PBS containing 2% BSA (Sigma, Buchs, Switzerland). Human TDP-43-specific antibodies were diluted to the indicated concentrations and incubated 1 hr. at room temperature. Binding was determined using a donkey anti-human IgGγ-specific secondary antibody conjugated with HRP (Jackson ImmunoResearch, USA), followed by measurement of HRP activity in a standard colorimetric assay. EC₅₀ values were estimated by a non-linear regression using GraphPad Prism software (San Diego, USA). Exemplary titration curves obtained with the 41D1, 21G1, 31D2, and 8F8 antibodies are shown in FIG. 4.

As disclosed in Table 6, antibodies NI-205.41D1 (FIGS. 4A and E), NI-205.51C1 and NI.205-21G2 bound to human TDP-43 with high affinity at subnanomolar EC₅₀ of 60 pM, 180 pM and 240 pM, respectively. No binding was observed to the phospho-TDP-43 C-terminal peptide. Antibodies NI-205.1A9, NI-205.3F10, NI-205.14W3, NI-205.98H6, NI-205.44B2, NI-205.9E12A, NI-205.8A2, NI-205.15F12, NI-205.10D3, NI-205.38H2, NI-205.29E11, NI-205.9E12D, NI-205.31C11, NI-205.113C4, NI-205.25.25F3, NI-205.10H7, NI-205.8C10, and NI-205.87E7 bound to human TDP-43 but not to the phospho-TDP-43 C-terminal peptide with nanomolar EC₅₀. For these antibodies EC₅₀ values ranged from 1 to 18 nM (see Table 6). Antibody NI-205.21G1 (FIGS. 4B and F) bound to full length TDP-43 at 4.1 nM EC₅₀ and recognized phospho-TDP-43 C-terminal peptide with lower affinity at 49.5 nM EC₅₀. Antibodies NI-205.31D2 (FIGS. 4C and G), NI-205.14H5, NI-205.36D5, NI-205.19G5 and NI-205.68G5 showed preferential binding to the phospho-TDP-43 C-terminal peptide with EC₅₀ values that ranged from 0.7 to 17 nM (see Table 6). In contrast, antibodies NI-205.8F8, NI-205.8F8 (FIGS. 4D and H) and NI-205.20A1 bound exclusively to the human phospho-TDP-43 C-terminal peptide with high affinity at nanomolar EC₅₀ of 5 nM, 7 nM and 16 nM, respectively (see Table 6) consistent with the idea that phosphorylation of serine 409 and/or serine 410 was required for binding.

TABLE 6 EC₅₀ binding of human-derived TDP-43 antibodies to recombinant human TDP-43 and phospho TDP-43 C-terminal peptide. EC₅₀ [nM] Antibody full length TDP-43 phospho-TDP-43 peptide NI-205.41D1 0.06 no binding NI-205.51C1 0.18 no binding NI-205.21G2 0.24 no binding NI-205.1A9 1.0 no binding NI-205.3F10 1.4 no binding NI-205.14W3 1.5 no binding NI-205.98H6 2.6 no binding NI-205.44B2 2.8 no binding NI-205.9E12A 3.7 no binding NI-205.8A2 7.2 no binding NI-205.15F12 7.2 no binding NI-205.10D3 7.3 no binding NI-205.38H2 8.2 no binding NI-205.29E11 10.4 no binding NI-205.9E12D 11.2 no binding NI-205.31C11 11.0 no binding NI-205.113C4 13.2 no binding NI-205.25F3 13.3 no binding NI-205.10H7 15.3 no binding NI-205.8C10 15.6 no binding NI-205.87E7 17.2 no binding NI-205.21G1 4.1 49.5 NI-205.31D2 >41.0 0.69 NI-205.14H5 >100 0.90 NI-205.36D5 >72.0 4.3 NI-205.19G5 >200 13.6 NI-205.68G5 >100 16.9 NI-205.8F8 no binding 5.1 NI-205.58E11 no binding 6.9 NI-205.20A1 no binding 15.8

Example 7 Human TDP-43 Antibody Binding Analysis by ELISA and Western Blotting Direct ELISAs

Direct ELISA assays were performed substantially as described in Example 1. Briefly, fragments of TDP-43 (SEQ ID NO:94) comprising amino acids 2-106 (domain I), 99-204 (domain II), 183-273 (domain III), 258-414 (domain IV) and full length TDP-43 (2-414) were coated onto ELISA plates at equal coating concentration of 6.6 pg/ml. Binding of the human-derived antibodies was determined by direct ELISA. Examples of the obtained results are shown in FIG. 5. Antibodies NI-205.41D1 (FIG. 5A), NI-205.14W3 (FIG. 5C), NI-205.44B2 (FIG. 5E), NI-205.10D3 (FIG. 5G), and NI-205.10H7 (FIG. 5L) bound specifically to TDP-43 domain IV (aa 258-414). Antibody NI-NI-205.98H6 (FIG. 5D) bound specifically to TDP-43 domain III (aa 183-273). Antibodies NI-205.1A9 (FIG. 5B), NI-205.38H2 (FIG. 5H), and NI-205.31C11 (FIG. 5K) specifically recognized TDP-43 domain II (aa 99-204) whereas antibodies NI-205.9E12A (FIG. 5F), NI-205.29E11 (FIG. 5I), NI-205.9E12D (FIG. 5J), and NI-205.8C10 (FIG. 5M) bound to TDP-43 domain I (aa 2-106). All the human-derived TDP-43 specific antibodies also recognized full length human TDP-43. To control for coating efficiency of the different recombinant TDP-43 domains, commercially available antibodies binding to full length TDP-43 and a specific TDP-43 domain were used (FIG. 5W): i) Ab50930 (Abcam, UK), TDP-43 domain I; ii) TARDBP monoclonal antibody (M01), clone 2E2-D3 (Abnova 23435, Abnova, Taiwan), TDP-43 domain III and iii) Ab82695 (Abcam, UK), TDP-43 domain IV. Control antibodies bound to full length TDP-43 and their specific TDP-43 domain.

Binding to Distinct TDP-43 Domains by Western Blot

Recombinant full length TDP-43, TDP-43 domain I (amino acid residues 2-106 of SEQ ID NO:94), TDP-43 domain II (amino acid residues 99-204 of SEQ ID NO:94), TDP-43 domain III (amino acid residues 183-273 of SEQ ID NO:94), and TDP-43 domain IV (amino acid residues 258-414 of SEQ ID NO:94) were resolved by SDS-PAGE. Binding to specific TDP-43 domains of the human-derived antibodies was determined by Western Blot analysis.

Examples of the obtained results are shown in FIG. 6. Antibodies NI-205.41D1 (FIG. 6A), NI-205.14W3 (FIG. 6F), NI-205.8A2 (FIG. 6H), NI-205.15F12 (FIG. 6I), NI-205.10D3 (FIG. 6J), NI-205.10H7 (FIG. 6L) and NI-205.21G1 (FIG. 6M) bound specifically to TDP-43 domain IV (aa 258-414). Antibodies NI-205.51C1 (FIG. 6B), NI-205.3F10 (FIG. 6E) and NI-205.98H6 bound specifically to TDP-43 domain III (aa 183-273) whereas antibodies NI-205.21G2 (FIG. 6C), NI-205.1A9 (FIG. 6D) and NI-205.31C11 (FIG. 6K) specifically recognized TDP-43 domain II (99-204 aa). These thirteen human-derived TDP-43 specific antibodies also recognized full length human TDP-43. Only antibody NI-205.10D3 (FIG. 6J) recognized an additional unspecific signal, most probably an E. coli-derived protein contaminant. NI-205.68G5 (FIG. 6N) and NI-205.20A1 (FIG. 6O), two antibodies showing preferential or exclusive binding to the phospho-TDP-43 C-terminal peptide, did not recognize recombinant full length TDP-43 or any of its fragments. Commercially available TDP-43 specific antibody 2E2-D3 (Abnova 23435, Abnova, Taiwan) (FIG. 6P) was used as positive control for human TDP-43 detection whereas the anti-human IgG Fcγ-specific antibody (FIG. 6Q) was used as a negative control.

Human-derived antibodies NI-205.44B2, NI-205.9E12A, NI-205.38H2, NI-205.29E11, NI-205.9E12D, NI-205.113C4, NI-205.25F3, NI-205.8C10 and NI-205.87E7 recognized full length TDP-43 but did not identify a specific TDP-43 fragment (data not shown).

Example 8 Epitope Mapping with Synthetic Peptides (PepSpotting)

The epitopes recognized by the human-derived TDP-43 specific antibodies within the human TDP-43 protein were mapped using pepscan membranes (PepSpots, JPT Peptide Technologies, Berlin, Germany) with 101 linear 15-meric peptides with 11 aa overlap between individual peptides covering the entire human TDP-43 protein sequence. The pepscan mapping was performed substantially as described in Example 3. Briefly, the peptides were spotted onto nitrocellulose membranes that were then activated for 5 min. in methanol and subsequently washed at room temperature in TBS for 10 min. Table 7 summarizes binding epitopes for the different human-derived TDP-43-specific antibodies identified using PepSpot.

TABLE 7 Binding epitopes within the human TDP-43 protein sequence for the different human-derived TDP-43-specific antibodies identified using PepSpot. NA-not applicable. Effect of phosphorylation at Antibody Binding epitope Ser409 and/or Ser410 residues NI-205.41D1 317-SINPAMMAAAQAALQQSWGMMGNLASQ-343 NA (SEQ ID NO: 323) NI-205.51C1 201-DMTEDELREFF-211 NA (SEQ ID NO: 125) NI-205.21G2 121-KEYFSTF-127 NA (SEQ ID NO: 128) NI-205.3F10 213-QYGDVMDVFIP-223 NA (SEQ ID NO: 123) NI-205.98H6 249-IIKGISV-255 NA (SEQ ID NO: 315) NI-205.44B2 345-NQSGPSG-351 NA (SEQ ID NO: 316) NI-205.8A2 381-AAIGWGSASNA-391 NA (SEQ ID NO: 124) NI-205.15F12 397-FNGGFGS-403 NA (SEQ ID NO: 317) NI-205.10D3 289-FGNSRGGGAGL-299 NA (SEQ ID NO: 318) 389-SNAGSGSGFNG-399 (SEQ ID NO: 319) NI-205.113C4 133-VQVKKDL-139 NA (SEQ ID NO: 127) NI-205.10H7 269-QLERSGRFGGN-279 NA (SEQ ID NO: 320) NI-205.8C10 17-EIPSEDD-23 NA (SEQ ID NO: 321) NI-205.87E7 9-EDENDEP-15 NA (SEQ ID NO: 126) NI-205.21G1 390-414 Ser409/Ser410 phosphorylation Antibody Binding epitope Effect of phosphorylation at Ser409 and/or Ser410 residues partially inhibited binding NI-205.31D2 390-414 Bound to peptide phosphory- lated at Ser409 and Ser410 NI-205.14H5 390-414 Bound to peptide phosphory- lated at Ser409 and/or Ser410; weak binding also observed independent of phosphorylation NI-205.36D5 390-414 Bound to peptide phosphory- lated at Ser409; simultaneous Ser410 phosphorylation abrogates binding NI-205.19G5 390-414 Bound to peptide phosphory- lated at Ser409; simultaneous Ser410 phosphorylation abrogates binding NI-205.68G5 390-414 Bound to peptide phosphorylated at Ser409 and/or Ser410 NI-205.8F8 390-414 not determined NI-205.58E11 390-414 not determined NI-205.20A1 390-414 Bound to peptide phosphorylated at Ser409 and Ser410

Determination of NI-205.41D1 Binding Epitope by ELISA Assays.

Full length TDP-43 (2-414) and TDP-43 C terminal fragments comprising amino acids 258-414 (domain IV), 258-384, 258-375, 258-362, 258-353, 258-319, 317-414 and 340-414 were coated onto ELISA plates at equal coating concentration of 10 μg/ml. Binding of NI-205.41D1 antibody to specific TDP-43 fragments was determined by direct ELISA. Examples of the data obtained are provided in FIG. 7A. NI-205.41D1 bound to all recombinant fragments except fragments 258-319 and 340-414, indicating that NI-205.41D1 binding epitope was in the C-terminal TDP-43 region 317-353. NI-205.41D1 antibody bound to full length TDP-43.

Full length TDP-43 (2-414), wild-type TDP-43 domain IV comprising residues 258-414 of SEQ ID NO:94 (TDP-43 258-414) and a mutant TDP-43 domain IV (TDP-43 258-414 AMM321GGG) carrying the A to G substitution at residue 321, M to G substitution at residue 322, and M to G substitution at residue 323 were coated onto ELISA plates at equal coating concentration of 10 μg/ml. Binding of NI-205.41D1 antibody to specific TDP-43 domain IV variants was determined by direct ELISA (FIG. 7B). NI-205.41D1 specifically bound to full length TDP-43 and to wild type TDP-43 domain IV, but not to the mutant TDP-43 domain IV, indicating that one or more of the mutated residues was essential for NI-205.41D1 binding to human TDP-43. To control for coating efficiency of the different recombinant TDP-43 species, commercially available antibody 12892-1-AP binding to full length TDP-43 was used.

Synthetic biotinylated peptides comprising residues 316-353 (TDP-43 316-353), 316-343 (TDP-43 316-343) and 316-333 (TDP-43 316-333) of SEQ ID NO:94 were coated on streptavidin-coated plates at equal coating concentration of 10 μg/ml. Binding of NI-205.41D1 antibody to specific TDP-43 C-terminal peptides was determined by direct ELISA (FIG. 7C). NI-205.41D1 specifically bound to peptides TDP-43 316-353 and TDP-43 316-343 but not to peptide TDP-43 316-333. This result is consistent with the idea that residues 334-343 of SEQ ID NO:94 at the TDP-43 C-terminal region are involved in NI-205.41D1 antibody binding to human TDP-43. Our results are consistent with an understanding that the binding epitope of antibody NI-205.41 is discontinuous between residues 317-343 of SEQ ID NO:94 and is formed by two independent binding regions: the first one comprising residues 321-323 of SEQ ID NO:94 and the second one comprising residues 334-343 of SEQ ID NO:94.

Example 9 The Human-Derived TDP-43 Specific Antibodies Interact with Native TDP-43

Pure full-length TDP-43 protein has a natural propensity to aggregate. Therefore, only very small quantities of soluble, full-length TDP-43 were recovered under standard purification conditions. We thus developed a recombinant expression and purification strategy for isolating large quantities of functional 6× His-SUMO-tagged full-length human TDP-43 from Escherichia coli using KSCN and arginine, mild chaotropic agents known to preserve native protein structure while preventing protein aggregation.

Plasmids: Polynucleotides encoding human full-length TDP-43 (1-414 of SEQ ID NO:94) and its truncations residues 101-265 and residues 220-414 of SEQ ID NO:94 were amplified using standard procedures and subcloned into a modified pET19-b (Novagen) vector resulting in 6× His and SUMO tags at the N-terminus of the protein encoded by the amplified polynucleotides. A schematic representation of the 6× His/SUMO tagged recombinant polypeptides is shown in FIG. 8B.

Protein expression and purification: 6× His/SUMO tagged TDP-43 expression plasmids were transformed into BL21(DE3) Star Escherichia coli (Invitrogen). Bacterial cultures were grown to an OD600 of 1.0 at 37° C. and induced with 1 mM IPTG for 16 h at 18° C. After pelleting, cells were lysed by microfluidization in purification buffer with protease inhibitors (40 mM HEPES (pH 7.5), 1.5 M KSCN, and 1 mM tris(2-carboxyethyl)phosphine (TCEP), 1 mM PMSF, 5 μM pepstatin, 1 mM benzamine, 10 μM bestatin, 10 μM E-64, 20 μM leupeptin, 1.5 μM aprotinin). To generate properly folded full-length TDP-43, TDP-43 (101-265) and TDP-43 (220-414), the corresponding 6× His-SUMO tagged fusions proteins were purified on Ni-NTA agarose resin (Qiagen) following the manufacturer's instructions, using purification buffer for binding and washing. Bound proteins were eluted from Ni-NTA resin with the same buffer containing 250 mM imidazole and further purified on a preparative 5200 size exclusion column (GE Healthcare) following the manufacturer's instructions using purification buffer. Fractions containing monomeric TDP-43 proteins were pooled, and re-formulated in a buffer containing 40 mM HEPES (pH 7.5), 400 mM arginine, 1 mM TCEP by dialysis. 6× His-SUMO-TDP43 (101-265) was additionally purified using the same purification strategy but altering buffer compositions by substituting 1.5 M KSCN with 0.5M KCl. To prepare unfolded 6× His-TDP-43, cells were lysed by microfluidization in a Tris-imidazole buffer (50 mM Tris (pH 7.5), 20 mM imidazole, 150 mM NaCl) with protease inhibitors. The insoluble pellet was washed sequentially with the following buffers containing protease inhibitors: B-PER buffer (Pierce) containing 2 mM MgCl₂, followed by Tris-imidazole buffer. Washed pellets were next solubilized in 8 M urea, 20 mM sodium phosphate (pH 7.8). Urea soluble material was then purified on Ni-NTA agarose resin following the manufacturer's instructions, using denaturing washing and elution conditions. Sedimentation and diffusion coefficients determination (FIG. 8C) as well as SDS-PAGE separation (FIG. 8A) were carried out by standard methods. (Laue, T. et al., (1992) in Analytical Ultracentrifugation in Biochemistry and Polymer Science (Harding, S. E., ed) Royal Society of Chemistry, Cambridge, UK).

Capture ELISA: 96 well plates (Thermo Fisher Scientific) were coated with anti 6× His mouse monoclonal antibody (Clontech) diluted to a concentration of 1 μg/ml in PBS buffer (137 mM NaCl, 8.05 mM Na₂HPO₄, 1.5 mM KH₂PO₄, 2.7 mM KCl, pH 7.4) at 4° C. overnight. Non-specific binding sites were blocked for 1 hr at RT with PBS containing 1% BSA (Sigma) and 0.05% Tween-20 (Fisher Scientific). 6× His-SUMO-TDP43 proteins at a concentration of 1.7 μM were allowed to bind to antibody-coated plates for 1 hr at RT in PBS buffer containing 1% BSA, 300 mM arginine and 0.1% PEG 5000, pH 7.5. Plates were incubated for 1 hr at RT with human antibodies of present invention, titrated in a three-fold dilution series, followed by HRP conjugated anti-human IgG Fc y (Jackson ImmunoResearch) in PBST containing 1% BSA. HRP activity was measured in a standard colorimetric assay. EC₅₀ values were calculated using a four-parameter logistic curve fit on Softmax pro software (Molecular Devices).

RNA binding assay: Equilibrium binding affinities of TDP-43 constructs for RNA were determined using fluorescence polarization. 5′TYETM fluorophore labeled RNA substrates, specific RNA (TYETM-UGUGUGUGUGUG) (SEQ ID NO: 312) and RNA control (TYETM-UUUUUUUUUUUU) (SEQ ID NO: 313) (Integrated DNA Technologies), were incubated at a concentration of 5 nM for 30 min at 25° C. with TDP-43 (final concentrations 0 to 20 μM) in incubation buffer as indicated. Fluorescence polarization was measured with the plate reader fluorometer Envision (PerkinElmer) at each concentration of TDP-43 in a 96 well plate format with an excitation at 645 nm and emission at 665. K_(d) _(S) were calculated using the quadratic equation for tight binding (Morrison equation) using Sigmaplot (Systat Software Inc.). To determine the stoichiometry of RNA/TDP-43 binding, the same fluorescence polarization experimental set up was used with the addition of 95 nM of unlabeled RNA of the same sequence for a total 100 nM RNA concentration (>7× higher than the previously determined K_(d) values). Stoichiometries were calculated by measuring the intercept of two straight lines, one fit using data points of the partially bound state, and the other using data points of the fully bound state.

The recombinant full-length TDP-43 was monomeric by sedimentation analysis (FIG. 8C) in buffer containing 400 mM arginine. A minimum of 300 mM arginine was maintained in analytical assays when monomeric native TDP-43 was desired, because aggregation was observed at lower arginine concentrations. Consistent with arginine not adversely affecting TDP-43 activity, our recombinant, full-length TDP-43 binds an RNA of previously established specific sequence (UGUGUGUGUGUG (SEQ ID NO:312)) with at least 30 fold higher affinity than to a generic unspecific sequence (UUUUUUUUUUUU (SEQ ID NO:313)) (FIG. 9).

We also purified a 6× His/SUMO tagged fragment of TDP-43 comprising amino acid residues 101-265 of SEQ ID NO: 94 from which the C-terminal domain (amino acids 265 to 414) known to mediate aggregation was removed. The 6× His/SUMO tagged 101-265 truncated TDP-43 fragment, purified with or without chaotropes maintained a binding affinity to the specific RNA sequence very similar to the previously reported K_(D) (˜14 nM) in spite of the very different analytical methods used (FIG. 9). See, Kou Nucleic Acids Res. 2009, 37:1799-808. The stoichiometry of RNA/TDP-43 binding was also the same regardless of purification strategy, indicating that there was no significant difference in the denatured protein population between the two preparations (FIG. 9). Together, these data indicated that the purified recombinant pure full length TDP-43 was in its native folding state.

We measured the binding affinity of the human-derived TDP-43 specific antibodies provided herein to properly folded 6× His/SUMO tagged TDP-43 using a capture ELISA in which native TDP-43 was immobilized without direct adsorption on the surface of the ELISA plate. This was achieved by immobilizing an anti 6× His antibody which then captured native TDP-43. Binding to the anti 6× His tag by folded 6× His/SUMO tagged full-length human TDP-43 was achieved at 300 mM arginine concentration, ensuring a monomeric state of TDP-43. After this immobilization step, binding by human antibodies was tested in regular buffers without interference of TDP-43 aggregation. An example of the titration curves generated is shown in FIG. 10. Table 8 summarizes affinities (EC₅₀ [nM]) to folded, full length 6× His/SUMO tagged TDP-43, or to a 6× His/SUMO tagged truncation construct containing the C-terminal, aggregation prone region of TDP-43 (residues 220-414 of SEQ ID NO: 94) by this capture ELISA method.

TABLE 8 EC₅₀ [nM] binding of human-derived TDP-43 antibodies to properly folded recombinant 6xHis/SUMO tagged full length TDP-43 and 6xHis/SUMO tagged truncated TDP-43 comprising residues 220-414. Antibody full length TDP-43 TDP-43 residues 220-414 NI-205.41D1 0.07 0.10 NI-205.51C1 1.1 no binding NI-205.21G2 3.6 no binding NI-205.1A9 >98 no binding NI-205.3F10 >90 no binding NI-205.14W3 7.4 1.6 NI-205.98H6 46 20 NI-205.44B2 >125 33.5 NI-205.9E12A no binding — NI-205.8A2 34 4.6 NI-205.15F12 16.3 9.7 NI-205.10D3 >90 20.5 NI-205.38H2 >120 no binding NI-205.29E11 >100 >97 NI-205.9E12D no binding no binding NI-205.31C11 21.1 no binding NI-205.113C4 no binding no binding NI-205.25F3 >120 >100 NI-205.10H7 30.9 6.45 NI-205.8C10 no binding — NI-205.87E7 no binding no binding NI-205.21G1 4.4 0.33 NI-205.31D2 41.0 19.4 NI-205.14H5 >100 — NI-205.36D5 >72.0 >60 NI-205.19G5 no binding — NI-205.68G5 no binding — NI-205.8F8 >94 — NI-205.58E11 no binding — NI-205.20A1 no binding —

Example 10 Assessment of Human-Derived TDP-43 Antibody Binding to TDP-43 in FTLD-U Case and Control Hippocampal Tissues

Human cortical, hippocampal, and spinal cord FTLD-U and control tissues were obtained from the IDIBAPS Biobank (Banc de Teixits Neurologics, Barcelona). Immunohistochemistry was performed on 5 μm thick paraffin embedded sections using EDTA-based epitope retrieval prior to conducting the otherwise standard immunohistochemical procedures with Elite ABC kits (Vector Laboratories) with DAB (Thermo Scientific). Immunohistochemistry was performed using the human TDP-43 antibodies of the invention at 50nM concentration. Control stainings were done using mouse monoclonal antibody 2E2 against human TDP-43 (Abnova), rabbit polyclonal antibody p409/p410 raised against TDP-43 p409/p410 (CosmoBio), and rabbit polyclonal antibody p409/p410 raised against TDP-43 p409/p410 (CosmoBio).

The capacity of the human derived anti-TDP-43 antibodies described herein to recognize native and pathological forms of TDP-43 was characterized by immunohistochemistry experiments on human FTLD-U case (10) and control (7) hippocampal tissues. TDP-43 is a predominantly nuclear protein which shuttles to and from the cytoplasm. Under pathological conditions it accumulates in the nucleus and particularly in the cytoplasm, and the pathology is typically characterized/classified based on cellular localization; NCI—neuronal cytoplasmic inclusion, NII—neuronal intranuclear inclusion, and dystrophic neuritic pathology (review Mackenzie et al., Lancet Neurology, 9: 995-1007 (2010)). In FTLD-U and ALS patient tissues, the protein is also found to be phosphorylated. The human TDP-43 binding characteristics of the antibodies disclosed herein were compared to that of commercially available antibodies commonly used to diagnose cases post-mortem. The 2E2-D3 control antibody (epitope mapped to aa205-222; Zhang et al., Neurosci. Lett., 434:170-174 (2008)) recognized nuclear and cytoplasmic TDP-43 accumulation in hippocampal pyramidal neurons (FIG. 11A) and granule cells (FIG. 11B), as well as TDP-43 in dystrophic neurites (FIG. 11C). On control case tissues, 2E2-D3 recognized predominantly nuclear TDP-43. The phosphorylation specific antibody, p403/p404 (raised against CNGGFGS(p)S(p)MDSK (SEQ ID NO:324); Hasegawa et al., Ann Neurol, 64(1):60-70 (2008)) recognized (FIG. 11D) cytoplasmic TDP-43 in pyramidal cells, (FIG. 11E) nuclear and cytoplasmic accumulation in granule cells, as well as (FIG. 11F) TDP-43 in dystrophic neurites. A second phosphorylation specific antibody, p409/p410 (raised against CMDSKS(p)S(p)GWGM (SEQ ID NO:325); Hasegawa et al., Ann Neurol, 64(1):60-70 (2008)) bound to TDP-43 accumulating in the nucleus and cytoplasm of (FIG. 11G) pyramidal cells and (FIG. 11H) granule cells, as well as (FIG. 11I) TDP-43 in dystrophic neurites.

The human-derived anti-TDP-43 antibodies described herein displayed various staining patterns, including binding to nuclear, cytoplasmic, and neuritic forms of TDP-43. Several of the human-derived anti-TDP-43 antibodies described herein specifically bound to disease forms of TDP-43, compared to staining on control case tissues from healthy individuals. (FIG. 11, and Table 9). For example, antibodies NI-205.68G5, NI-205.14W3, NI-205.21G1, and NI-205.41D1, selectively bound to pathological forms, i.e. to neuritic TDP-43, and nuclear and cytoplasmic TDP-43 in hippocampal granule cells. Antibodies NI-205.14W3, NI-205.21G1, and NI-205.41D1 specifically bound to pathological forms of TDP-43 in FTLD-U patient tissues without binding to control case tissues (compare for NI-205.41D1 staining in FTLD-U patient tissues (FIG. 11Y) and control case tissue (FIG. 11Z)).

Antibody (FIG. 11J) NI-205.10D3 bound predominantly to nuclear TDP-43, while (FIG. 11K) NI-205.8C10 bound to TDP-43 in cytoplasm and axons. Unlike the control anti-TDP-43 antibodies analyzed, a sub-set of the human anti-TDP-43 antibodies reported herein bound predominantly cytoplasmic TDP-43, rather than nuclear TDP-43. Antibodies that bound predominantly cytoplasmic TDP-43 include (FIG. 11L) NI-205.15F12, (FIG. 11M) NI-205.8A2, (FIG. 11N) NI-205.3F10, (FIG. 11O) NI-205.21G2, (FIG. 11P) NI-205.8F8, (FIG. 11Q) NI-205.31C11, (FIG. 11R) NI-205.36D5, (FIG. 11S) NI-205.31D2, (FIG. 11T) NI-205.10H7, and (FIG. 11U) NI-205.14H5. Antibodies (FIG. 11V) NI-205.68G5, (FIG. 11W) NI-205.14W3, (FIG. 11X) NI-205.21G1, and (FIG. 11Y) NI-205.41D1 bound to neuritic TDP-43 and TDP-43 accumulating in the nucleus and cytoplasm in hippocampal granule cells.

TABLE 9 Assessment of human-derived TDP-43 antibody binding to TDP-43 in FTLD-U case and control hippocampal tissues. Case and control samples were also stained with 2E2-D3, p403/p404, p409/p410 control anti-TDP-43 antibodies. Antibody Staining by Immunohistochemistry Antibody FTLD-U Case tissue Control tissue NI-205.41D1 cytoplasmic and nuclear in no binding granule cells + neuritic NI-205.51C1 no binding ND NI-205.21G2 cytoplasmic ND NI-205.1A9 no binding ND NI-205.3F10 cytoplasmic cytoplasmic NI-205.14W3 cytoplasmic and nuclear in no binding, cytoplasmic in granule cells + neuritic neurons (in some cases) NI-205.98H6 no binding ND NI-205.44B2 no binding ND NI-205.9E12A no binding ND NI-205.8A2 cytoplasmic cytoplasmic NI-205.15F12 cytoplasmic in granule cells ND NI-205.10D3 nuclear nuclear NI-205.38H2 no binding ND NI-205.29E11 no binding ND NI-205.9E12D no binding ND NI-205.31C11 cytoplasmic cytoplasmic NI-205.113C4 no binding ND NI-205.25F3 no binding ND NI-205.10H7 cytoplasmic cytoplasmic NI-205.8C10 cytoplasmic + axonal (one no binding case) NI-205.87E7 no binding ND NI-205.21G1 cytoplasmic and and no binding nuclear in granule cells + neuritic NI-205.31D2 cytoplasmic cytoplasmic NI-205.14H5 cytoplasmic cytoplasmic NI-205.36D5 cytoplasmic cytoplasmic NI-205.19G5 no binding ND NI-205.68G5 cytoplasmic + neuritic (one ND case) NI-205.8F8 cytoplasmic cytoplasmic NI-205.58E11 no binding ND NI-205.20A1 no binding ND 2E2-D3 Nuclear, cytoplasmic and Nuclear (cytoplasmic in neuritic some controls) p403/p404 Nuclear, cytoplasmic and no binding neuritic p409/p410 Nuclear, cytoplasmic and No binding neuritic ND—not determined

The screen for human anti-TDP-43 antibodies using denatured recombinant TDP-43 and TDP-43 390-414 peptide phosphorylated at residues S409 and S410 resulted in the generation of antibodies that cover most natural and disease-related epitopes of human TDP-43. The human anti-TDP-43 antibodies disclosed herein identify new and interesting epitopes of TDP-43, and provide novel conformational information specific to the disease process of TDP-43 proteinpathies. For example, the NI-205.14W3, NI-205.21G1, and NI-205.41D1 bound to TDP-43 with high affinity and were specific to pathological forms of TDP-43 on FTLD-U tissues in comparison to control cases. While these three antibodies had similar pathological TDP-43 specific staining pattern in immunohistochemistry, they recognized distinct epitopes in the aggregation prone C-terminal region of TDP-43: NI-41D1 bound to a discontinuous epitope in the C-terminal portion of TDP-43 and NI-21G1 bound to a phosphorylation prone region of TDP-43. Additionally, the NI-205.14H5 and NI-205.31D2 antibodies had high affinity for TDP-43 phosphorylated at one or both of residues S409 and S410, and specifically stained cytoplasmic TDP-43 in immunohistochemistry. Furthermore, NI-205.21G2 and NI-205.51C1 also demonstrated high affinity for TDP-43, and bound to epitopes N-terminal to the predicted caspase cleavage site, with NI-205.51C1 binding to RNA-recognition motif 2 (RRM2). NI-205.10D3 specifically stained nuclear TDP-43 in both FTLD-U and control case tissues, suggesting that it bound to endogenous/native forms of TDP-43.

Example 11 Acute Brain Penetration Study

TDP-43_G348C transgenic mice (Swamp et al., Brain 134 (2011), 2610-2626) are intraperitoneally injected with 30 mg/kg human anti-TDP-43 antibody or equal volume of PBS at day 1 and day 4. At day 5, mice are perfused under anesthesia with PBS containing 1 Unit/ml heparin. Blood, brain and spinal cord are collected for analyses. Right hemisphere of the brain is frozen at −80° C., left hemisphere of the brain and the spinal cord are post fixed in 10% neutralized formalin at 4° C. for two days before being embedded in paraffin block and sectioned. Plasma is stored at −80° C. in aliquots.

Brain protein extraction: brain protein fractions are extracted using standard experimental methods, for example, frozen right hemisphere is weighed and homogenized in 5 volumes (5 mL/g of wet tissue) of a solution containing 50 mM NaCl, 0.2% diethylamine, protease inhibitors (Roche Diagnostics GmbH) and phosphatase inhibitor (Roche Diagnostics GmbH). Samples are then transferred to polycarbonate tubes and added another 5 volume of homogenization solution, and kept on ice for 30 min. Soluble fraction is then collected after centrifugation at 100,000 g, 4° C. for 30 min. This soluble fraction is used in human IgG assay. The pellet is re-suspended in 3 volumes of PBS with protease and phosphatase inhibitor. After centrifugation at 16,000 g, 4° C. for 30 min, supernatants and pellets are stored separately at −80° C. for further insoluble TDP-43 extraction.

Human antibody and TDP-43 is detected and quantitated in the brain protein extracts using standard experimental methods. For example, human IgG-specific sandwich ELISA: 2 μg/ml of goat anti-human IgG Fab (Jackson) in 50 mM carbonate ELISA coating buffer (pH9.6) is used as capture antibody. Half-area 96-well microtitre plates are coated with 30 μl/well with capture antibody at 4° C. over night. The plate is then washed 4 times with PBS containing 0.1% Tween 20 before incubating with 50 μl/well PBS containing 2% BSA at room temperature for one hour. Soluble fractions of brain extracts, plasma samples and human antibody standard are diluted in PBS containing 2% BSA and 0.1% Tween 20. 30 μl of the diluted samples are added into each well and incubated at room temperature for one hour. The plate is then washed with 200 μl/well PBS containing 0.1% Tween 20 for four times before incubated with HRP-conjugated donkey anti-human Fcγ (Jackson, diluted at 1:10,000 in PBS containing 2% BSA and 0.1% Tween 20) at room temperature for one hour. The plate is then washed with 200 μl/well PBS containing 0.1% Tween 20 for four times before adding 20 μl/well TMB (1:20 in 10 mM citrate solution pH=4.1). The reaction is then stopped by adding 10 μl 1M H₂SO₄ to each well. Antibody standard curve is obtained from serial dilutions of control antibody. Antibody concentrations in plasma and brain samples are calculated according to the standards. Brain human IgG level is then converted to μg antibody/gram fresh brain tissue.

Neuronal penetration of the administered human anti-TDP-43 antibody is detected by immunohistological staining of the brain tissue sections obtained from human anti-TDP-43 antibody treated and control animals. For example, free-floating tissue sections are washed in Tris-Triton pH7.4 (50 mM Tris, 150 mM NaCl, 0.05% Triton X-100), incubated in 1% H202 PBS for 30 min, and incubated with a blocking solution containing 2% normal goat- and horse serum in Tris-Triton and with additional 0.2% Triton X-100 for 1 h at room temperature. The sections are then incubated with biotinylated donkey anti-human IgG (H+L) (Jackson Immunoresearch Labs, 709-065-149) at 1:200 in blocking solution for 16 h at 4° C. with agitation at 100 rpm to detect neuronal human IgG. The tissue-bound biotinylated antibody is visualized by peroxidase chromogenic reaction using the Vectastain Elite ABC kit (Vector Laboratories, PK6100, 1:100). The enzymatic reaction is stopped with ice cold PBS and the sections is washed in PBS 3 times. The sections are then mounted on glass slides and air dried over night before they are counterstained with hemalum solution (Carl Roth GmbH+Co. T865.1). After dehydration steps, the slides are covered with coverslips before being scanned with the Olympus dotSlide 2.1 virtual microscopy system. Neuronal anti-human IgG staining observed in the antibody treated animals, but not in the control animals, indicates that the human anti-TDP-43 antibody enters the neurons.

Example 12 Chronic Study with Anti-TDP-43 Antibodies

TDP-43_GG348C transgenic mice (Swamp et al., Brain 134 (2011), 2610-2626) are intraperitoneally injected with 10 mg/kg, 3 mg/kg of antibody solution, or equal volume of PBS control. Each treatment group has 20-25 mice. The treatment is carried out once a week for 26 weeks. Alternatively, the treatment is carried out twice a week for 13 weeks. Body weight is monitored every two weeks. Mice are perfused under anesthesia at the end of the treatment period. Brain, spinal cord and blood is collected. Half brain and spinal cord are post-fixed in 10% formalin for three days before being embedded in paraffin block. 4-6 μm thick sections cut from these tissue blocks are used for immunohistochemistry studies. The other half brain is weighted and deep frozen at −80° C. for biochemical analyses.

Drug effects are evaluated by comparing the level and distribution of TDP-43, including the level and distribution of pathological forms of TDP-43 in antibody treated and control animals using immunohistochemistry. Tissue samples obtained from antibody treated and control animals are stained with an anti-TDP-43 antibody, e.g., an anti-TDP-43 antibody specific for pathological forms of TDP-43, using standard histological methods. In one embodiment, the antibody used in the histochemical analysis is the same as the antibody administered to the animals. In another embodiment, the antibody used in the histochemical analysis is different from the antibody administered to the animals. Therapeutic efficacy of the human anti-TDP-43 antibodies disclosed herein is indicatied by a reduction in the level, or absence of pathological forms of TDP-43 in antibody treated animals relative to control animals.

Drug effects are also evaluated by comparing the level of TDP-43, including the level of pathological forms of TDP-43 in antibody treated and control animals using ELISA or Western-blot. Therapeutic efficacy of the human anti-TDP-43 antibodies disclosed herein is indicatied by a reduction in the level, or absence of pathological forms of TDP-43 in antibody treated animals relative to control animals.

The present invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, and any compositions or methods which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. 

1.-51. (canceled)
 52. An antibody or antigen-binding fragment thereof that binds to human TDP-43 and comprises: (i) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively; (ii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:131, SEQ ID NO:132, and SEQ ID NO:133, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:135, SEQ ID NO:136, and SEQ ID NO:137, respectively; or (iii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:260, SEQ ID NO:261, and SEQ ID NO:262, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:264, SEQ ID NO:265, and SEQ ID NO:266, respectively, wherein the antibody or antigen-binding fragment thereof comprises polyethylene glycol or a detectable label selected from the group consisting of an enzyme, a radioisotope, a fluorescent compound, a chemiluminescent compound, a bioluminescent compound, and a heavy metal.
 53. The antibody or antigen-binding fragment thereof of claim 52, wherein: (i) the VH consists of the amino acid sequence set forth in SEQ ID NO:10; and the VL consists of the amino acid sequence set forth in SEQ ID NO:14; (ii) the VH consists of the amino acid sequence set forth in SEQ ID NO:130; and the VL consists of the amino acid sequence set forth in SEQ ID NO:134; or (iii) the VH consists of the amino acid sequence set forth in SEQ ID NO:259; and the VL consists of the amino acid sequence set forth in SEQ ID NO:263.
 54. The antibody or antigen-binding fragment thereof of claim 52, wherein the antibody or antigen-binding fragment is selected from the group consisting of an Fab, an Fab′, an F(ab′)₂, an Fd, an Fv, a single-chain Fv (scFv), a single-chain antibody, and a disulfide-linked Fv (sdFv).
 55. An anti-TDP-43 single chain antibody or scFv antibody comprising: (i) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively; (ii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:131, SEQ ID NO:132, and SEQ ID NO:133, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:135, SEQ ID NO:136, and SEQ ID NO:137, respectively; or (iii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:260, SEQ ID NO:261, and SEQ ID NO:262, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:264, SEQ ID NO:265, and SEQ ID NO:266, respectively.
 56. A method of reducing the accumulation of pathological TDP-43 deposits or reducing pathological TAR-DNA-binding protein 43 kDa (TDP-43) distribution in a human subject in need thereof, the method comprising administering to the human subject an effective amount of an anti-TDP-43 antibody comprising: a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively; or (ii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:260, SEQ ID NO:261, and SEQ ID NO:262, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:264, SEQ ID NO:265, and SEQ ID NO:266, respectively.
 57. The method of claim 56, wherein the VH is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of (i) SEQ ID NO:10 or (ii) SEQ ID NO:259.
 58. The method of claim 56, wherein the VL is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of (i) SEQ ID NO:14 or (ii) SEQ ID NO:263.
 59. The method of claim 56, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO:10 and the VL comprises the amino acid sequence of SEQ ID NO:14; or (ii) the VH comprises the amino acid sequence of SEQ ID NO:259 and the VL comprises the amino acid sequence of SEQ ID NO:263.
 60. The method of claim 56, wherein the antibody is a human antibody, humanized antibody, chimeric antibody, or murinized antibody.
 61. The method of claim 56, wherein the antibody is an antigen-binding antibody fragment.
 62. The method of claim 61, wherein the antigen-binding antibody fragment is selected from the group consisting of a single chain Fv fragment (scFv), a F(ab′) fragment, a F(ab) fragment, and a F(ab′)₂ fragment.
 63. The method of claim 56, wherein the antibody is attached to a drug.
 64. The method of claim 56, wherein the antibody is a component of a composition comprising a pharmaceutically acceptable carrier.
 65. The method of claim 64, further comprising administering an additional agent useful for treating a TDP-43 proteinopathy.
 66. The method of claim 56, wherein the subject is suffering from a TDP-43 proteinopathy selected from the group consisting of argyrophilic grain disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ALS-Parkinsonism dementia complex of Guam, corticobasal degeneration, Dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration (FTLD), frontotemporal dementia, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, Parkinson's disease dementia, Parkinson-dementia complex in Kii peninsula and Pick's disease.
 67. A method of reducing the number or frequency of TAR-DNA-binding protein 43 kDa (TDP-43) positive inclusion-positive neurons in the brain or spinal cord in a human subject in need thereof, the method comprising administering to the human subject an effective amount of an anti-TDP-43 antibody, comprising: (i) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively; or (ii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:260, SEQ ID NO:261, and SEQ ID NO:262, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:264, SEQ ID NO:265, and SEQ ID NO:266, respectively.
 68. A method of reducing the amount or concentration of neuritic TAR-DNA-binding protein 43 kDa (TDP-43) protein in the brain or spinal cord in a human subject in need thereof, comprising administering to the subject an effective amount of an anti-TDP-43 monoclonal antibody comprising: (i) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively; or (ii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:260, SEQ ID NO:261, and SEQ ID NO:262, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:264, SEQ ID NO:265, and SEQ ID NO:266, respectively.
 69. A method for in vivo detection of TDP-43 in the brain, the method comprising: administering to a human subject an antibody or antigen-binding fragment thereof that specifically binds to TDP-43, wherein the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively; (ii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:131, SEQ ID NO:132, and SEQ ID NO:133, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:135, SEQ ID NO:136, and SEQ ID NO:137, respectively; or (iii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:260, SEQ ID NO:261, and SEQ ID NO:262, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:264, SEQ ID NO:265, and SEQ ID NO:266, respectively, wherein the antibody or antigen-binding fragment thereof is attached to a detectable label; and detecting the detectable label in the brain of the human subject, to thereby detect TDP-43 in the brain of the human subject.
 70. A method of diagnosing a TDP-43 proteinopathy in a subject, the method comprising: (a) assessing the level of TDP-43 in a sample from the subject to be diagnosed with an antibody or antigen-binding fragment thereof that specifically binds to TDP-43, wherein the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively; (ii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:131, SEQ ID NO:132, and SEQ ID NO:133, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:135, SEQ ID NO:136, and SEQ ID NO:137, respectively; or (iii) a heavy chain variable region (VH) comprising VH complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:260, SEQ ID NO:261, and SEQ ID NO:262, respectively; and a light chain variable region (VL) comprising VL complementarity determining regions 1, 2, and 3 with the amino acid sequences set forth in SEQ ID NO:264, SEQ ID NO:265, and SEQ ID NO:266, respectively; and (b) comparing the level of TDP-43 to a reference standard that indicates the level of the TDP-43 in one or more control subjects, wherein a difference or similarity between the level of the TDP-43 and the reference standard indicates that the subject suffers from a TDP-43 proteinopathy. 